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Abstract 
In vivo and in vitro studies of 4-vinylcyclohexene diepoxide in wild-caught 
female brushtail possums (Trichosurus vulpecula) and Norway rats (Rattus 
norvegicus) and its potential as a fertility control agent    
by 
Anna Mae Burd 
 
In New Zealand (NZ), the brushtail possum (Trichosurus vulpecula) poses a major threat to native 
flora and fauna and it is the main wildlife vector for bovine tuberculosis. Primary control utilizes 
lethal means but these methods have limited efficacy long-term and are associated with 
environmental impact concerns. Fertility control has become more popular as it is potentially more 
effective, sustainable and humane. The industrial chemical, 4-vinylcyclohexene diepoxide (VCD) may 
serve as an ideal chemosterilant candidate for investigation. Oral gavage studies have shown that 
VCD reduces the pool of non-regenerating immature ovarian follicles in rodents, resulting in 
premature ovarian failure and sterility. The first objective of these studies was to examine the effects 
of orally administered VCD on female possum ovarian follicle populations. Orally delivered VCD had 
no effect on the primordial follicles of adult female possums and two formulations aimed at 
improving VCD uptake and efficacy did not change this outcome. The second objective examined the 
uptake and metabolism of orally administered VCD in female possums and rats in vivo. VCD 
concentration in the blood of rats was significantly greater than in possums while concentrations of 
VCD in the stomach were comparable between species. VCD dosing did not alter pH of stomach 
contents of possums while that of rats was increased and sustained for 6 hours. VCD-induced 
reductions in ovarian and liver glutathione levels were observed in the rat with no effects in the 
possum. It was determined that the highly acidic environment of the stomach of possums poses an 
initial barrier for orally delivered VCD. Without sufficient quantities of VCD reaching the liver and 
ovaries of possums, it was not possible to compare species differences in metabolism in vivo. The 
third objective examined the fate of VCD when exposed to acidic environments and stomach 
contents and the effects of VCD on liver metabolism in vitro in possums and rats. VCD hydrolysis in 
stomach contents was slower in possums compared with rats suggesting that possum stomach 
contents are able to retain VCD longer, thus potentially modulating VCD toxicity. GSH levels in 
possum liver tissue were less affected when incubated with VCD compared with rats, suggesting an 
increased detoxifying capacity of possums. Preliminary data on the ability of possum liver 
microsomes to convert VCD’s parent compound, 4-vinycyclohexene, to VCD corroborated the GSH 
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findings. Collectively, these findings suggest that VCD may not be suitable for possum fertility control 
when delivered orally in a raw unprotected chemical state. Encapsulation of VCD with an additional 
active compound, triptolide, is being examined as a novel chemosterilant (ContraPest®, SenesTech®, 
Flagstaff, Arizona). The fourth objective examined ContraPest® efficacy in wild-caught female Norway 
rats. The ovarian primordial follicle pools of ContraPest®-consuming rats were reduced compared 
with controls. The proposed protection of the active components within ContraPest® from stomach 
acid by encapsulation may provide the first step for its potential use in possums. Further work 
demonstrating the efficacy of ContraPest® in rodents will be required before further inestigation on 
possums can be proposed. 
Keywords: Brushtail possum, Trichosurus vulpecula, Norway rat, Rattus norvegicus, fertility control, 
pest control, chemosterilant, bait, 4-vinylcyclohexene diepoxide, ovary, follicle, stomach pH, 
glutathione, metabolism. 
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Chapter 1 
General Introduction 
The aim of the studies presented here was to examine a potential fertility control agent, 4-
vinylcyclohexene diepoxide (VCD), for its potential use for control of New Zealand pest mammals, 
specifically the brushtail possum. The first research aim was to examine the effects of an oral VCD 
dose on the primordial follicle populations in adult female possums (Objectives 1a and 1b). Based on 
results obtained from the first objective, the following 3 objectives were formulated using a flow 
diagram developed prior to the start of experimentation (Figure 1.1). The uptake and metabolism of 
orally administered VCD in the possum was next examined (Objective 2a). Comparisons were made 
to that of wild Norway rats and previous literature in rodents. The effects of acid and stomach contents 
of each species were then examined in vitro for their actions on VCD (Objective 2b). The third 
research aim compared differences in the metabolism of VCD and its parent compound, 4-
vinycyclohexene (VCH), between rats and possums (Objectives 3a and 3b). Finally, a novel 
chemosterilant (ContraPest
®
, SenesTech Inc
®
) was examined for its potential as a rodent fertility 
control method in wild-caught Norway rats (Objective 4a and 4b).  Pending successful application for 
its use as a rodent chemosterilant, the formulation and application methods for ContraPest
® 
may 
subsequently provide an opportunity for its use as a control method for possums in New Zealand.  
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Figure 1.1 Flow diagram of potential research objectives based on the outcome derived from the 
initial gavage pilot study in possums.   
 
 Research objectives 1.1
To achieve the aims outlined above the following questions and research objectives were identified: 
1. Will an oral dose of VCD induce primordial follicle reductions in adult female possums?  
a. Identify an effective dosing regimen for orally delivered VCD and examine is effects 
on female possums (Chapter 4) as they relate to: 
i. The general health of the animal 
ii. The primordial ovarian follicle pool of the animal  
b. Investigate potential formulations to improve the uptake and efficacy of orally 
delivered VCD in female possums (Chapter 4) as it relates to: 
i. The general health of the animal 
ii. The primordial ovarian follicle pool of the animal  
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2. Is VCD absorbed from the stomach into the blood of possums in a similar fashion to that of 
rats? Once absorbed, is VCD metabolised in a similar fashion in possums as documented in 
rats? 
a. Examine in vivo differences in VCD-induced ovarian toxicity between possums and 
rats (Chapter 5) as it relates to: 
i. VCD uptake from the stomach into the blood of each species 
ii. The effect of a bolus dose of VCD on the stomach acidity of each species  
iii. VCD’s effects on metabolism as measured by changes in glutathione levels of 
the red blood cells, plasma, liver and ovaries of each species.   
b. Verify in vivo results of possums and rats through in vitro examination of VCD effects 
(Chapter 5) as they relate to: 
i. The effect of acid on VCD over time and concentrations ranges  
ii. The effect of stomach acidity of each species on VCD   
3. Is possum metabolism more similar to that of rats or to that of mice?  
a. Compare and contrast the in vitro metabolism of VCD’s parent compound, 4-
vinylcyclohexene, in possum and rat liver microsomes as measured by cytochrome 
P450 (Chapter 6) 
b. Compare and contrast the in vitro metabolism of VCD in possum and rat liver 
microsomes as measured by glutathione (Chapter 6)  
4. Can ContraPest® serve as a chemosterilant for the control of rodent pests in New Zealand?   
a. Examine palatability and consumption rates of ContraPest® with and without pellet 
food provided (Chapter 7) 
b. Identify and ideal baiting regimen (i.e. efficacy of a pre-feed period) (Chapter 7) 
c. Examine the effects of ContraPest® on the ovarian follicle populations of rats (Chapter 
7)   
 General comments 1.2
The four data chapters in this thesis (Chapters 4-7) have been written as thesis chapters to avoid 
redundancy. However, they will be reformatted as manuscripts as per the requirements of each 
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individual journal. Details on individual publications arising from this thesis are presented in Table 
1.1. 
 
Table 1.1 Manuscript details and status of each chapter. 
Chapter Title Authors Journal Status 
4 
Effects of orally delivered 4-
vinylcyclohexene diepoxide on 
the ovarian follicle populations of 
female brushtail possums 
Burd, AM; Scobie, S; 
Brown, S; Dyer, CA; 
Duckworth, JA 
Wildlife 
Research 
In 
preparation 
5 and 6 
Uptake and metabolism of 4-
vinylcyclohexene diepoxide in 
wild female brushtail possums 
and Norway rats 
Burd, AM; Ketelaars, L; 
van Grinsven, N; van 
der Hee, B; Brown, L; 
Brown, S; Trought, K; 
Duckworth, JA 
PLOS ONE 
In 
preparation 
7 
Examination of a novel bait 
containing 4-vinylcyclohexene 
diepoxide and triptolide in wild 
female Norway rats 
Burd, AM; Mayer, LP; 
Hinds, LA; Barrell, GK; 
Duckworth, JA; Dyer, 
CA 
European 
Journal of 
Wildlife 
Research 
In 
preparation 
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Chapter 2 
Literature review  
 Pests of New Zealand 2.1
Prior to human colonization, the only known mammals present in New Zealand (NZ) were bats and 
pinnipeds. The lack of land-dwelling mammals favoured the evolution of flightless birds such as the 
iconic Kiwi. The first records of land-dwelling mammals arrival to NZ was during Polynesian 
colonization (AD 1250-1300). These included the Kiore (Pacific rat, Rattus exulans) and the Kurī 
(Polynesian domestic dog, Canis familiaris subspecies; extinct) which later interbred with the 
European dog (Canis familiaris). European colonization (from circa 1769) resulted in the introduction 
of 54 mammalian species into New Zealand, some of which have become pests. Of the established NZ 
pests 57% negatively impact 359 threatened taxa (King, 2005). This review will focus on two of the 
most common invasive species in NZ, the brushtail possum (Trichosurus vulpecula) and the Norway 
rat (Rattus norvegicus). I will discuss the nature of their introduction, current lethal control methods 
and the development of non-lethal, fertility control management strategies for these NZ pest species. I 
will present an overview of current fertility control methods being examined with focus on a novel 
chemosterilant, 4-vinylcyclohexene diepoxide (VCD), which shows promise because of its ability to 
induce permanent infertility.   
 The brushtail possum 2.2
In the mid-1850s the Australian brushtail possum was introduced to NZ by European settlers to 
establish a fur trade (Clout and Ericksen, 2000). Controversy over the damaging effects of possums to 
the native forests first arose in the 1920s and continued until 1947 when the NZ Government instituted 
the legalisation of poison baiting and penalized any harbouring or liberation of possums. Between 
1950 and 1970, the need for possum control using poisons grew steadily. By the late 1960s it was 
recognized that possums were likely vectors for bovine tuberculosis (Tb), spurring the Government to 
continue to increase possum control efforts (Clout and Ericksen, 2000). Brushtail possums are now 
considered to be the main wildlife vector for Tb in livestock, thus forming a significant threat to NZ 
dairy, beef and deer product exportation. Presently, possums inhabit 90-95% of mainland NZ (Cowan, 
2000) at densities up to ten times higher than those found in Australia (Cowan, 2005; PCE, 2000). 
Current lethal and non-lethal methods for possum control in NZ are described below.    
 The Norway rat 2.3
The Norway rat was the first of the four rodents in the Muridae family to be unintentionally introduced 
to NZ by European settlers. Since their introduction, they have spread rapidly throughout the North 
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Island and South Island due to their adaptive nature and commensalism with humans. Additionally, it 
has been documented that they have colonized >60 offshore islands (Innes, 2005). Similar to the 
brushtail possum, the Norway rat is a predatory pest on native fauna such as ground-dwelling birds 
like the Kiwi. Furthermore, because they are commensal pests, they cause undesirable effects to 
society, for example gnawing on items such as electrical wiring in homes, cars, and businesses; 
spoiling food by defaecation; damaging food containers; and harbouring of zoonoses (infectious 
diseases that spread from non-human animals to humans). In the hope of negating these effects, 
control methods have been wide spread throughout NZ and are reviewed in detail below. 
 Lethal control methods 2.4
Since the mid-1950s, the NZ Government has employed the use of broad spectrum poisons to control 
pest populations. Sodium monofluoroacetate (also known as 1080), cholecalciferol (Vitamin D3), 
Feratox® (encapsulated cyanide), and brodifacoum have been widely used throughout NZ forests to 
control possums, whereas rodent control has mainly focused on eradication from off-shore islands 
using aerial and ground baiting (primarily with 1080 or brodifacoum) (Cowan, 2005). Recent 
estimates of 2.8 million hectares (10%) of NZ’s land is subject to such control methods (Nugent et al., 
2012). Removal of Kiore (R. exulans), ship (R. rattus) and Norway rats has been highly successful 
with more than half of the populated islands now rodent-free (Innes, 2005). Of the four rodent species 
in NZ, only the ship rat has been specifically targeted on the North and South islands. Because of their 
similarities to possums (impacts, habitat and dispersion) these two species are now routinely co-
targeted in mainland poison operations. Control of the house mouse (Mus musculus) has been 
minimal, mainly due to inadequate understanding of their effects in the environment, and has included 
commercial poisoning, fumigation, trapping and repellent use. Additionally, house mouse populations 
on off-shore islands have been indirectly targeted following 1080 aerial drops aimed at targeting 
possums (Innes, 2005).  
Poison control efforts often report >80% reduction in pest species, though failures do occasionally 
occur. Ingestion of a sub-lethal dose can lead to bait shyness (Hardy et al., 1983), hampering control 
efforts long-term. Reduced interspecific competition can occur due to increased food and resource 
availability for surviving animals, thereby increasing reproduction potential (Clinchy et al., 2001; 
Eason et al., 2011; PCE, 2000). Such effects are most prevalent in rodent species due to their high 
fecundity. Rodents are able to rebound in numbers that can exceed the original population in a short 
period of time. Immigration and re-establishment of pest species following the cessation of control 
operations can also diminish effectiveness (Eason et al., 2011; Green and Coleman, 1984; Isaac, 2005; 
Ji et al., 2004; Nugent et al., 2012). There is also great pressure from the public sector to halt  poison 
control because of its associated costs, need for repeat operations, potential to enter public water-
supply catchments, persistence in soil and plants, potential lethal effects to non-target species and its 
general inhumane nature (Clout, 1999; Eason et al., 2011; PCE, 1994, 2000, 2011; Veitch and Clout, 
2001). Death from cholecalciferol and brodifacoum poisoning can take anywhere from 4-36 days 
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(Eason, 2002) and 15-28 days (Eason et al., 1996) respectively, demonstrating the inhumaneness of 
their use as a form of possum control. In addition, persistence of brodifacoum in possum muscle and 
liver tissues poses a risk for transfer of residues through the food chain into wildlife, domesticated 
animals, and humans (Eason et al., 1996). Studies have shown that ingestion of toxins can occur 
through direct bait consumption or by indirect methods such as feeding on poisoned carcasses. Non-
target species that have been affected include birds, dogs, cats, cattle, sheep, pigs, lizards, frogs and 
invertebrates (Eason, 2002; Notman, 1989; Spurr and Powlesland, 1997). Collectively, these negative 
side effects support the need for a more publically acceptable, effective and sustainable control 
method to reduce and maintain low pest populations, particularly of possums and rodents, throughout 
mainland NZ. One such option may be to target the reproductive output of the target species.   
 Ovarian and follicular development  2.5
Development of the undifferentiated gonad through to folliculogenesis during the oestrous cycle is 
highly conserved in mammalian species. However, differences between eutherians and marsupials do 
exist, especially regarding the timing of events. Using a rodent model, I will review key events in 
ovarian development and follicle maturation taking special note of the differences in possum biology 
where applicable.   
In mice, primordial germ cells (PGCs) are first observed in the endoderm (yolk sac) on gestational day 
(GD) 8 and migrate to the genital ridge by GD 11-12. In possums however, PGCs originate in the 
nephrostomial canals of the mesonephros and can be first observed migrating to the genital ridge just 
before birth (GD 15-17.5) (Ullmann, 1996). Following gonadal ridge formation, the PGCs begin to 
invade and proliferate within the undifferentiated gonad (mouse, GD 14.5; possum, GD 17.5; Figure 
2.1). Gonadal sexual differentiation can be determined by GD 13.5 in the rat (GD 12.5 in the mouse) 
whereas in the possum, this occurs after birth on approximately post natal day (PND) 2 (Eckery et al., 
1996; Hirshfield, 1991).  In both species, differentiation of the testis precedes that of ovarian 
differentiation. Initiation of meiosis in the germ cells (GCs) in rodents is initiated around GD 14.5 and 
by GD 18.5 the maximum amount of GCs is reached (~75,000 in the rat) (Hirshfield, 1991). In the 
possum, germ cell meiosis is initiated around PND 35-40 with the maximum number reached around 
PND 50-70 (Eckery et al., 1996; Shackell et al., 1996).   
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Figure 2.1 Stages of oogenesis (not drawn to scale) during initial follicular recruitment for the 
rodent (mice and rats) and possum. Adapted from Frankenberg et al. (1996). 
 
Following the cessation of mitotic division, GCs begin to transform into oocytes through meiotic 
division. In the rat, meiotic GCs are first observed on GD 17.5 (GD 16.5 in the mouse) while in the 
possum this occurs around PND 35-40 (Eckery et al., 1996; Frankenberg et al., 1996; Hirshfield, 
1991). In both species, mass attrition of the GCs populations occurs shortly after with approximately 
65% (PND 2) and 80% (PND 80-90) of GCs lost to atresia in the rat and possum, respectively. Rat 
primordial follicle formation begins around birth and by PND 2 much of the primordial follicle pool 
has formed (Hirshfield, 1991; McGee and Hsueh, 2000). On the other hand, the primordial follicle 
pool in possums begins to form around PND 50-70 (Eckery et al., 1996; Eckery et al., 2002b; Shackell 
et al., 1996; Ullmann, 1996). These species differences in timing of events is continued throughout the 
transition from primordial to pre-ovulatory follicles with numerous preantral and antral follicles 
present by PND 30 in the rat and ~200 days of possum pouch life (Eckery et al., 1996; Hirshfield, 
1991; Shackell et al., 1996) (Figure 2.1). For clarification, pre-pubertal development of follicles will 
be referred to as initial recruitment whereas post-pubertal follicle development occurring during each 
oestrous cycle will be referred to as cyclic recruitment (Figure 2.2) (McGee and Hsueh, 2000).  
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Figure 2.2 The folliculogenesis life cycle depicting initial and cyclic recruitment of follicles. Adapted 
from McGee and Hsueh (2000). 
 
Rats become sexually mature around 32-36 days of age (Goldman et al., 2007) while possums reach 
sexual maturity at 1 year (Tyndale-Biscoe, 1955). The age at which each species reaches sexual 
maturity reflects the differences in their life cycles (rodents, 1-2 year life span (Berg and Simms, 1960; 
Solleveld et al., 1984); possums, 8-9 years (Clinchy et al., 2004)). The oestrous cycle, which is 
regulated by the hypothalamic pituitary gonadal (HPG) axis feedback loop (Figure 2.3), lasts for 4 to 5 
days in the rat (Goldman et al., 2007) and 26.5 ± 1.3 days in the possum (Duckworth et al., 1998).   
The biphasic pattern of cyclic recruitment of follicles during the oestrous cycle is similar between the 
species with the exception that rodents are polyovulatory while possums are monovulatory (McGee 
and Hsueh, 2000; Rodger et al., 1992). Phase 1 of follicular cyclic recruitment involves maturation of 
a small cohort of primordial follicles and their oocytes (Figure 2.2) (Rodger et al., 1992). Once 
follicular growth is initiated, primordial follicles are committed to either growing to ovulation (i.e. 
dominant follicle) or they will become atretic and die (Figure 2.2) (Crawford et al., 2011). Primordial 
follicles are both nonsteroidogenic and gonadotrophin and steroid hormone independent (Skinner, 
2005). The factors that regulate the initiation and growth of primordial follicles is not well understood, 
although it is widely accepted that local growth factors are involved (Crawford et al., 2011). Details on 
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these local growth factors as they related to eutherians and marsupials are reviewed in Skinner (2005) 
and Crawford et al. (2011), respectively.  
The transition from a primordial follicle to a primary follicle involves several changes. The GCs 
change from squamous to cuboidal (Hirshfield, 1991) and begin expressing follicle stimulating 
hormone (FSH) receptors (Eckery et al., 2002c; McGee and Hsueh, 2000). Theca interstitial cells 
(differentiated stromal cells) are recruited and begin to surround the primary follicles. In eutherians, 
expression of luteinizing hormone (LH) receptors in theca cells is first observed at this stage (McGee 
and Hsueh, 2000). However, in possums, LH receptor expression in theca cells does not occur until the 
time of antrum formation (phase 2, discussed below) (Crawford et al., 2011). In addition, the zona 
pellucida (ZP) begins to form around the oocyte within the primary follicle (Hirshfield, 1991; Mate, 
1998). The ZP is a glycoproteinaceous matrix which functions as a species-selective substrate for 
sperm binding, an agonist for spermatozoon acrosome reaction, defence against polyspermy, and as 
protection for the embryo during the early stages of development until implantation of the blastocyst 
occurs (Mate, 1998; Wassarman and Litscher, 2008). The ZP matrix of mice and possums contains 
three glycoproteins, designated ZP1, ZP2 and ZP3 while a fourth glycoprotein (ZP4) has recently been 
reported in species such as rats, hamsters, humans and monkeys (Ganguly et al., 2008; Hoodbhoy et 
al., 2005; Hughes and Barratt, 1999; Izquierdo-Rico et al., 2009; McCartney and Mate, 1999). The 
follicles and their oocytes continue to grow, increasing both in size and number of GCs present. 
During this time FSH does not seem to be essential, rather it appears to be involved in a facilitating 
manner (Crawford et al., 2011; McGee and Hsueh, 2000). For a full cellular description of each 
follicle stage and the associated follicle diameters for rats and possums refer to the histology section of 
Chapter 3.  
Phase 2 commences when the oocytes have reached their maximum diameters. At this stage only 
growth of the follicles occurs and formation of a fluid-filled antrum begins (Figure 2.2) (McGee and 
Hsueh, 2000; Rodger et al., 1992). Within the cohort of growing follicles, the selection for the most 
dominant follicle is believed to be achieved through the expression of LH receptors in their associated 
GCs. In possums, LH receptor expression can be found in the GCs of all healthy antral follicles 
(Crawford et al., 2011). Thus, selection for the dominant follicle is less clear but it is thought that 
down-regulation of anti-Müllerian hormone (AMH) GC expression may help GC differentiation and 
maturation of the follicle in possum (Crawford et al., 2011). Follicles not selected for ovulation 
undergo atresia (Figure 2.2).   
Gonadotrophin releasing hormone (GnRH), which is derived from the hypothalamus, controls the 
secretion of the gonadotrophins (LH and FSH) from the anterior pituitary gland (Figure 2.3) 
(Crawford et al., 2011; Skinner, 2005). The secretion profiles of LH and FSH in possums is, in many 
ways, very similar to that of eutherians (Crawford et al., 2011). As a follicle develops in preparation 
for ovulation (follicular phase of oestrous cycle), LH induces theca cells to increase the conversion of 
cholesterol to androgens (androstenedione and testosterone) while the GCs begin to increase their 
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capacity to biosynthesize and secrete oestradiol (E2) and progesterone (P4) under the influence of FSH 
(Craig et al., 2011; Skinner, 2005). Ovarian-derived E2 and P4 secretion provides positive feedback on 
the hypothalamus, allowing for increased GnRH secretion and subsequently, LH and FSH secretion 
(Figure 2.3). This positive feedback HPG axis loop increases the levels of circulating LH, FSH, E2 and 
P4. Ovulation of the oocyte is preceded by an LH surge (10-12 hours in rats) which is concomitant 
with an E2 and FSH surge. For successful rupture of the follicle wall and subsequent oocyte release an 
increase of intrafollicular P4 is required (Robker et al., 2009).  
 
 
Figure 2.3 The hypothalamic-pituitary-gonadal (HPG) feed-back loop. Hormonal feedback may be 
positive (+) or negative (-) depending on the stage of the reproductive cycle. GnRH: 
gonadotrophin releasing hormone; FSH: follicle stimulating hormone; LH: luteinizing 
hormone.    
 
After ovulation of the oocyte, the luteal phase of the oestrus cycle begins. It is characterized by the 
luteinisation of the surrounding GCs under the influence of LH forming a progesterone-producing 
organ, the corpus luteum (CL). At the end of an oestrous cycle or pregnancy, prolactin release then 
induces luteolysis (luteal cell death) forming a non-steroidogenic corpus albicans (CA) (Hirshfield, 
1991).  
A clear difference in gestation and lactation lengths exists between rodents and marsupials. In rodents, 
if insemination occurs, then the CL is maintained and continues to secrete P4 to support the pregnancy 
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which lasts for 21 ± 1 days (Whittingham and Wood, 1983). In contrast, pregnancy (16.5 ± 1 day) in 
possums occurs within the luteal phase of the oestrous cycle (26.5 ± 1.3 days) (Duckworth et al., 1998; 
Eckery et al., 2002a; Hinds, 1990). Thus, pregnancy occurs during the period when P4 is being 
secreted by the CL and comprises approximately 60% of the oestrous cycle. There is no evidence that 
pregnancy affects the function of the possum CL although it is required at parturition (Eckery et al., 
2002a; Hinds, 1990). In both rats and possums, the oestrous cycle is suppressed during lactation which 
lasts for 21 ± 1 days for rodents (Whittingham and Wood, 1983) and approximately 6 months for 
possums (Cowan, 1989).  
Clearly, there are considerable differences between rats and possums in the timing of reproductive 
events. However, there are similarities in the stages of development and growth within the ovary. 
Development of a successful fertility control method will require a detailed understanding of the 
reproductive biology of a target species. If the aim is to utilize the same (or a similar) fertility control 
method for several species, understanding of the similarities and differences in their reproductive 
biology becomes even more important. Below I discuss current methods being examined for 
mammalian fertility control with special focus on their relevance for rats and possums.  
 Non-lethal (fertility) control methods 2.6
Research investigating fertility control as an alternative, humane, and non-lethal approach to 
controlling pest populations has increased in recent years. Ideally, an useful contraceptive agent 
should have the following properties: 1) long-term, reversible or permanent sterility; 2) low production 
and application cost; 3) easy delivery to the pest population of interest; 4) minimal or no harmful 
effects on target species other than reduced fertility; 5) no negative impacts on non-target species; and 
6) environmentally neutral (DeNicola et al., 1997; Humphrys and Lapidge, 2008).  Fertility control 
may provide the advantage of reducing toxin application rate, thereby reducing risk of environmental 
contamination, associated application costs, and primary and secondary poison risks to non-target 
species (Duckworth et al., 2006).  
The effectiveness of fertility control in rodent populations has been demonstrated using surgical 
sterilization and sex steroid inhibition. It has been estimated that 70-80% female sterility will be 
required to significantly reduce the population size of a specific species (Chambers et al., 1999b; 
Jacob et al., 2004; Jacob and Matulessy, 2004). Furthermore, fertility control effects may be more 
pronounced in an open field population where rats may be exposed to predation and other 
management strategies, such as the use of rodenticides and traps. Models for brushtail possum 
populations have shown that fertility control can provide a long-term, sustainable approach to 
maintaining pest populations at a low level. Spurr (1981) predicted that a population will return to its 
former level within 10 or 14 years following a 70% or 90% poison kill, respectively. In contrast, if 
70% of a population is permanently sterilized, it will take 23 years for the population to return to its 
former level (Spurr, 1981). Similarly, Barlow (1991) demonstrated that a 70% kill would reduce and 
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sustain low population levels of possums for up to 8 years. In contrast, 50-60% sterilization, followed 
by an annual sterilization rate of 18%, would be sufficient to continually maintain a population at 35-
40% below its natural equilibrium long-term (Barlow, 1991). A five year field study examining the 
effect of surgical sterilization on possum population dynamics demonstrated that a 50% sterility rate 
would reduce per capita recruitment by 50% when a population was close to carrying capacity 
(Ramsey, 2005). Furthermore, studies have shown that fertility control may reduce breeding related 
contact between possums, thereby reducing horizontal disease transmission between animals (Caley 
and Ramsey, 2001; Ramsey, 2007).  
Collectively, these modelling and experimental field studies illustrate that fertility control could offer 
an effective and sustainable alternative method for the long-term control of pest populations in 
addition to the potential to reduce disease transmission between individuals. Current approaches being 
investigated include hormonal manipulation and immunological and chemical sterilization. For the 
purposes of this review only significant findings in rodents and marsupials will be discussed in detail. 
2.6.1 Immunological sterilization  
An immunological fertility control agent works by stimulating an immune response against 
reproductive proteins (or antigens), thereby interfering with reproduction (Arthur et al., 2007; Barlow, 
2000; Miller et al., 1998). Immunological fertility control has been investigated extensively in 
eutherian mammals (Barfield et al., 2006; Barlow, 2000; Chambers et al., 1999a; Gupta and Bansal, 
2010; Hardy et al., 2006) and marsupials such as the tammar wallaby, koala, eastern grey kangaroo 
and the brushtail possum (Bradley et al., 1999; Cowan, 1996; Cowan, 2000; Duckworth et al., 2006; 
Mate and Hinds, 2003; Mate et al., 1998).   
One area of focus for fertility control has been on targeting the ZP proteins surrounding the oocyte. 
Wildlife populations such as feral horses (Equus calballus) (Kirkpatrick et al., 1990), white-tailed deer 
(Odocoileus virginianus) (Kirkpatrick et al., 1995), and captive zoo animals (Frank et al., 2005; 
McShea et al., 1997) are currently being controlled using porcine ZP (pZP) immunocontraceptive 
vaccines (Kirkpatrick et al., 2011). pZP contraceptive control of these species is highly effective (75 – 
100%), although annual boosters are required during the first 2-3 years. pZP is also beneficial because 
it causes minimal behavioural effects, no debilitating side effects and, although infertility is temporary, 
this allows for better control and management of these specific populations over time (Kirkpatrick et 
al., 2011). New vaccine formulations offer greater efficacy and reduced treatment costs (Miller et al., 
1998). The current route of administration is via hand injection after capture or using remote dart 
delivery. Although remote delivery will not be feasible for control of most species (e.g. rodents), in the 
case of large bodied mammals which can be easily accessed routinely in large groups (e.g. captive 
animals; seasonal breeders), such methods are suitable.  
Successful reductions in fertility following immunization with pZP or bacterially produced 
recombinant ZP3 (rZP3) have also been demonstrated in several other species including bonnet 
 14 
monkeys (Bagavant et al., 1994; Govind et al., 2002; Kaul et al., 2001), baboons (Govind and Gupta, 
2000), dogs (Gupta et al., 2011; Mahi-Brown et al., 1985; Srivastava et al., 2002), rabbits (Bhatnagar 
et al., 1992; Dietl et al., 1982; Kerr et al., 1999; Wood et al., 1981), mice (Clydesdale et al., 2004; 
Hardy et al., 2003; Jackson et al., 1998; Li et al., 2007; Lloyd et al., 2003; Millar et al., 1989), 
hamsters (Hasegawa et al., 1992), wallabies (Kitchener et al., 2002), and brushtail possums 
(Duckworth et al., 1999; Duckworth et al., 2007). Again, the current route of administration is via 
injection and therefore alternative routes (i.e. oral/nasal) for ZP delivery have been examined in mice 
(Zhang et al., 2011) and possums (Cui et al., 2010; Duckworth and Cui, 2004; Walcher et al., 2008).  
Bacterial ghost vectors (BGVs) and virus-like particles (VLPs) have been examined as potential 
delivery systems for ZP antigens. BGVs consist of the cell membranes of recombinant bacteria which 
have been genetically engineered to express target reproductive molecules (Mayr et al., 2005) while 
VLPs are lipoprotein nanoparticles artificially created to resemble virus capsids that incorporate target 
reproductive antigens (Pattenden et al., 2005). Both BGVs and VLPs lack genetic material and 
therefore cannot replicate (Cui et al., 2010; Duckworth and Cui, 2004; Walcher et al., 2008). VLPs 
expressing ZP3 have been shown to reduce litter sizes and suppress fertility in mice when 
subcutaneously injected (Choudhury et al., 2009). To date, there have been no reports on orally or 
nasally delivered VLPs expressing ZP antigens. Intranasal co-administration with mouse ZP (mZP) 
DNA and protein vaccines encapsulated in chitosan reduced fertility and mean litter size of female 
C57BL/6 mice while not affecting normal follicular development (Zhang et al., 2011). In female 
possums, oral and intranasal delivery of a BGV expressing possum ZP2 or ZP3 antigens produces 
successful humoral and mucosal immune responses as well as reduced fertilization rates (36% relative 
to controls) (Cui et al., 2010; Duckworth and Cui, 2004; Walcher et al., 2008). It seems that an 
oral/nasal route utilizing BGVs may be feasible for inducing successful ZP-induced 
immunocontraception although further development will be required for its use on large scale pest 
control operations.  
Viral vectored immunocontraception (VVIC) has been examined as a potential immunological control 
agent because of its potential for a low cost-benefit ratio, its natural disseminating properties and it can 
be species-specific (Chambers et al., 1999a; Hardy et al., 2006; McLeod et al., 2008; Redwood et al., 
2008). Murine cytomegalovirus (MCMV) has been examined as a potential vector for the expression 
of a murine ZP3 (mZP3) gene (Farroway et al., 2002; Hardy et al., 2006; Lloyd et al., 2010; Lloyd et 
al., 2003; Redwood et al., 2007; Singleton et al., 2001; Smith et al., 2005). MCMV is a mouse-specific 
betaherpesvirus which is readily carried in wild house mouse populations and is naturally occurring in 
Australia. Anti-mZP3 antibodies block the ability of sperm to penetrate the egg for fertilization, 
thereby inducing infertility (Wassarman, 1999). Laboratory trials have demonstrated infertility in 
nearly all mice inoculated with recombinant MCMV expressing mZP3 (Lloyd et al., 2007; Lloyd et 
al., 2003; O'Leary et al., 2008; Redwood et al., 2005) but infectivity of the modified viruses was 
compromised (Hardy et al., 2006). These findings, however noteworthy, need to be repeated in wild, 
outbred rodent populations. Release of any self-disseminating fertility control agents would require a 
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thorough understanding of their potential impacts and would need to meet local and international 
regulatory requirements to safe guard against unintended consequences (Williams et al., 2001). 
Various VVIC methods have also been examined in possums with varying results. Zheng (2007) 
identified two possum intestinal enteroviruses, W1 and W6, as potential VVICs (Zheng, 2007). 
Infection with the W1 or W6 strain did elicit antibody responses in both captured and wild-dwelling 
possums. However, antibody response was variable, short-lived and distribution of the enterovirus was 
limited (Zheng and Chiang, 2007; Zheng et al., 2010). In Australia, macropod herpesvirus (MaHV) 
infection is common amongst macropod marsupials and at least one strain has been identified and 
tested as a potential vector in NZ possums. Possums infected with MaHV-1 showed transient infection 
at inoculation sites but a systemic and latent infection was not generated (Zheng et al., 2001; Zheng et 
al., 2004). Although there is no evidence that eutherians can be infected with MaHV, it is highly 
pathogenic and can cause negative side effects including transient infertility, lingual ulcers, discharge 
from the eyes and nose and, in extreme cases, death (Speare et al., 1989). Because of these undesirable 
effects and the lack of infectivity, no further research has been reported on the use of MaHV for 
control of NZ possums.  
Other possum-specific viruses that have been identified as potential disseminating delivery systems 
include adenovirus and coronavirus (Rice and Wilks, 1996; Thomson et al., 2002), papillomavirus 
(Perrott et al., 2000), and a type D retrovirus identified as TvERV(D) (Baillie and Wilkins, 2001). 
Much work will be required to determine the individual viral infectivity of each potential 
disseminating delivery system and ultimately its ability to reduce possum fertility. In addition, there is 
concern for accidental or intentional (illegal) transfer of a disseminating delivery system to Australia 
where possums are endemic and protected (Gilna et al., 2005). Therefore, if successful, use of a VVIC 
for possum control will need to be carried out with caution.  
Immunization utilizing endogenous hormones has also been widely examined. Gonadotrophin 
releasing hormone (GnRH) is a decapeptide present in both males and females. Multiple reports have 
demonstrated effective blocking of fertility in a range of species with the use of GnRH made 
immunogenic via coupling with various carrier proteins (Gupta and Bansal, 2010; Kirkpatrick et al., 
2011; Miller et al., 1998). Miller et al. (1997) injected Norway rats with GnRH vaccines made 
immunogenic via coupling to the carrier protein keyhole limpet haemocyanin (KLH). Through the 
action of antibodies binding to GnRH, reductions in FSH and LH from the anterior pituitary gland and 
eventual atrophy of the gonads is induced, leading to temporary infertility (Figure 2.3). The authors 
demonstrated 100% infertility in both male and female rats for the duration of the study (12 months) 
and predicted infertility to last through the rodent’s lifetime (1-3 years). However, several booster 
injections over a three month period were required to establish infertility (Miller et al., 1997).  
The GnRH vaccine, GonaCon™, is a single shot, injectable vaccine developed by the USDA National 
Wildlife Research Center (Miller et al., 2004) and has demonstrated long-term infertility (2-4 years) in 
a range of species, both male and female (Kirkpatrick et al., 2011; Mauldin and Miller, 2007). 
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GonaCon™ halts reproduction by eliciting antibodies to native GnRH (Figure 2.3). GonaCon™ was 
examined as a potential management strategy for black-tailed prairie dogs (C. ludovicianus) and the 
high antibody titres indicate that it will likely control prairie dog fertility for ≥1 year (Yoder and 
Miller, 2010). Further work will be required to determine if GonaCon™ will be effective as a 
contraceptive agent for prairie dog populations.  
A long-term study examined the effects of GonaCon™ on the fertility and behaviour of male and 
female tammar wallabies, Macropus eugenii (Snape et al., 2011). GonaCon™ vaccination resulted in 
100% infertility in adult males (>2 years) and females (>4 years) for the duration of the study. 
Behavioural observations during the study revealed that males, when vaccinated as juveniles, showed 
reduced rates of sexual behaviour compared with controls. Interestingly, when control males were 
housed with vaccinated males, they showed decreased rates of agonistic behaviour compared with 
when they were housed with untreated males. Although behavioural changes were observed during the 
study, it was determined that animal welfare was not negatively impacted.   
GonaCon™ use in brushtail possums has demonstrated efficacy and examination into an oral or nasal 
route is underway (Cross et al., 2011). A single injection of GonaCon™ produced anti-GnRH 
antibodies and rendered >70% females infertile for 2 years (Cross et al., 2011). A proof of concept 
study examined the effects of poly(ethylcyanoacrylate) (PECA)  nanoparticles containing D-Lys
6
-
GnRH when administered into the caecum of brushtail possums. Their results demonstrated that 
sufficient bioactive peptide was able to reach the pituitary gland to evoke a response as demonstrated 
by increased blood LH levels (Kafka et al., 2011). Further investigation into potential oral or nasal 
delivery will be necessary for this method to be used in a large-scale operation for control of possum 
populations in NZ.  
At the moment, there remain several limitations to immunological fertility control. These include the 
generally temporary nature of the infertility, the need for repeat exposure to maintain infertility, 
inconsistent responses, and a reliance on an immune response for effectiveness. In some cases animals 
do not generate an immune response to the vaccine (non-responders) (Mann et al., 2009). There is 
concern that if there is a genetic basis to this non-responsiveness then natural selection for non-
responsive progeny may occur over time resulting in populations that develop resistance to the 
reproductive agent (Cowan, 2001; Magiafoglou et al., 2003). Furthermore, modelling studies have 
demonstrated that permanent sterilization will be more effective in reducing and then sustaining lower 
pest populations compared with temporary sterilization (Spurr, 1981), supporting the case for an 
irreversible fertility control management system. In order for such technology to be feasible for wild 
pest populations, an oral route of delivery will be necessary.  
2.6.2 Chemosterilization 
Chemical sterilization (chemosterilization) offers another option for fertility control. A chemosterilant 
can be defined as a chemical, whether endogenous (hormonal manipulation) or exogenous (xenobiotic 
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manipulation), that can induce temporary or permanent sterility (Marsh and Howard, 1970). 
Chemosterilants can inhibit fertility by altering the hormones which control ovarian or testicular 
function (Gao and Short, 1993, 1994a, b) or by directly affecting the function and physiology of the 
ovary or testis.   
Hormonal chemosterilization 
Endocrine signalling by hormones plays a vital role in reproduction (Figure 2.3), thus it was one of the 
first targets for early investigations of fertility control. Hormonal chemosterilization is accomplished 
by suppressing reproductive activity with the use of hormone agonists, antagonists, or toxins.  
Proof of concept studies have been carried out investigating the use of a GnRH toxin conjugate, 
GnRH-PAP (pokeweed antiviral protein) in possums (Eckery et al., 2001). Possum pituitary cells 
cultured with GnRH-PAP showed decreased LH secretion and LH-containing cell numbers suggesting 
that the toxin was able to induce cellular death. Possums treated with GnRH-PAP by injection showed 
depressed circulating levels of LH and FSH although the effect was temporary and hormone levels 
returned to normal within 3 weeks (Eckery et al., 2001). Delivery of GnRH through an oral (or 
oronasal) route of administration in the possum examined the use of the previously discussed VLPs 
(Cross et al., 2011). Orally delivered VLPs chemically conjugated to GnRH (GnRH-VLP) resulted in 
an immune response in possums, although the response was lower than when injected (Cross et al., 
2011).Although these studies demonstrate proof of concept, hormonal sterilization was temporary, 
reversible, not species-specific, and the current routes of administration are not practical for wildlife 
populations.   
A hormonal implant containing a GnRH agonist, deslorelin, has been examined as a potential method 
for fertility control delivery. The action of deslorelin on the anterior pituitary results in suppression of 
steroidal hormone production, follicular development and ovarian cycles (Figure 2.3). Its use as a 
potential fertility control method has been investigated in several marsupials including the brushtail 
possum (Eymann et al., 2013; Eymann et al., 2007; Lohr et al., 2009), the tammar wallaby (M. 
eugenii) (Herbert et al., 2007, 2012; Herbert et al., 2004a; Herbert et al., 2004b, 2005) and the eastern 
grey kangaroo (M. giganteus) (Herbert et al., 2006; Wilson et al., 2013; Woodward et al., 2006). 
Eymann et al. (2007) examined the effects on fertility of subcutaneous deslorelin implants in male and 
female NZ possums. Following deslorelin implantation, female reproduction was inhibited for at least 
one breeding season, but such effects were temporary and reversible while males showed no reduction 
in fertility despite reduced circulating testosterone and FSH levels (Eymann et al., 2007). Similar 
results were reported in brushtail possums in Australia where 80% of treated females showed no 
evidence of breeding at study completion (18 months) (Lohr et al., 2009). Recent examination of the 
effects of deslorelin implants in rodents demonstrated reductions in ovarian weight, pre-antral follicle 
numbers, circulating gonadotrophin levels, and overall disruption of the oestrous cycle (Alkis et al., 
2011; Cetin et al., 2012; Grosset et al., 2012; Smith et al., 2012). The current route of administration 
(surgical implantation or dart gun) (Herbert et al., 2010) and the temporary (6 to 18 months) and 
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reversible nature of this method make it suitable for veterinary or captive (e.g. zoo) animal use. 
However, these same characteristics are not appropriate for wild pest populations, especially 
considering reports on decreased sexual behaviour in many species (Bertschinger et al., 2001; Patton 
et al., 2006; Woodward et al., 2006).  
Hormonal manipulation has also be achieved through the use of the cholesterol mimic, 20,25-
diazacholesterol (DiazaCon™) which inhibits cholesterol production. Cholesterol is required for the 
synthesis of steroid reproductive hormones, such as testosterone and progesterone. Therefore, 
inhibition of cholesterol production indirectly inhibits reproduction. Oral treatment with DiazaCon™ 
has caused reduced reproductive output in black-tailed prairie dogs (Cynomys ludovicianus) (Nash et 
al., 2007) and evidence for its effectiveness has been demonstrated in female grey squirrels (Siurus 
carolinensis) (reduced cholesterol levels (Mayle et al., 2012) and antibody titre response (Yoder et al., 
2011)). Intraperitoneal injection of 20,25-diazacholesterol dihydrochloride (SC 12937) caused 
antispermatogenic and antifertility effects in male Parkes strain mice (Singh and Chakravarty, 2003). 
Although DiazaCon™ administration demonstrates effectiveness via the oral route, the effects have 
been shown to last only up to 6 months and it may not be suitable for wild animal populations if 
alteration of the reproductive hormones affects sexual behaviour. Furthermore, DiazaCon™ is cleared 
slowly and bioaccumulation does occur with repeated treatment (Nash et al., 2007; Yoder et al., 2011).    
Natural compounds occurring in various parts of plants have been found to disrupt or inhibit 
reproduction and therefore have been examined for their contraceptive potential (Tran and Hinds, 
2013). Plant-derived compounds which specifically target the ovary have been identified and a full 
review by Tran and Hinds (2013) discusses their effects when orally administered. Cessation of 
treatment with any of the currently examined plant-derived compounds does result in the return of 
normal fertility (Tran and Hinds, 2013). However, 6 plant species (Azadirachta indica, Hibiscus 
rosasinensis, Melia azedarach, Momordica charantia, Trichosanthes cucumerinas and Tripterygium 
wilfordii) have been identified as potential candidates for contraceptive use as they specifically target 
ovarian follicle development and function (Tran and Hinds, 2013). For the purposes of this review, 
focus will be on the active ingredient, triptolide (Figure 2.4) derived from T. wilfordii (thunder god 
vine). 
Triptolide  
Triptolide (TR) was first discovered to have anti-fertility effects in males (e.g. oligozoospermia and 
asthenozoospermia) (Huynh et al., 2000; Lue et al., 1998; Qian et al., 1986; Qian et al., 1988; Zhen et 
al., 1995) and these effects have been confirmed in wild-caught male laboratory black rats (R. rattus) 
treated with a bait containing TR (Singla et al., 2012). More recently, the effects of orally administered 
TR in females rats have been examined (Liu et al., 2011; Xu and Zhao, 2010). Oral administration of 
60 or 120 µg TR/kg/day for 35 days to female Sprague Dawley (SD) rats caused a significant increase 
in both healthy and apoptotic secondary ovarian follicles compared with controls (Xu and Zhao, 
2010). No observed changes in the primordial or primary follicle pools were noted. Additionally, the 
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oestrous cycles were lengthened in animals receiving the higher TR dose (120 µg TR/kg/day) relative 
to controls (Xu and Zhao, 2010). A similar study examining the effects of orally delivered TR (100, 
200 or 400 µg/kg/day, 90 days) on the fertility of female SD rats found that the two highest TR doses 
caused decreases in ovarian and uterine weight, reduced serum levels of E2 and P4, increased serum 
levels of FSH and LH and overall reduced staining for the presence of the E2 receptor alpha (ERα) in 
the uterus and ovaries relative to controls (Liu et al., 2011). The only observed effect following 
treatment with a low TR dose (100 µg/kg/day; 90 days) was reduced P4 levels and ERα staining 
relative to controls.       
 
 
Figure 2.4 The chemical structure of triptolide (360.4 g/mol).    
 
Lue et al. (1998) first suggested that TR’s method of action was involved in alterations of the 
intracellular calcium (Ca
2+
) influx pattern (Lue et al., 1998). Following specific [
3
H]triptolide-binding 
activity, Leuenroth et al. (2007) identified the Ca
2+
 channel, polycycstin-2 (PC2), as a putative target 
protein for TR binding (Leuenroth et al., 2007). PC2 is a product of a gene mutation found in type 2 
autosomal dominant polycystic kidney disease (ADPKD) and is a member of a subfamily of the 
transient receptor potential (TRP) superfamily (Koulen et al., 2002). It was determined that TR causes 
an increase in intracellular Ca
2+
 release through a PC2-dependent pathway (Leuenroth et al., 2007). 
Signal transduction pathways that control the decision for a cell to divide, differentiate or die are 
activated by increases in intracellular Ca
2+
 (Ermak and Davies, 2002; McKinsey et al., 2002; Orrenius 
et al., 2003). Additionally, intracellular Ca
2+
 influx following cellular stress can be sufficient to trigger 
or modulate apoptosis (Orrenius et al., 2003). Therefore, their findings suggest that TR is acting 
directly on the ovarian follicle populations rather than the steroids involved in the HPG axis (Figure 
2.3). Further evidence suggesting TR’s involvement in calcium-dependant cellular regulation is TR’s 
ability to induce apoptosis in tumor cells as well as sensitizing tumor cells to apoptosis via α-mediated 
tumor necrosis factor (TNF) (Lee et al., 1999) without being mutagenic (Kupchan, 1977; Shamon et 
al., 1997).   
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Current investigation utilizing TR in combination with another chemosterilant, 4-vinylcyclohexene 
diepoxide (VCD), is being undertaken by researchers at SenesTech Inc
®
 (Flagstaff, AZ, USA). 
Preliminary findings from their laboratory have demonstrated that female SD rats consuming a bait 
containing VCD and TR have reduced numbers of primordial, primary and secondary follicles (Dyer 
et al., 2013) as well as reduced litter sizes (Drs L. P. Mayer and C. A. Dyer, unpublished). A full 
review of the ovarian follicle depleting effects of VCD is discussed below.    
Non-hormonal chemosterilization   
Non-hormonal chemosterilants that induce premature ovarian failure could potentially serve as fertility 
control agents due to their permanent fertility-inhibiting characteristics. In a young, cycling ovary, 
recruitment of primordial follicles for development occurs continuously, yet little is known about the 
factors that control this process. After initial recruitment of any given follicle, it can progress through 
several stages of growth (primary, preantral, antral, and pre-ovulatory) to reach ovulation. During the 
process of follicular maturation many follicles and their oocytes undergo atresia (apoptosis or 
programmed cell death) with only ~400 of the ~2 million oocytes contained within primordial follicles 
progressing to ovulation (Hirshfield, 1991; Hirshfield and Midgley Jr, 1978; Palumbo and Yeh, 1994). 
Some recent investigations have suggested that stem-cell populations may exist that could give rise to 
follicular germ cells following ovarian failure, but this concept has yet to be confirmed (Johnson et al., 
2004; White et al., 2012; Zou et al., 2009).  
The immature ovarian follicle pool can be affected by a variety of xenobiotic compounds (see review 
and references cited in Table 2.1). Chemical groups which have been shown specifically to target 
ovarian function in laboratory animals include: chemotherapeutic agents such as cyclophosphamide 
(CPA) and cisplatin; ionizing radiation; polycyclic aromatic hydrocarbons (PAHs; commonly found in 
cigarette smoke) such as 7,12-dimethylbenz(a)anthracene (DMBA), 3-methylcholanthrene (3-MC), 
and benzo[a]pyrene (BaP); endocrine distruptors such as bisphenol-A (BPA), medroxyprogesterone 
acetate (MAP) and diethylstilboestrol (DES); and occupational chemicals containing an epoxide 
moiety (which are able to bioactivate by epoxidation) such as 1,3-butadiene (BD) and  
vinylcyclohexene (VCH) and its epoxide metabolite 4-vinylcyclohexene diepoxide (VCD). Although 
the xenobiotic mechanisms for ovarian toxicity are not fully understood, in general they target and 
destroy the oocytes located within the follicles which ultimately lead to loss of these follicle structures 
and onset of premature ovarian failure (POF; menopause in humans). Depending on the dosing 
regimen and route of exposure, development of ovarian tumours (granulosa cell tumours, mesothelial 
adenomas, and mixed benign tumours) are often associated with the loss of ovarian follicles. A general 
review of the positive and negative side effects of commonly studied ovarian toxicants is provided in 
Table 2.1. 
  
Table 2.1 A summary of commonly studied ovarian toxicants and the positive effects (*as they relate to pest fertility control), and negative effects (**as they 
relate to animal humaneness). Due to the exhaustive bodies of work on these topics, reviews which cover each topic in depth have been provided. 
ΔEffects evident >90 days of daily gavage; ‡Effects also observed in humans. 
Chemical 
Primary 
animal 
model 
*Positive effects **Negative effects 
Benzo(a)pyrene (BaP)(Kappeler and Hoyer, 2012; Mark-
Kappeler et al., 2011a) 
Mouse 
Depletion of primordial and primary ovarian 
follicles via necrosis 
‡Carcinogenic; ovarian tumours 
Bisphenol-A(Cabaton et al., 2013; Kappeler and Hoyer, 2012; Mark-
Kappeler et al., 2011a; Rogers et al., 2013) 
Mouse; rat 
Decreased primordial follicles; increase in growing 
follicles; endocrine disruptor 
Meiotic disturbances; disruption of energy 
metabolism and brain function; alteration 
of immune response 
2-Bromopropane (2-BP)(Ichihara, 2005) Rat 
Depletion of primordial, primary and antral 
follicles; increased rates of follicular atresia; 
disruption of estrous cycle; reduced ovarian and 
uterine weights and ovulated ova 
‡Neurotoxic; ‡hematopoietic depletion; 
reduction of bone marrow (males) 
1,3-butadiene (BD) (Kappeler and Hoyer, 2012; Mark-Kappeler 
et al., 2011a; Maronpot, 1987) 
Mouse Depletion of preantral and antral follicles ‡Carcinogenic 
Cisplatin(Kappeler and Hoyer, 2012; Mark-Kappeler et al., 2011a) Rat 
Depletion of all ovarian follicle types; increased 
atretic secondary and antral follicle numbers 
‡Carcinogenic 
Cyclophosphamide (CPA) (Kappeler and Hoyer, 2012; Mark-
Kappeler et al., 2011a) 
Mouse; rat 
Reduced health and depletion of all ovarian follicle 
types; reduced implantation sites; malformed 
offspring 
‡Mutagenic; ‡carcinogenic 
Diethylstilboestrol (DES) (Kappeler and Hoyer, 2012; Mark-
Kappeler et al., 2011a; Marselos and Tomatis, 1993) 
Mouse; rat 
Reduced oocyte quality; endocrine disruptor; 
reduced litter size 
‡Vaginal carcinomas; ‡Uterine, oviduct and 
ovarian  abnormalities; chromosomal 
aberrations and DNA disruption; genotoxic 
effects 
7,12-Dimethylbenz(a)anthracene (DMBA) 
(Bhattacharya and Keating, 2011; Kappeler and Hoyer, 2012; Mark-
Kappeler et al., 2011a) 
Mouse; rat Depletion of all ovarian follicle types via apoptosis ‡Carcinogenic; ovarian tumours 
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Table 2.1 continued:  
Chemical 
Primary 
animal 
model 
*Positive effects **Negative effects 
Isopropyl methanesulphonate (IMS) (Kappeler and 
Hoyer, 2012; Mark-Kappeler et al., 2011a) 
Mouse Destruction of oocytes within small follicles ‡Mutagenic; ‡carcinogenic; ovarian tumours 
Medroxyprogesterone acetate (MAP)(Barnes and 
Meyer, 1964; Hayden et al., 1989; Keskin et al., 2009; Loretti et al., 2004; 
Oguge and Barrell, 1996) 
Rat; rabbit; 
cat; dog 
Reduced ovulation rate; ‡cessation of ovulation; 
impairment of gestation or parturition; foetal 
death ‡endocrine disruptor 
Abnormal mammary gland growth; ovarian 
cysts; pyometra; cystic endometrial 
hyperplasia 
3-Methylcholanthrene (3-MC) (Kappeler and Hoyer, 2012; 
Mark-Kappeler et al., 2011a) 
Mouse 
Depletion of primordial and primary ovarian 
follicles via necrosis 
‡Carcinogenic; ovarian tumours 
1,4-Di(methanesulfonoxy)-butane (busulfan; 
Myleran) (Bishop and Wassom, 1986; Kappeler and Hoyer, 2012; 
Mark-Kappeler et al., 2011a) 
Mouse; rat 
Destruction of oocytes within small follicles; 
depletion of all ovarian follicle types 
Cytotoxicity; teratogenic; mutagenic; 
hematopoietic depletion; 
Trimethylenemelamin (TEM) (Kappeler and Hoyer, 2012; 
Mark-Kappeler et al., 2011a) 
Mouse Destruction of oocytes within small follicles ‡Mutagenic; ‡carcinogenic; ovarian tumours 
4-Vinylcyclohexene diepoxide (VCD) (Kappeler and 
Hoyer, 2012; Mark-Kappeler et al., 2011a; NTP, 1986) 
Mouse; rat 
Depletion of primordial and primary ovarian 
follicles; ovarian and uterine atrophy 
ΔHyperplasia of the forestomach; Δtoxic 
nephrosis 
 
2
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Of all the known ovotoxic chemicals one in particular, VCD, has been singled out as a model chemical 
for studying ovarian toxicity (Hoyer and Sipes, 1996; Kappeler and Hoyer, 2012; Van Kempen et al., 
2011). VCD, a cyclohexene formed during synthesis of industrial chemicals, is an epoxide metabolite 
of its parent compound, VCH (Figure 2.5). Toxicology studies have shown that a short duration of 
treatment with VCD (3-30 days) specifically targets and depletes the pool of primordial and small 
primary ovarian follicles in rode  ts (Figures 2.2 and 2.6) (Devine et al., 2004; Kao et al., 1999; Mayer 
et al., 2001; Mayer et al., 2002; Sahambi et al., 2008; Smith et al., 1990b). In addition, short duration 
treatment with VCD in rodents results in minimal to nil effects on other organs such as the liver, 
spleen, kidneys, and adrenal glands (Burd, 2009; Haas et al., 2007; Mayer et al., 2004; Mayer et al., 
2010; Muhammad et al., 2009; Sahambi et al., 2008). Reduced ovarian and uterine weights in rodents 
following VCD treatment have been reported (Lohff et al., 2005; Lohff et al., 2006; Mayer et al., 
2004; Mayer et al., 2002; Muhammad et al., 2009; Sahambi et al., 2008) although these are likely 
downstream effects resulting from loss of the ovarian follicle pools and disruption of the HPG axis 
(Figure 2.3).  
 
 
Figure 2.5 Metabolic pathway of VCH and VCD. VCH: 4-vinylcyclohexene; VCD: 4-vinylcyclohexene 
diepoxide; CYP450: cytochrome P450; EH: epoxide hydrolase; GST: glutathione S-
transferase. Adapted from Salyers (1995). 
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Figure 2.6 Ovary schematic depicting the follicular stages and the downstream effects of VCD. 
Histological images, adapted from Mayer et al. (2004), are representative images for a 
(A) healthy and (B) VCD-treated ovary of an adult Sprague Dawley rat. The schematic 
of follicle types within the ovary (C; images not drawn to scale) depicts the order in 
which follicles mature from the most immature (primordial) to pre-ovulatory (antral) 
as well as the post-ovulatory structures (corpus luteum, corpus albicans).   
 
In order to simulate human worker exposure the National Toxicology Program (NTP) investigated the 
toxicological effects and carcinogenic activity of VCD over a 14-day, 13-week, and 2-year study in 
male and female rats and mice (NTP, 1986). The most prevalent effects were following 2 years of 
daily gavage with VCD (200 or 400 mg/kg/day) which included forestomach hyperplasia, adenomas 
and carcinomas, ovarian neoplasms and death. The NTP concluded that there was clear evidence for 
VCD-induced carcinogenicity following chronic exposure to the chemical (NTP, 1986). However, 
such extreme dosing regimens are not required to induce ovarian senescence; rather acute, short 
duration treatment is sufficient with no reported mutagenic or carcinogenic side-effects (Burd, 2009; 
Haas et al., 2007; Mayer et al., 2004; Mayer et al., 2010; Muhammad et al., 2009; Sahambi et al., 
2008). Therefore, concern for its potential carcinogenic properties is not warranted for use of VCD as 
an ovotoxic model or chemosterilant. A large body of work has been dedicated to understanding 
VCD’s follicle-depleting mode of action and its metabolic pathways. Here I will review the current 
body of knowledge on VCD with focus on its use as a potential chemosterilant for pest mammals.   
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VCD: method of action  
Studies in rodents to elucidate the mode of action of VCD-induced follicular depletion initially 
determined that VCD treatment increases the natural process of atresia (Fernandez et al., 2008; Hu et 
al., 2001a; Hu et al., 2001b; Hu et al., 2006; Kao et al., 1999; Mayer et al., 2002; Springer et al., 
1996a; Takai et al., 2003). The selective nature of VCD ovarian toxicity is believed to be due to the 
poor ability of primordial and primary follicles to convert VCD to its inactive tetrol metabolite (Flaws 
et al., 1994). VCD treatment increases the expression and activation of bax and Bad (proteins that 
promote apoptosis), caspase-3 (a proteolytic enzyme present during induction of apoptosis), and 
mitogen activated protein kinases (MAPKs which are associated with intracellular signalling pathways 
for apoptosis) (Hoyer et al., 2001; Hoyer and Sipes, 2007). However, more recent findings suggest that 
these effects may reflect downstream responses to VCD induced ovarian toxicity rather than initiating 
effects (Figure 2.7) (Fernandez et al., 2008; Keating et al., 2009; Keating et al., 2010; Mark-Kappeler 
et al., 2010; Mark-Kappeler et al., 2011b).   
 
 
Figure 2.7 Currently proposed VCD method of action in primordial and primary follicles. Adapted 
from P. J. Devine (unpublished). 
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Fernandez et al. (2008) examined cell survival signal pathways in immature follicle populations of 
post natal day (PND) 4 Fischer 344 rat ovaries following in vitro exposure to VCD. Findings revealed 
that VCD treatment reduced oocyte-derived Kit mRNA, a pro-survival gene, which preceded an 
increase in granulosa cell-derived Kitl mRNA (Fernandez et al., 2008). The ligand for KIT, KITL is 
produced in granulosa cells and is able to initiate folliculogenesis, stimulate oocyte and primordial 
follicle development, and act as an antiapoptotic factor on primordial follicles. These findings suggest 
that the oocyte may be initially affected by VCD and as a feedback response to decreased oocyte 
survival signals the granulosa cells produce more KITL. Furthermore, addition of exogenous KITL 
resulted in a dose-dependent attenuation of VCD-induced primordial follicle loss, supporting the 
suggestion that VCD compromises the KIT/KITL survival signalling pathway of primordial and 
primary follicles (Figure 2.7) (Fernandez et al., 2008).   
A study was conducted to determine if KIT was directly targeted by VCD as the ovarian toxic 
mechanism in immature follicles (Mark-Kappeler et al., 2011b). Results demonstrated that a change in 
KIT receptor phosphorylation is an initial and critical component of VCD-induced ovarian toxicity, 
supporting previously reported findings (Figure 2.7). Furthermore, the high expression of oocyte 
derived KIT and granulosa cell derived KITL during immature follicle growth helps to explain and 
support evidence for the ability of VCD to target primordial and primary follicle populations while not 
affecting other tissues in the body. Although other tissues expressing KIT may be a target of VCD, 
such tissues are able to repair themselves whereas primordial follicles are incapable of being replaced 
following cellular destruction. This may explain why there are no observed long-term effects in other 
tissues following VCD exposure and, hence, the physiological specificity of VCD on immature follicle 
populations.  
To examine further the role of VCD in the KIT/KITL signalling pathway, Keating et al. (2009) studied 
the role of phosphatidylinositol-3 kinase (PIK3) inhibition on VCD induced ovarian toxicity (Figure 
2.7). KIT activates the PIK3 kinase signalling pathway which has been shown to activate and recruit 
immature follicles (Reddy et al., 2005). Using LY294002 to inhibit the PIK3 signal pathway, the 
primordial follicle pool was protected from VCD-induced follicle loss while primary follicle numbers 
were depleted. The authors concluded that primordial follicles are not the direct target of VCD; rather 
VCD targets and destroys small primary follicles, resulting in increased recruitment of primordial 
follicles into the primary follicular pool (Keating et al., 2009). In fact, Mark-Kappeler et al. (2010) 
demonstrated supporting results when examining anti-Müllerian hormone (AMH) protein expression 
during VCD treatment. AMH protein is expressed in granulosa cells of maturing primary follicles and 
inhibits primordial follicle recruitment into the growing follicle pool. Results showed that AMH 
protein expression was reduced following VCD treatment. The authors concluded that the reduced 
expression of AMH protein following VCD treatment may be contributing to the acceleration of 
primordial follicle recruitment thought to be caused by VCD (Mark-Kappeler et al., 2010).    
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To elucidate further the role of PIK3 and its downstream signal pathway members, Keating et al. 
(2010) examined time points prior to VCD-induced ovarian toxicity in vitro using post natal day 
(PND) 4 Fischer 344 rat ovaries. Their results demonstrated that the initial effects of VCD are a result 
of altered sub-cellular oocyte-derived distributions of KIT protein and two downstream signals of 
PIK3, phosphorylated AKT (pAKT) and forkhead transcription factor family (FOXO3) proteins 
(Figure 2.7). AKT has been shown to play an important role in the PIK3 signalling pathway and 
FOXO3 is involved in regulation of primordial follicle recruitment (Castrillon et al., 2003; Reddy et 
al., 2005). VCD-induced ovarian toxicity was not associated with changes in mRNA encoding the Kit, 
Akt1, and Foxo3 genes. Therefore, it seems that VCD is targeting the post-translational protein 
signalling pathway and that any decrease in gene transcription is a subsequent response. Overall, these 
findings seem to indicate that VCD-induced ovarian toxicity is targeting the oocyte rather than 
granulosa cells in primordial and primary follicles (Keating et al., 2010).  
VCD: metabolism and detoxification   
4-Vinylcyclohexene (VCH), the parent compound of VCD, is metabolized to VCD in a Phase I 
reaction (also referred to as biotransformation) primarily by the hepatic-derived enzyme superfamily 
cytochrome P450 (CYP450) (Doerr-Stevens et al., 1999; Doerr et al., 1996; Springer et al., 1996c) 
(Figure 2.5). Phase I metabolism is usually a prerequisite for Phase II conjugative metabolism (also 
known as detoxification) wherein lipophilic compounds are converted to more water-soluble 
metabolites for excretion (Rushmore, 2002; Xu et al., 2005). Through Phase II reaction, VCD is 
further metabolized in the liver and, to a lesser extent, in the ovary to a non-active tetrol metabolite 
([1,2-dihydroxy] ethyl-1,2-dihydroxycyclohexane) (Figure 2.5) though the action of microsomal 
epoxide hydrolase (mEH) and glutathione-S-transferase (GST) (Cannady et al., 2002; Devine et al., 
2001; Flaws et al., 1994; Keating et al., 2008a; Keating et al., 2008b; Salyers, 1995). mEH catalyses 
the hydration of alkene epoxides and arene oxides while GST catalyses glutathione (GSH) conjugation 
with compounds to increase their elimination from the body.  
It has been hypothesized that VCD ovarian toxicity is largely due to repeat exposure, thereby 
overwhelming and ultimately reducing the capacity of the detoxifying enzymes. Keating et al. (2008a) 
demonstrated in vitro that continual exposure to VCD in B6C3F1 mouse ovaries initially increases 
expression of GST enzymes (day 4). However, by day 6 to 8 there was no change in GST expression 
compared to controls, suggesting the overwhelming nature of repeated VCD treatment on the ovarian 
detoxifying pathways (Keating et al., 2008a). In a follow-up study, the authors demonstrated GST’s 
ability to down regulate pro-apoptotic activity, thereby increasing its protective role in the ovary 
(Keating et al., 2008a). It was revealed that GSTp is able to form a protein complex with the pro-
apoptotic c-jun N-terminal kinase (JNK) and its downstream molecule c-jun, thereby down-regulating 
their activity (Hu et al., 2002; Keating et al., 2010). Collectively these studies suggest that the VCD 
can be readily detoxified. However, with repeated or continual exposure, the detoxifying enzymes can 
become overwhelmed, allowing VCD-induced ovarian toxicity to surpass enzymatic activity.    
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Species differences in VCD uptake and metabolism have been demonstrated in laboratory-bred mice 
and rats (Kao et al., 1999; Keller et al., 1997; Salyers, 1995; Smith et al., 1990a; Smith et al., 1990b). 
It has been demonstrated that VCD distributes faster from the blood into the tissues of mice compared 
with rats while excretion of VCD metabolites was primarily through the urine in both species (Salyers, 
1995; Smith et al., 1990a). In addition, VCD metabolites are eliminated faster in rats and the urinary 
metabolite profile of each species suggests different pathways for VCD metabolism (Salyers, 1995; 
Smith et al., 1990a). Comparison of enzymatic metabolism of VCH and VCD revealed that mice have 
higher Phase I metabolic activity but slower Phase II activity rates compared with rats, resulting in the 
capability of mice to metabolise VCH faster than rats. As VCH is detoxified to VCD via CYP450, 
VCD accumulates faster in mice compared with rats due to their slower Phase II activity and are mice 
are therefore more susceptible to VCD-induce ovarian toxicity (Doerr-Stevens et al., 1999; Doerr et 
al., 1996; Smith et al., 1990a; Smith et al., 1990b).  
VCD: effective oral fertility control method?  
In order for VCD to be an effective fertility control agent for pest species it must be deliverable by an 
oral route. In an assessment of VCD as a potential fertility control management strategy, several 
studies have examined the effects of oral VCD administration on the fertility of female rats (Burd, 
2009; Herawati et al., 2010). Two paired long-term breeding studies examined oral VCD 
administration effects on the fertility of female SD rats and their in utero exposed female offspring 
(Burd, 2009). Primordial follicle counts from pregnant females orally dosed with 500 mg VCD/kg for 
10 days (gestational days 8-17) were reduced by 82% compared with controls. When exposed in utero 
to VCD, female offspring primordial follicle counts were reduced by 28% and 31-35% of controls 
(500 mg VCD/kg, gestational days 6-20 and 8-17, respectively) (Burd, 2009). It is well understood 
that the biological properties of the placenta allow small (<1000 g/mol), lipid-soluble molecules, such 
as VCD (140.14 g/mol), to cross rapidly in a flow-dependent manner (Morgan, 1997). Thus, the 
properties of VCD would suggest that placental transfer of the chemical would occur readily. The 
follicle reducing effects of VCD have also been examined on outbred wild population of female 
ricefield rats (R. argentiventer). Results demonstrated that 15 days of oral gavage with VCD (0, 500 or 
750 mg/kg/day) caused a dose dependent decline in primordial follicle numbers (Herawati et al., 
2010).  
Effectiveness of orally delivered VCD on the fertility of male rats and mice has also been examined 
(Hooser et al., 1995; Schmuki, 2009). Male mice intraperitoneally injected with VCD (40 – 320 
mg/kg/day; 5 – 30 days) had reduced testicular weights and testicular damage. Cessation of treatment 
resulted in recovery of the testicular tissue (Hooser et al., 1995) suggesting that if fertility effects had 
occurred, such effects were likely reversible. Fifteen days of oral VCD gavage (500 mg/kg/day) 
caused SD rat testicular and epididymal weights to increase (day 47 post-treatment). No effects on 
reproductive function of treated males were reported (Schmuki, 2009). These findings in male rodents 
are not surprising considering the continual nature of the spermatogenesis cycle (Clermont, 1972; 
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Clermont and Harvey, 1967) and demonstrate VCDs specificity in its permanent sterilizing effects on 
female reproduction.   
As previously mentioned, researchers at SenesTech Inc
®
 (Flagstaff, AZ, USA) have established 
efficacy of the chemosterilant bait, ContraPest
®
, at reducing the immature and pre-antral follicle pools 
in adult female SD rats. The current formulation of ContraPest
®
 contains both VCD and TR. 
Therefore, because TR is known to reduce male and female fertility (e.g. oligozoospermia and 
asthenozoospermia) (Huynh et al., 2000; Lue et al., 1998; Qian et al., 1986; Qian et al., 1988; Zhen et 
al., 1995), this may provide an additional avenue for the control of pest mammals.        
Recently, VCD’s use as a chemosterilant for Australian and NZ marsupials has been proposed. 
Although the timing of follicle development and maturation in marsupials and rats is different (as 
previously discussed in section 2.5), the underlying events are similar. Therefore, it can be postulated 
that VCD-induced primordial follicle depletion observed in rodents may have an equivalent effect in a 
marsupial species. To date, there is only one published report on the effects of VCD in marsupials 
(Koehn, 2008). Adult female and male tammar wallabies (Macropus eugenii) were treated with 
subcutaneous (s.c.) injections of 0, 46 or 183 mg VCD/kg/day for 15 days (n = 5-6/treatment) or with 
intramuscular (i.m.) injections of 0 or 100 mg/kg/day VCD for 9 and 15 days (n = 2-3/treatment). 
There were no changes in the primordial follicle pool of treated animals which may, in part, be due to 
the low robustness of the study (i.e. low sample size) or the route of administration. In addition, 
injection site reactions occurred in all VCD treated groups (males and females), requiring cessation of 
treatment on day 5 in one group (183 mg VCD/kg/day) (Koehn, 2008). Considering the severity of 
injection site reactions in captive wallabies, investigation of the possibility for an oral route of VCD 
administration is warranted for wild-dwelling marsupials such as the NZ brushtail possum.  
 Summary 2.7
There is an on-going need for sustainable, effective, humane and affordable methods of pest control in 
NZ. The chemosterilant VCD could potentially satisfy such needs as it is an orally active compound 
that causes permanent infertility in female mammals. The purpose of the studies reported here was to 
examine the effects of orally delivered VCD on wild-caught adult female possums’ health, internal 
organs and immature ovarian follicle populations. Potential species differences in the fate and 
metabolism of VCD were also examined in vivo and in vitro in wild female rats and possums. In 
addition, the palatability and follicle depleting effectiveness of ContraPest
® 
(SenesTech Inc
®
) was 
tested in wild-caught female Norway rats.  
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Chapter 3 
General Methodology  
 Reagents 3.1
4-Vinylcyclohexene diepoxide (batch # BCBB9360 and BCBC1500) was purchased from Sigma-
Aldrich (Auckland, NZ; cat. 94956). Sunfield sunflower oil, used as a carrier liquid for VCD and for 
vehicle control, was purchased from Tasti Products Ltd (Auckland, NZ). Cyclohexanone, purchased 
from May and Baker LTD, Dagenham, England (cat. BC00595) and 4-vinyl-1-cylohexene 1,2-epoxide 
(VCH 1,2-isomer; lot #MKBL783V; cat. 106-86-5) were used as internal standards for gas 
chromatography. Ethyl acetate, used to extract VCD and its metabolites, was obtained from Fisher 
Scientific (cat. 141-78-6). Attane™ isoflurane, purchased from Bomac Laboratories Ltd (Auckland, 
NZ; cat. 26675-46-7), was used as a general inhalation anaesthetic during gavage procedures. Sodium 
pentobarbital, used as the euthanizing agent, was purchased from ProVet (Auckland, NZ).   
 Animals  3.2
Mature female brushtail possums (live weight 2.5 - 4.0 kg) and Norway rats (live weight 100 - 300 g) 
were captured in North Canterbury, NZ using cage traps set along farmland-bush margins. Animals 
were housed and acclimatized indoors for 4 - 6 weeks in individual cages with constant temperature 
(20 ± 5°C) and a light:dark cycle that followed the external environmental photoperiod. On a daily 
basis, animals were provided with cereal-based pellets formulated for possums or rats (CRT Reliance 
Feeds, Rolleston, NZ), fresh fruit and vegetables and water ad libitum. All experimental procedures 
were carried out with the approval of the Animals Ethics Committee of Landcare Research, Lincoln 
and in accordance with Part 6 of the New Zealand Animal Welfare Act 1999. 
 Glutathione analysis 3.3
Glutathione (GSH) activity levels in red blood cells (RBCs), plasma and hepatic (liver) and ovarian 
tissues were analysed using methods described in the GSH assay kit (Sigma, cat# CS0260) with the 
following changes: a stock solution of 10 mM GSH was stored in aliquots for up to 3 months at -20°C 
and then diluted down to create the GSH standards as needed; 96-well plates were kept on ice until 
commencement of the 5 min incubation; the plate was shaken for 5 seconds prior to absorbency 
reading to ensure even distribution of sample and reagents; the plate reader was kept at 37°C during 
readings. To reduce enzymatic degradation, all samples were slowly defrosted on ice prior to analysis 
and all samples were run in triplicate. Total GSH content (nmol/µL or mg tissue) in each sample was 
calculated using the following formula: [ΔA412/min(sample) * dil]/[ΔA412/min(1 nmole) * vol] where 
ΔA412/min(sample) is the slope generated by the sample with background absorbency removed;  
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ΔA412/min(1 nmole) is the slope generated from the standard curve for 1 nmole of GSH; dil is the 
dilution factor of the original sample; and vol is the volume (mL) of sample in the reaction. Final GSH 
concentrations were then converted to µmol and multiplied by the 5-sulfosalicylic acid (SSA) dilution 
factor (RBCs and plasma, 1x; liver and ovary, 28x) to achieve µmol GSH per µL or mg of tissue. For 
details on the GSH standard curve please refer to section 3.6.1.   
 Gas chromatography assay sample preparation 3.4
VCD and its metabolites were extracted and quantified on gas chromatography (GC) by placing 
samples into glass scintillation vials and then VCD extracted by the addition of two times the sample 
volume of ethyl acetate (EA) containing an internal standard. In three successive rounds, samples were 
vortex mixed for 30 seconds and then shaken for 10 minutes at 200 rpm. Phases were separated by 
centrifugation at 3,000 x g for 10 minutes and the organic layer analysed for VCD quantification as 
outlined in section 3.5.  
 Gas chromatography analysis 3.5
VCD quantification in biological samples was achieved utilizing a 6890N Network GC (Agilent 
Technologies) equipped with a DB5-ms column (60 m x 0.25mm; J&W Scientific, Folsom, CA) and a 
flame ionization detector (FID). The nitrogen carrier gas flow rate was 0.5ml/min. The FID gas flow 
rates for hydrogen and air were 50 and 400 ml/min respectively, with a combined flow of 60ml/min. 
Split injection was used with a split ratio of 20:1, a spit flow of 10.5 ml/min and a total flow of 13.6 
ml/min at 15 psi. The injection volume was 1.0 µL. The initial oven temperature was held at 100°C 
and then ramped up to 130°C at a rate of 2°C/min and held at the final temperature of 200°C at a rate 
of 13°C/min for 15 minutes. The injection and detector temperatures were held at 250°C and 280°C, 
respectively. VCD chromatography revealed two peaks. Thus, VCD was quantified by first adding 
together the area under the curve (AUC) for each VCD peak. Total VCD AUC and the internal 
standard AUC were then compared against the standard curve of each corresponding analyte for total 
VCD recovery and correction factors for loss due to methods. The retention times for the analytes 
were as follows: VCD peak 1, 10.8 min; VCD peak 2, 11.0 min (Figure 3.1); VCH, 2.7 min (Figure 
3.2); VCH 1,2-isomer, 4.7 min (Figure 3.3); cyclohexanone, 3.4 min (Figure 3.4); ethyl acetate, 2.0 
min (Figures 3.1 – 3.4). All samples were run in triplicate. The practical quantitation limit (PQL) for 
VCD was 0.371 mM. For details on the VCD and internal standard curve and assay validation test 
refer to section 3.6.2. 
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Figure 3.1 Representative image of a gas chromatograph of 4-vinylcyclohexene diepoxide (VCD; 
0.913 mM). VCD peak 1, 10.825 minutes; VCD peak 2, 11.014 minutes; ethyl acetate, 
2.049 minutes. 
 
 
Figure 3.2 Representative image of a gas chromatograph of 4-vinylcylohexene (VCH; 0.87 mM). 
VCH, 2.738 minutes; ethyl acetate, 1.937 minutes. 
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Figure 3.3 Representative image of a gas chromatograph of 4-vinyl-1-cylohexene 1,2-epoxide (VCH-
isomer; 1.05 mM). VCH-isomer, 4.77 minutes; ethyl acetate, 2.049 minutes. 
 
 
Figure 3.4 Representative image of a gas chromatograph of cyclohexanone (1.18 mM). 
Cyclohexanone, 3.4 minutes; ethyl acetate, 2.05 minutes.  
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 Preparation of standard curves 3.6
3.6.1 GSH 
Standard GSH samples were created by diluting a stock solution of GSH (10 mM in ultrapure water; 
w/v) with a 5% solution of 5-sulfosalicylic acid, creating a standard GSH range from 0.78 to 50 µM. 
All standards were run in duplicate and were made fresh for each run. The standard curve was 
generated by subtracting the background absorbency from each standard absorbency reading and then 
the average absorbency of each standard pair was calculated and graphed against the standard 
concentration range (Figure 3.5).  
 
 
Figure 3.5 Representative image of a standard curve for glutathione (GSH). 
 
3.6.2 VCD, VCH and VCH 1,2-isomer 
For each chemical, standards were made up fresh for each run in EA and then diluted down to the 
desired concentration. All standards were run in triplicate. For the standard curve for each chemical, 
refer to Figures 3.6 to 3.9.   
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Figure 3.6 Representative image of standard curves for upper 4-vinylcyclohexene diepoxide (VCD) 
concentration range (A; 5.0 – 100 mg/mL) and lower VCD concentration range (B; 5.0 – 
1000 µg/mL).   
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Figure 3.7 Representative image of a standard curve for 4-vinylcyclohexene (VCH). 
 
 
Figure 3.8 Representative image of a standard curve for 4-vinyl-1-cylohexene 1,2-epoxide (VCH 1,2-
isomer). 
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Figure 3.9 Representative image of a standard curve for cyclohexanone. 
 
 Histology and Follicle Analysis 3.7
For each species, ovaries were trimmed of fat, weighed and placed into 10% neutral-buffered formalin 
solution for 48 hours and then transferred to 70% ethanol until processing. Ovaries were paraffin-
embedded, serially sectioned (5 µm), mounted, and stained with Harris hematoxylin and Eosin Y (1%) 
prior to cover-slip application. Ovarian follicles were counted in every 20
th
 section to avoid double 
counting of larger follicles. To ensure consistency, follicles were assessed by the same examiner who 
was blinded to experimental conditions. Follicles were identified based on the following criteria: 
primordial (oocyte surrounded by a single layer of ≥ 50% elongated flattened granulosa cells; rat, ≤ 
20µm diameter; possum, ≤ 60 µm diameter; Figure 3.10); primary (oocyte surrounded by a single 
layer of ≥ 50% cuboidal granulosa cells; rat, 20-70 µm diameter; possum, 60-200 µm diameter; Figure 
3.11); secondary (oocyte surrounded by two or more layers of cuboidal granulosa cells as well as a 
somatic layer that may or may not contain a fluid filled antrum with a diameter less than the oocyte; 
rat, 70-390 µm diameter; possum, 200-450 µm diameter; Figure 3.12); and antral (oocyte surrounded 
by multiple layers of granulosa cells containing a fluid filled antrum with a diameter larger than the 
oocyte; rat, 80-320 µm diameter; possum, > 450 µm diameter; Figure 3.13) (Hirshfield and Midgley 
Jr, 1978; Pedersen and Peters, 1968). The corpus luteum (CL) was comprised of healthy, uniformly-
sized luteal cells (rat, >320 µm diameter; possum, >4 mm diameter; Figure 3.14). Total primordial and 
primary follicle counts were estimated using a correction factor formula (Gougeon and Chainy, 1987) 
as follows: Nt = (N0 x St x ts)/(S0 x d0) where Nt : total number of follicles, N0 : number of follicles 
observed in the ovary, St : total number of sections in the ovary, ts : thickness of the section (µm), S0 : 
total number of sections observed, and d0 : mean diameter of the nucleus of that follicle type. Counts 
for secondary and antral follicles and copora lutea were directly collated.   
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Figure 3.10 Representative image of primordial ovarian follicular structures (T. vulpecula, x40). 
Primordial follicles were classified as an oocyte surrounded by a single layer of 
elongated flattened granulosa cells; rat, ≤ 20µm diameter; possum, ≤ 60 µm diameter. 
Oocyte (oo); nucleus (nu); granulosa cells (gc). 
 
 
Figure 3.11 Representative image of primary ovarian follicular structures (T. vulpecula, x40).  
Primary follicles were classified as an oocyte surrounded by a single layer of ≥ 50% 
cuboidal granulosa cells; rat, 20 - 70 µm diameter; possum, 60 - 200 µm diameter. 
Oocyte (oo); nucleus (nu); granulosa cells (gc). 
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Figure 3.12 Representative image of secondary ovarian follicular structures (T. vulpecula, x40). 
Secondary follicles were classified as an oocyte surrounded by two or more layers of 
cuboidal granulosa cells as well as an additional somatic layer that may or may not 
contain a fluid filled antrum with a diameter less than the oocyte; rat, 70 - 390 µm 
diameter; possum, 200 - 450 µm diameter. Oocyte (oo); nucleus (nu); nucleolus (no); 
granulosa cells (gc). 
 
 
Figure 3.13 Representative image of antral follicular structures (T. vulpecula, x25). Antral follicle 
were classified as an oocyte surrounded by multiple layers of granulosa cells 
containing a fluid filled antrum with a diameter larger than the oocyte; rat, 80 - 320 
µm diameter; possum, > 450 µm diameter. Oocyte (oo); nucleus (nu); antrum (an); 
granulosa cells (gc). 
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Figure 3.14 Representative image of corpus luteum (CL) within possum (T. vulpecula) ovarian tissue 
(x10). A CL was classified as a postovulatory follicle containing luteal cells; AF: antral 
follicle; rat, >320 µm diameter; possum, >4 mm diameter. 
 
 Statistical analysis  3.8
Statistical significance was established at α=0.05. Normally distributed data were analysed by 
Student’s t-test or one-way ANOVA (analysis of variance). Tests for normality (Shapiro-Wilk) and 
variance (Levene) were performed to ensure that ANOVA assumptions were not violated. Non-
normally distributed data were analysed using a Mann-Whitney or Kruskall-Wallis test. Where 
appropriate, Box-Cox transformations were performed for non-normally distributed data. All data 
were analysed in using JMP® 10.2 (SAS, Cary, NC) software. Data are presented as means ± SEM 
(standard error of the mean).  
  41 
Chapter 4 
Effects of orally delivered 4-vinylcyclohexene diepoxide on the 
health and ovarian follicle populations of female brushtail possums  
 Introduction 4.1
Throughout New Zealand the brushtail possum (Trichosurus vulpecula) poses a serious threat to 
native fauna and flora and, through its role as a primary vector of the disease, bovine tuberculosis, to 
the health of domestic livestock and feral game species (Cowan, 2005). Current methods for control 
include poisons and trapping. Although effective in the short-term, there are public concerns about the 
animal welfare and environmental impacts of conventional lethal control methods (PCE, 2011). New 
cost-effective and more humane approaches to possum control are needed. 
Fertility control has received much interest as an alternative and more publicly acceptable method of 
pest control.  One approach is to utilize chemicals that specifically target the reproductive function of 
pest species and can induce permanent sterility (Marsh and Howard, 1970; Mauldin and Miller, 2007). 
4-Vinylcyclohexene diepoxide (VCD), an organic compound formed during industrial processes and 
used as a reactive diluent for diepoxides and epoxy resins, shows potential as a chemosterilant in 
mammals. Toxicology studies in rodents have shown that VCD reduces the pool of primordial ovarian 
follicles, resulting in a rapid onset of ovarian senescence and permanent sterility (Kao et al., 1999; 
Springer et al., 1996b; Springer et al., 1996c).  
VCD-induced reductions in immature follicle populations have primarily been achieved via injection 
(intramuscular or intraperitoneal) of the chemical (Hoyer and Sipes, 2007). However, to utilize VCD 
as a fertility control agent for pest species, an oral route for exposure will be essential. A paired 
reproductive study demonstrated that 10 days of VCD treatment (500 mg/kg/d) during gestation 
caused an 82% depletion of parental dam primordial follicles compared with controls. Additionally, 
offspring exposed in utero to 10 or 15 days of VCD (500 mg/kg/d) had a 28% and 31-35% reduction 
in primordial follicles compared with controls, respectively (Burd, 2009). Oral dosing of female 
Sprague Dawley laboratory rats with 500 or 750 mg/kg VCD for 15 consecutive days caused 58% and 
88% depletion of primordial follicles, respectively (Dr. L.A. Hinds, CSIRO, Australia, unpublished 
data).  Orally administered VCD has also been demonstrated to reduce the immature follicle pool in 
wild ricefield rats (R. argentiventer) in a dose dependant manner (Herawati et al., 2010). Collectively, 
these studies demonstrate that VCD can reduce the immature follicle populations in rodents through 
the oral route of delivery.  
To date, no studies on the efficacy of orally-delivered VCD have been undertaken in marsupial species 
such as the brushtail possum. The purpose of the studies reported here was to: 1) investigate the effects 
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of orally administered VCD on the health and ovarian follicle populations of adult female possums; 2) 
identify the optimal dosage and duration of treatment to induce primordial follicle depletion; and 3) 
identify formulations to improve the efficacy of orally delivered VCD in adult female possums.  
 Materials and Methods 4.2
4.2.1 Reagents 
VCD, sunflower oil, Attane™ isofluorane, and sodium pentobarbital were obtained from vendors and 
used for experimental procedures as previously outlined in Chapter 3. Quick-EZE
®
 tablets (780 mg 
CaCO3, 130 mg Mg CO3 and 130 mg Mg2O8Si3 per tablet), used as an antacid pre-treatment, were 
obtained from Nestle (Auckland, NZ). Intralipid
®
 (20% fat emulsion containing glycerol, 22.3 g/L; 
triglycerides, 202 g/L; and phospholipids, <0.5 g/L), a sterile lipid emulsion, was used as a gavage 
carrier liquid and was purchased from Pharmatel (Auckland, NZ; cat. 835041-54). Liquid carbon 
dioxide, purchased from BOC (Christchurch, NZ), was used to freeze teeth to the microtome base for 
aging analysis. 
4.2.2 Animal procedures  
For each study, possums were randomly allocated into treatment groups using a randomized block 
design stratified by live weight prior to trial start. Under anaesthesia (5% isoflurane in O2 at 2 L/min) 
blood samples (2-3 mL) were collected from the ventral tail vein prior to trial start and on the final 
treatment day and plasma was stored at -20°C for analysis (see section 4.2.4). Possums were 
anesthetized daily and, once lightly sedated, gavaged with control or treatment solution (3.5 – 8.5 mL). 
Gavage tubes consisted of commercially purchased vinyl tubing (ID 3 mm, OD 5 mm, 30 cm long) 
attached to a 3-way stop cock and a 10 mL syringe. For each treatment group one tube was used and 
tubes were discarded daily. Live weight was measured daily prior to treatment to adjust VCD dose and 
monitor general animal health during the study. In an attempt to minimize handling and anaesthetic 
stress, possums were prepared for anaesthesia by transferring each possum in their nest box to the 
treatment area. Isofluorane was administered through a tube directly into the nest box. Following 
treatment, possums were placed back into their nest box and transferred into their cage before 
regaining consciousness, thus allowing the animal to wake naturally in a safe and familiar 
environment. Animals were visually monitored for up to 4 hours post-treatment.  
Treatment protocol for Study 1 
Animals were gavaged daily for 13 days with sunflower oil (vehicle control, n = 8), or a low dose of 
VCD (500 mg/kg mixed 1:3 w/v) in oil (n = 8) or a high dose of VCD (750 mg/kg mixed 1:3 w/v) in 
oil (n = 8). The treatment duration and selected doses were based on previous rodent studies 
demonstrating significant immature follicle depletion following oral treatment (Burd, 2009; Herawati 
et al., 2010).  
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Treatment protocol for Study 2 
To improve the effectiveness of oral VCD two new formulations were tested. These included a 
lipoprotein formulation (Intralipid
®
 20%) shown to improve uptake and palatability of VCD in rodents 
(Dr. C. A. Dyer, SenesTech Inc., USA, pers. comm.) and the use of antacids (Quick-EZE
®
 tablets) to 
reduce the breakdown of VCD to its inactive tetrol metabolite by acid conditions in the stomach. Both 
formulations were predicted to increase the uptake and effectiveness of VCD. Animals were gavaged 
daily for 10 days in 2 blocks of 5 days with 2 rest days between treatment phases. Control groups 
included (1) 2.05 mL/kg  lipoprotein solution (Intralipid 20%; n = 6), (2) 3.0 mL antacid pre-treatment 
solution (containing 1.275 g of powdered Quick-EZE
®
 tablets; 956.3 mg CaCO3, 156.8 mg Mg CO3, 
156.8 mg Mg2O8Si3) suspended in distilled water followed by 2.05 ml/kg sunflower oil (n = 6), or (3) 
2.05 ml/kg sunflower oil only (n = 6). Hereafter control treatment groups will be reported as C-IT 
(group 1), C-QE (group 2), and C-O (group 3). VCD treatment groups included (1) 750 mg VCD/kg 
mixed 1:3 (w/v) in lipoprotein solution (n = 10) or (2) 3.0 mL antacid pre-treatment solution 
(containing 1.275 g powdered Quick-EZE® tablets suspended in distilled water) followed by 750 mg 
VCD/kg mixed 1:3 (w/v) in sunflower oil (n = 10). Hereafter VCD treatment groups will be reported 
as VCD-IT (group 1) and VCD-QE (group 2).  
4.2.3 Tissue collection 
Prior to euthanization, intracardiac blood was collected into lithium heparinised tubes and then 
animals were euthanized with an intracardiac injection of pentobarbitone (125 mg/kg) and the 
following tissues excised, trimmed of fat, weighed and examined for gross pathology: complete 
reproductive tract, ovaries, liver, kidneys and adrenal glands. In addition, the length and width of each 
uterus, vaginal culs-de-sac and ovarian follicles (>1 mm) were recorded. Unovulated follicles and 
ovulation sites were enumerated. Ovaries, adrenal glands, kidneys and a portion of the liver were fixed 
in 10% buffered-neutral formalin solution for histological analysis.  
4.2.4 Inductively coupled plasma optical emission spectrophotometer analysis 
To determine if calcium toxicity was occurring following the pre-treatment with antacid, total calcium 
(Ca) and magnesium (Mg) were measured in pre- and post-treatment plasma collected from Study 2 
animals. Plasma samples were diluted 1:5 (w/v) with ultrapure water to for analysis preparation. 
Samples were analysed with an axially aligned inductively coupled plasma optical emission 
spectrophotometer (ICP-OES) (Varian 720, Mulgrave, Australia). The ICP ultrasonic seaspray 
nebulizer and cyclonic spray chamber operating conditions and flow injection system used are listed in 
Table 4.1. Calibration standards and internal standards were serially diluted from Merck ICP standard 
solutions.  
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Table 4.1 Inductively coupled plasma optical emission spectrophotometer (ICP-OES) instrumental 
parameters employed for the determination of total plasma calcium and magnesium 
concentration. 
Forward power 1.2 kW 
Nebulizer flow rate 0.9 L/min 
Plasma gas flow rate 15.0 L/min 
Auxiliary gas flow rate 1.5 L/min 
Solution uptake rate 1.0 mL/min 
Analytical wavelengths Ca: 370.6, Mg: 279.6 
 
4.2.5 Tooth cementum analysis 
To determine the age of individual possums the cementum deposition layers were counted using an 
adaptation of published methods (Clout, 1982; Pekelharing, 1970). The right mandible of each animal 
was boiled in water for 1-2 hours and the second and third molars removed. Teeth were decalcified for 
4 hours in the commercial decalcifying agent RDO (Clout, 1982) and then gently rinsed with water. 
Using a freezing microtome (Reichert Jung 1205, Vienna, Austria) 10 - 20 sections (20 µm) were cut 
serially through the cementum peninsula (central portion of tooth between the roots). Sections were 
mounted onto glass slides and air dried for 24 hours. Slides were stained with Erlich’s haematoxylin 
and water (50:50 v/v) for one hour and then gently rinsed with water and a coverslip applied. 
Cementum layers (narrow dark-staining bands) were counted at x40 or x100 magnification on 3 - 5 
sections to determine the age of each animal. To ensure consistency, cementum layers were assessed 
by a single examiner who was blinded to experimental conditions. 
4.2.6 Histology and follicle analysis 
Ovaries, liver and kidneys were trimmed of fat, weighed and then prepared for histological 
examination as previously outlined in Chapter 3. Complete blood counts were measured at Gribbles 
Veterinary (Christchurch, NZ) and analysis performed as outlined in section 4.2.8. Liver and kidney 
sections were assessed by an experienced veterinary pathologist (Gribbles Veterinary) for signs of 
abnormal pathology. The qualitative remarks were divided into 5 major categories of background 
changes for each tissue. The liver background categories included: 1) lymphocyte aggregates within 
lobules or cells (range: few; moderate; many); 2) macrophage clusters; 3) periacinar hepatocytes 
containing brown granular material (range: few; moderate; many); 4) Kupffer cells containing brown 
granular material (range: few, moderate; many); 5) hepatocytes containing brown granular material 
(range: few, moderate; many). Kidney background changes included: 1) collecting tubules containing 
dark blue granular material in lumen; 2) outer cortical, focal infiltrate of lymphocytes (range: single; 
few; many); 3) scattered granules containing black material; 4) tubules with syncytial-like cells; 5) 
tubules that lack the eosinophilia and have large nuclei. For each sample, a score ranking from 0-3 was 
applied as follows: 0 = 0 to 1 categories present; 1 = 1 to 2 categories present; 2 = 2 to 3 categories 
present; 3 = 4 to 5 categories present.  
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4.2.7 In vitro stomach pH analysis 
The effects of Quick-EZE
® 
(QE) and Intralipid
®
 (IT) on stomach pH of possums were analysed in 
vitro. Stomach contents from four female possums were pooled and the initial pH measured. Stomach 
contents were then divided into 5 gram aliquots and treated in triplicate as follows: 1) control (no 
additives); 2) low QE dose (214.0 µL); 3) high QE dose (500.0 µL); 4) low IT dose (83.0 µL); 5) high 
IT dose (123.0 µL). The low QE dose was calculated by dividing the sample size (5.0 g) by a high 
average weight of possum stomach contents (70.0 g), resulting in 7.14 % w/w. This percentage was 
then multiplied by the volume of QE dose provided in the study (3.0 mL), resulting in a 214.0 µL of 
QE spike treatment. The high QE dose was calculated by dividing the sample size (5.0 g) by a low 
average weight of possum stomach contents (30.0 g), resulting in 16.7 % w/w. This percentage was 
then multiplied by the volume of QE dose provided in the study (3.0 mL), resulting in a 500.0 µL of 
QE spike treatment.  
Intralipid treatment was calculated based on the treatment regimen outlined in study two (controls, 
2.05 mL Intralipid/kg; VCD, 2.05 mL VCD mixed 1:3 v/v with Intralipid/kg). The low dose, 
representing VCD treatment, was calculated by dividing an average VCD Intralipid dose (2.05 mL/kg 
* 3.0 kg live weight = 6.15 mL dose * 67.0 % (1:3 v/v) = 4.12 mL Intralipid) by an average weight of 
possum stomach contents (50.0 g), resulting in an 83.0 µL Intralipid spike treatment. The high dose, 
representing control treatment, was calculated by dividing an average Intralipid dose (2.05 mL/kg * 
3.0 kg live weight = 6.15 mL Intralipid) by an average weight of possum stomach contents (50.0 g), 
resulting in a 123.0 µL Intralipid spike treatment. Treatment vials were vortex mixed for 15 seconds 
and the pH measured at 5, 45 and120 minutes post-treatment. Stomach vials were kept in a 37ºC water 
bath during the length of the experiment to replicate in vivo conditions.  
4.2.8 Statistical analysis  
All general statistical procedures were run as previously mentioned in Chapter 3. In addition, live 
weights during treatment were analysed using a repeated measure test with animal identification as a 
random variable and treatment group defined by time. Ovarian follicle estimates were tested for 
covariance to ovarian weight and animal age at death and normalized where appropriate. Live weight 
covariance was determined for all post mortem organ weights. Data were normalized to live weight 
where appropriate by dividing the organ weight by live weight. Individual pre- and post-treatment 
CBC data from Study 1 were analysed against reference ranges using a Z-test. Additionally, mean 
CBC pre-treatment levels were tested against post-treatment levels to determine if any time-dependent 
effects had occurred. Liver and kidney histological reports were analysed using a Wald test with an 
ordinal logistics fit.  
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 Results   4.3
4.3.1 Study 1 
Treatment and necropsy parameters 
Animal live weight, food consumption and body condition were monitored daily during treatment (13 
days). Animals lost an average of 19.3 grams of live weight per day, regardless of treatment (p < 
0.0001; Figure 4.1). Following treatment on day one, 5 of 8 animals treated with a low VCD dose 
(500mg/kg) and 2 of 8 animals treated with a high VCD dose (750 mg/kg) vomited. On treatment day 
2 only one animal treated with a high dose of VCD vomited. No other adverse signs were reported 
during treatment across all groups. Animal age was similar across all treatment groups (p > 0.713) 
with an average age of 3.47 ± 0.31 years (Table 4.2). There were no significant differences between 
control and VCD treatment groups in final live weight (p > 0.494) or the weights of the liver (p > 
0.980), paired kidneys normalized to live weight (p > 0.171), paired adrenal glands (p > 0.927), paired 
uterine tracts (p > 0.351), or paired ovaries (p > 0.483) (Table 4.2). The data from three animals were 
removed from the study due to: 1) on treatment day 9, one control animal was mistakenly given a 
VCD dose (500 mg/kg); 2) one control animal was found to be 10 years old and, thus, considered to be 
an outlier; and 3) one VCD treated animal (500 mg/kg) was found dead in her cage on the final day of 
treatment. A necropsy revealed normal appearance and parameters for the oesophagus, trachea, lungs 
and vital and reproductive organs. There were no signs of aspiration; however, the gastrointestinal 
tract appeared pale and contained loose, watery stool. The cause of death was undetermined.  
 
  47 
 
Figure 4.1 Change in live weight (as % starting weight) of wild-caught female brushtail possums 
during 13 days of daily oral VCD administration (0, 500 or 750 mg/kg; Study 1). Control 
(oil only), n = 6; 500 mg VCD/kg/d, n = 7; 750 mg VCD/kg/d, n = 8. Vertical bars 
represent ± SEM. 
 
Table 4.2 The effect of VCD administration on live weight (LW) and somatic and reproductive 
tissues of wild-caught female brushtail possums during Study 1.  Data are means ± 
SEM. 
 
Toxicology results 
Complete blood counts (CBC) were measured pre- and post-treatment to check for general toxicity. 
CBC results revealed differences between pre- and post-treatment levels across all treatment groups in 
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Treatment day 
Control 500 mgVCD/kg 750 mgVCD/kg
Measured parameter 
Treatment group 
Control VCD low dose (500 mg/kg) VCD high dose (750 mg/kg) 
N 6 7 8 
Age at death (year) 3.8 ± 0.7 3.6 ± 0.5 3.1 ± 0.5 
Final LW (kg) 2.83 ± 0.09 3.01 ± 0.09 2.86 ± 0.14 
Liver weight (g/kg LW) 21.1 ± 0.57 21.4 ± 1.40 21.2 ± 1.0 
Paired kidney weight (g) 12.4 ± 0.41 12.5 ± 0.53 11.3 ± 0.46 
Paired adrenal weight (g) 0.42 ± 0.03 0.42 ± 0.03 0.43 ± 0.02 
Paired uteri weight (g) 13.1 ± 1.84 13.4 ± 3.35 8.98 ± 1.69 
Paired ovary weight (g) 0.29 ± 0.03 0.28 ± 0.04 0.23 ± 0.04 
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haematocrit (HCT; p < 0.014), mean cell volume (MCV; p < 0.008), mean cell haemoglobin 
concentration (MCHC; p < 0.0001), neutrophils (p < 0.008), lymphocytes (p < 0.017), and eosinophils 
(p < 0.027). However, these effects were not treatment related (p > 0.057; Table 4.3). Pre- and post-
treatment CBC levels were also tested against the mean reference range for each parameter. The data 
revealed that post-treatment MCHC levels of controls and low dose VCD treatment groups were 
significantly higher than the reference range (p < 0.002 and p < 0.001, respectively; Table 4.3). 
Animals treated with a high dose of VCD had elevated MCHC levels compared with the reference 
range both pre- and post-treatment (p < 0.032 and p < 0.0001, respectively; Table 4.3). There were no 
other differences between pre- or post-treatment CBC parameters when compared with their 
corresponding reference ranges (p > 0.087; Table 4.3). The liver enzymes gamma-glutamyl transferase 
(GGT) and glutamate dehydrogenase (GLDH) were measured to determine liver toxicity. There were 
no treatment differences in GGT or GLDH levels across all treatment groups (p > 0.109 and p > 0.407, 
respectively; Table 4.3).   
 
  
Table 4.3 Haematological and liver enzyme parameters of wild-caught female brushtail possums recorded pre- and post-treatment during Study 1. Reference 
ranges were obtained from Gribbles Veterinary (Christchurch, NZ). Ŧ indicates post-treatment levels are different (p < 0.05) from pre-treatment 
levels; * indicates levels are different (p < 0.05) from the reference range. Data are means ± SEM. 
 
Measured parameter Reference range 
Pre-treatment Post-treatment 
Control 
VCD low dose (500 
mg/kg) 
VCD high dose (750 
mg/kg) 
Control 
VCD low dose (500 
mg/kg) 
VCD high dose (750 
mg/kg) 
Sample size N/A 6 7 8 6 7 8 
Red blood cells (1012/L) 5.1 – 7.2 5.73 ± 0.30 6.04 ± 0.22 5.91 ± 0.20 5.50 0.24 5.73 0.33 6.16 0.31 
Haemoglobin (g/L) 114 - 169 130.2 ± 5.80 132.4 ± 5.27 136.6 ± 3.83 124.8 4.94 126.3 8.41 141.4 5.75 
Haematocrit (%) 35 – 51 0.39 ± 0.02 0.40 ± 0.01 0.41 ± 0.01 Ŧ0.37 ±  0.01 Ŧ0.36 ± 0.02 Ŧ0.40 ± 0.02 
Mean cell volume (fL) 64 – 77 67.0 ± 1.44 64.6 ± 0.69 67.4 ± 1.24 Ŧ66.5 ± 1.06 Ŧ64.0 ± 0.65 Ŧ65.5 ± 1.0 
Mean cell haemoglobin (pg) 20-30 22.8 ± 0.31 21.9 ± 0.40 23.0 ± 0.27 22.8 ± 0.31 22.0 ± 0.44 23.1 ± 0.30 
Mean cell haemoglobin 
concentration (g/L) 
317 – 329 332.8 ± 4.06 333.3 ± 3.17 *335.9 ± 4.45 
* Ŧ341.5 ± 
1.78 
* Ŧ343.0 ± 5.78 * Ŧ 351.9 ± 1.99 
White blood cells (109/L) 2.3 – 14.3 7.97 ± 1.16 9.31 ± 1.40 9.48 ± 1.25 7.80 ± 0.94 8.97 ± 1.32 9.35 ± 1.0 
Neutrophils (109/L) 1.4 – 5.1 2.98 ± 0.59 3.44 ± 0.70 2.61 ± 0.49 Ŧ 3.50 ± 0.55 Ŧ 4.17 ± 1.26 Ŧ 4.43 ± 0.74 
Lymphocytes (109/L) 0.8 – 13.2 4.48 ± 1.15 5.19 ± 0.87 5.99 ± 1.05 Ŧ 3.87 ± 0.74 Ŧ 4.17 ± 0.77 Ŧ 4.33 ± 0.85 
Monocytes (109/L) 0.1 – 0.5 0.37 ± 0.15 0.37 ± 0.11 0.50 ± 0.08 0.28 ± 0.06 0.51 ± 0.15 0.44 ± 0.07 
Eosinophils (109/L) < 1.2 0.12 ± 0.03 0.33 ± 0.10 0.33 ± 0.11 Ŧ 0.10 ± 0.03 Ŧ 0.16 ± 0.04 Ŧ 0.18 ± 0.10 
Basophils (109/L) < 0.4 0.0 ± 0.0 0.01 ± 0.01 0.08 ± 0.04 0.03 ± 0.02 0.0 ± 0.0 0.01 ± 0.01 
Gamma-glutamyl transferase (IU/L) 0.0 – 10.0 N/A N/A N/A 4.17 ± 0.48 6.0 ± 0.58 7.38 ± 1.68 
Glutamate dehydrogenase (IU/L) 0.0 – 10.0 N/A N/A N/A 17.8 ± 3.26 18.3 ± 5.07 22.5 ± 3.77 
4
9 
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Follicle counts 
To determine if primordial follicle counts decrease with age or are correlated with ovarian weight, 
covariance was first determined for each variable. The data demonstrate no correlations between 
primordial follicle counts and age or ovarian weight (p > 0.943 and p > 0.095, respectively). There 
were no statistical differences in primordial follicle counts of animals dosed with a low (500 mg/kg) or 
a high concentration of VCD (750 mg/kg) compared to controls (p > 0.687, Figure 4.2).  
 
 
Figure 4.2 Effect of daily oral administration (13 days; Study 1) of VCD on mean total primordial 
ovarian follicle estimates in wild-caught female brushtail possums. Counts were 
recorded from the left ovary of each animal and total counts estimated using a 
correction factor formula (Gougeon and Chainy, 1987). Control (oil only), n = 6; 500 mg 
VCD/kg, n = 6; 750 mg VCD/kg, n = 7. Vertical bars represent + SEM. 
 
4.3.2 Study 2 
Treatment and necropsy parameters 
Animals were monitored daily for food consumption, body condition and live weight during treatment 
(10 days). Food consumption and body condition of animals appeared normal yet animals lost weight 
across all treatment groups during the 10 day study (p < 0.0001; Figure 4.3). Furthermore, VCD-IT 
and VCD-QE treatment resulted in a greater loss of live weight relative to control groups (p < 0.0002). 
Two VCD-IT animals vomited following treatment on day 2 while only one VCD-QE animal vomited 
following treatment on day 4. No other adverse signs were observed during treatment. Animal age was 
not significantly different across all treatment groups (p > 0.262) with an average age of 2.69 ± 0.31 
years (Table 4.4). There were no significant differences between control and VCD treatment groups in 
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final live weight (p > 0.641) or the weights of the liver (p > 0.249), paired kidneys (p > 0.181), paired 
adrenal glands (p > 0.689), paired uteri tract (p > 0.768), or paired ovaries (p > 0.514) (Table 4.4). 
Five animals were removed from the study due to various reasons: 1) one VCD-IT animal had lost 
>10% live weight by day 6 and was removed from further treatment, 2) one C-O animal was found to 
be 15 years old, thus, considered to be an outlier, and 3) three VCD-QE animals died during treatment. 
A full necropsy was performed for each animal. The oesophagus, trachea, lungs and somatic and 
reproductive organs of all animals appeared normal. Although there were no signs of aspiration in any 
of the animals, the gastrointestinal tract of two animals appeared pale and contained loose, watery 
stool. The cause of death was undetermined.  
 
 
Figure 4.3 Change in live weight (as % starting weight) of wild-caught female brushtail possums 
during 10 days of daily oral VCD administration (0 or 500 mg/kg; Study 2). Oil-only 
control (C-O), n = 6; Control + antacid pre-treatment (C-QE), n = 6; Intralipid control (C-
IT), n = 6; 750 mg VCD/kg carried in oil + antacid pre-treatment (VCD-QE), n = 7; 750 
mg VCD/kg carried in Intralipid (VCD-IT), n = 9. * indicates different (p < 0.05) from 
control. Vertical bars represent ± SEM. 
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Treatment Day 
Control + antacid pre-treatment (C-QE) Control + Intralipid (C-IT)
VCD + antacid pre-treatment (VCD-QE) VCD + Intralipid (VCD-IT)
Oil-Only Control (C-O)
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Table 4.4 The effect of VCD administration on live weight (LW) and weight of somatic and 
reproductive organs of wild-caught female brushtail possums during Study 2. Data are 
means ± SEM. 
 
Toxicology results 
To determine if animals pre-treated with an antacid were affected by the high calcium levels in the 
Quick-EZE
®
 tablets, total calcium (Ca) and magnesium (Mg) levels were measured in pre- and post-
treatment plasma on ICP-OES. When Ca and Mg levels were compared within treatment groups, there 
were no significant differences between pre- and post-treatment levels among all groups (p > 0.091; 
Figure 4.4). Comparison of pre- and post-treatment Ca and Mg levels between oil-only controls and 
control and VCD animals pre-treated with antacids revealed no significant differences (p > 0.171; 
Figure 4.4).  
When control groups for liver scores were compared with each other, there were no differences in 
scores (p > 0.588) so control data were pooled. Findings revealed no treatment effects in the liver of 
VCD-QE or VCD-IT treated animals when compared against controls (p > 0.339). For the kidney, the 
C-QE group had significantly higher scores than C-IT and C-O groups (p > 0.024; Table 4.5) and 
therefore control groups were not pooled. The data revealed no significant differences in kidney scores 
following treatment when control groups were compared with their corresponding VCD groups (p > 
0.401; Table 4.5).  
Measured 
parameter 
Treatment group 
Oil control  
(C-O) 
Antacid + oil 
control (C-QE) 
Intralipid 
control (C-IT) 
Antacid + VCD (750 
mg/kg) in oil  
(VCD-QE) 
VCD (750 mg/kg) in 
Intralipid (VCD-IT) 
Sample size 5 6 6 7 9 
Age at death 
(year) 
2.2 ± 0.7 3.0 ± 0.8 2.8 ± 0.9 1.9 ± 0.6 3.3 ± 0.6 
Final LW (kg) 2.85 ± 0.09 2.99 ± 0.08 3.12 ± 0.12 3.04 ± 0.12 3.00 ± 0.11 
Liver weight (g) 63.3 ± 5.49 65.9 ± 4.09 68.0 ± 7.23 79.8 ± 5.91 69.7 ± 4.10 
Paired kidney 
weight (g/kg LW) 
4.81 ± 0.18 4.99 ± 0.28 4.42 ± 0.15 4.96 ± 0.17 4.62 ± 0.13 
Paired adrenal 
gland weight (g) 
0.30 ± 0.03 0.31 ± 0.02 0.33 ± 0.04 0.30 ± 0.04 0.29 ± 0.02 
Paired uteri 
weight (g) 
7.79 ± 1.18 8.38 ± 1.57 13.9 ± 3.95 9.82 ± 1.73 12.2 ± 4.35 
Paired ovary 
weight (g) 
0.42 ± 0.05 0.37 ± 0.04 0.40 ± 0.07 0.31 ± 0.03 0.33 ± 0.04 
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Figure 4.4 Effect of daily oral administration (10 days; Study 2) of VCD on total plasma calcium and 
magnesium concentrations measured in female brushtail possums before and after 
treatment. Oil-only control, n = 6; Control + antacid pre-treatment, n = 6; 750 mg 
VCD/kg carried in oil + antacid pre-treatment, n = 7. Vertical bars represent ± SEM. 
 
Table 4.5 Histopathological scores (see text) of liver and kidneys of wild-caught female brushtail 
possums following oral treatment with two formulations aimed at improving the 
follicle depleting effects of VCD (Study 2). Values with different superscript letters are 
significantly different (p < 0.05). Data are means ± SEM. 
 
Follicle counts  
Age and ovarian weight covariance with primordial, primary and secondary follicle estimates were 
examined. It was determined that age was not correlated with follicle counts (p > 0.054). However, 
ovarian weight was correlated with primary (p < 0.002) and secondary (p < 0.015) follicle numbers but 
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Measured 
Parameter 
Treatment group 
Oil control 
(C-O) 
Antacid + oil 
control (C-QE) 
Intralipid 
control (C-IT) 
Antacid + VCD (750 
mg/kg) in oil (VCD-QE) 
VCD (750 mg/kg) in 
Intralipid (VCD-IT) 
N 5 6 6 7 9 
Liver 1.8 ± 0.2 2.0 ± 0.26 2.17 ± 0.31 2.29 ± 0.36 2.11 ± 0.35 
Kidneys 
0.8 ± 
0.37AC 
2.0 ± 0.26B 
0.83 ± 
0.31ABC 
1.85 ± 0.4ABC 1.11 ± 0.35ABC 
  54 
not with primordial follicle counts (p > 0.095). Therefore, primary and secondary follicle counts were 
normalized to ovarian weight and then checked for treatment differences. There were no differences in 
primordial, primary or secondary follicle counts of C-QE compared with VCD-QE (p > 0.336) and C-
IT compared to VCD-IT (p > 0.615; Figures 4.5 and 4.6). There were no significant differences in the 
control group’s primordial, primary or secondary follicle counts (p > 0.254). Therefore, all control 
group data were pooled for comparison against VCD treatment groups. Compared with controls, there 
were no significant differences in VCD-IT and VCD-QE primordial, primary and secondary follicle 
counts (p > 0.367; Figures 4.5 and 4.6).  
 
 
Figure 4.5 Effect of daily oral administration (10 days; Study 2) of VCD on mean total primordial 
ovarian follicle counts in wild-caught female brushtail possums. Counts were recorded 
from the left ovary of each animals and total counts estimated using a correction 
factor formula (Gougeon and Chainy, 1987). Oil-only control (C-O), n = 5; Control + 
antacid pre-treatment (C-QE), n = 6; Intralipid control (C-IT), n = 6; 750 mg VCD/kg 
carried in oil + antacid pre-treatment (VCD-QE), n = 8; 750 mg VCD/kg carried in 
Intralipid (VCD-IT), n = 9. Vertical bars represent + SEM. 
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Figure 4.6 Effect of daily oral administration (10 days; Study 2) of VCD on mean total primary and 
secondary ovarian follicle counts in wild-caught female brushtail possums. Counts 
were recorded from the left ovary of each animals and total counts estimated using a 
correction factor formula (Gougeon and Chainy, 1987). Oil-only control (C-O), n = 5; 
Control + antacid pre-treatment (C-QE), n = 6; Intralipid control (C-IT), n = 6; 750 mg 
VCD/kg carried in oil + antacid pre-treatment (VCD-QE), n = 8; 750 mg VCD/kg carried 
in Intralipid (VCD-IT), n = 9. Vertical bars represent ± SEM. 
 
Formulation effects on stomach contents pH  
The effects of Quick-EZE
® 
(QE) and Intralipid
®
 (IT) on stomach contents pH of possums were 
analysed in vitro. Addition of a low dose of the antacid Quick-EZE to possum stomach caused the pH 
to rise from 1.37 (starting pH) to 4.33 ± 0.08 within 5 minutes. The pH then stabilized at 5.19 pH ± 
0.03 by 45 minutes and remained at that pH up to 120 minutes. Similarly, a high dose of Quick-EZE 
caused possum stomach pH to quickly rise from 1.37 to 5.25 ± 0.06 within 5 minutes. At 45 minutes, 
the pH reached 6.17 ± 0.01 and stabilized at 6.68 ± 0.07 by 120 minutes. Treatment with a low and 
high dose of Intralipid resulted in minimal pH change with time (120 min) from 1.37 (starting pH) to 
1.69 ± 0.06 and 1.38 ± 0.07, respectively. Control stomach contents did not alter during the 120 
minute trial period (pH 1.37-1.38 ± 0.04).  
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 Discussion 4.4
The chemosterilant VCD was examined as a potential humane and sustainable pest control method for 
NZ brushtail possums. The primordial ovarian follicle pools of possums orally treated with either 500 
or 750 mg VCD/kg for 13 consecutive days were unaffected compared with controls. Previous studies 
examining the effects of oral administration of VCD (500 mg/kg) in Sprague Dawley rats have 
demonstrated significant primordial follicle depletion after 10 (Burd, 2009), 15 or 30 (Schmuki et al., 
2011) consecutive days. One possible reason for the lack of effects observed here is the highly acidic 
stomach environment of brushtail possums. Possum stomach contents pH ranges between 1.0 and 2.0, 
regardless of food consumption or digestion (Drs. J. A. Duckworth & F. Molinia, pers. comm.). 
Conversely, rodent stomach contents pH ranges between 3.2 (fed) and 3.9 (fasted) (McConnell et al., 
2008). When VCD is exposed to a pH of 1.0 in vitro, >99.9% of VCD is hydrolysed within 3 minutes 
(Chapter 6). It was hypothesized that the highly acidic stomach environment of the possum hydrolysed 
the VCD dose before the compound could be absorbed and then reach the target sites in the ovary. 
Therefore, a second study was designed to reduce the potential acidic breakdown of VCD in the 
possum stomach.   
Two formulations which were believed to protect and improve the oral efficacy of VCD were 
examined. The first formulation utilized a pre-treatment with the antacid Quick-EZE
® 
prior to dosing 
possums with VCD carried in oil. Previous work had shown that the gastric contents pH of possums 
orally gavaged with a suspension containing two Quick- EZE
® 
tablets was increased and remained 
elevated (pH 4.5-6.5) for at least seven hours (Drs. J. A. Duckworth & F. Molinia, pers. comm.).  It 
was predicted that an oral pre-treatment of antacids would reduce stomach acidity prior to VCD 
administration, thereby decreasing VCD hydrolysis. Results show that ten days of oral VCD treatment 
(750 mg/kg) administered with an antacid pre-treatment had no effect on immature follicle populations 
compared with controls. When possum stomach contents were incubated in vitro with a comparable 
Quick-EZE
® 
dose, the pH was increased from 1.37 to 5.19 – 5.25 within 5 minutes of exposure. These 
in vitro results support previous reports (Drs. J. A. Duckworth & F. Molinia, pers. comm.) and suggest 
that Quick-EZE
® 
may have been able to reduce the acidic breakdown of VCD to some extent. 
Nevertheless, the treatment did not appear to have any observable effects on the ability of orally 
delivered VCD to deplete immature follicle populations in the ovaries of VCD treated possums.  
The second approach to improve the oral efficacy of VCD was the use of a lipoprotein emulsion, 
Intralipid
®
, as an alternative carrier liquid for VCD. Intralipid
®
 is a sterile, homogenous fat emulsion 
containing soybean oil (20%), egg yolk phospholipids (1.2%) and glycerine (2.25%) and is readily 
absorbed across the gastric lining. VCD is lipophilic in nature and should therefore readily incorporate 
into lipid components of a carrier such as Intralipid
®
. In addition, previous studies have demonstrated 
that Intralipid
®
 improves the palatability of VCD in rodents (Dr. C. A. Dyer, pers. comm.). It was 
predicted that replacing the normal carrier liquid (oil) with Intralipid would improve VCD absorption 
from the gastric lining into the blood and may provide some protection from acidic degradation. VCD 
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(750 mg/kg) carried in Intralipid had no depleting effect on the immature follicle populations of 
possums. In vitro examination of possum stomach contents pH following Intralipid addition only 
slightly altered the pH from 1.37 to 1.71 after two hours. Therefore, despite the potential ability of 
Intralipid to increase VCD absorbency, it is likely that it was unable to protect VCD from the highly 
acidic environment of the possum stomach.   
The effect of orally delivered VCD on the health and body condition of female possums was also 
examined. Thirteen consecutive treatment days resulted in weight loss, irrespective of treatment. The 
possible cause of weight loss across all treatment groups may be a result of anaesthetic and handling 
stress. Wild brushtail possums living in Australia showed stress signs (wobbliness, low body mass) 
and decreased numbers of pouch young and reduced adult survivability following routine monitoring 
and handling procedures (Clinchy et al., 2001). During the trials reported here all attempts were made 
to keep animal stress to a minimum. However, it is likely that the possums experienced some stress as 
a result of repeated handling and anaesthesia as evidenced by the reduced weight gain observed across 
all treatment groups. 
To determine if any VCD-induced toxicity effects were occurring, internal organs were examined 
following each study and complete blood counts (CBC) and liver enzyme levels were analysed 
following Study 1. Oral VCD administration (10-13 days, 500-750 mg/kg) did not have any obvious 
effects on somatic or reproductive organs. These results could be expected based on similar VCD 
dosing regimens in rodents (Ito et al., 2009; Kodama et al., 2009; Muhammad et al., 2009). 
Comparison of pre- versus post-treatment CBC levels revealed that all animals, regardless of 
treatment, demonstrated altered CBC levels that were indicative of stress. However, only one 
parameter (MCHC) was outside of the reference range suggesting any stress-induced effects were 
minimal. In addition, liver enzyme levels and liver and kidney histological samples indicated normal 
organ function. Taken together, these data suggest that there were no VCD-induced toxicity effects, 
rather the altered CBC results were likely due to stress caused by repeated daily handling and 
anaesthesia. Similar haematological reports have been observed in wild possums following capture 
(Buddle et al., 1992).  The blood profiles of those animals returned to levels similar to that of 
frequently captured possums following caged housing for 1-3 weeks (Buddle et al., 1992) suggesting 
habituation to handling and the housing environment.  Thus it can be postulated that the altered CBC 
parameters reported here would return to similar levels measured during pre-treatment upon 
elimination of daily handling and anaesthesia.    
Possums treated for 10 days with VCD carried in Intralipid or an antacid pre-treatment followed by 
VCD carried in oil lost more live weight than controls. The weight loss cannot be attributed simply to 
the high dose of VCD delivered (750 mg/kg) as possums treated with the same VCD dose for 13 days 
did not experience significant weight loss associated with treatment. Rather it is likely that the 
formulations (Intralipid and antacids) used to increase VCD efficacy may have indirectly augmented 
weight loss. VCD-related effects on weight gain and food intake have been observed in rodents (Burd, 
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2009; Haas et al., 2007; Muhammad et al., 2009). It is possible that the formulations did in fact protect 
VCD to some extent, causing prolonged gastrointestinal exposure to VCD and the resulting effects on 
food intake and weight gain. It must be noted that food consumption during the studies was not 
measured directly, but rather observed. VCD treatment may have caused internal irritation resulting in 
VCD treated animals consuming less food than controls and thus affecting weight gain. VCD has been 
shown to cause irritation to the oesophagus, skin and stomach in rodents following long-term VCD 
treatment (NTP, 1986). Although the formulations to increase VCD efficacy may have worked, there 
may still have been insufficient amounts of the chemical reaching the target organs, ovaries, to induce 
follicle depleting effects.  
Potential VCD related deaths occurred during each study. One VCD treated animal (500 mg/kg) was 
found dead on the final day in Study 1 and three VCD animals receiving an antacid pre-treatment died 
during Study 2. Although most of the internal organs appeared normal, three of the four animals 
showed signs of irritated gastrointestinal tracts and disruption of water balance (pale tissue containing 
watery stool). It was initially speculated that the animals receiving VCD with an antacid pre-treatment 
died as a result of calcium toxicity from the Quick-EZE
® 
tablets. However, the post-treatment calcium 
and magnesium levels were similar to levels measured during pre-treatment. Therefore, it is more 
likely that these animals died as a result of VCD treatment rather than calcium toxicity following 
antacid administration. What may have occurred is that the antacid associated protection of VCD 
caused increased irritation to the gastrointestinal tract from prolonged VCD exposure (NTP, 1986). 
Thus is seems that, to some extent, VCD may have been protected from hydrolysis in the stomach, 
thereby enabling increased treatment related effects.  
VCD dosing regimens and formulations examined here had no obvious effect on the pool of immature 
follicles in healthy adult female possums. The use of Intralipid or antacid pre-treatment to increase 
VCD absorbency did seem to work as evidenced by treatment related weight loss, although it appears 
that insufficient levels of the chemical reached the ovaries to induce follicle depletion. Further 
understanding of the uptake and metabolism of VCD in the possum will be necessary if the chemical 
is to be considered for use as a chemosterilant. Therefore, in the following chapter the differences in 
enzymatic metabolism and uptake and distribution of orally delivered VCD in possums and rats will 
be investigated.   
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Chapter 5 
Fate and metabolism of 4-vinylcyclohexene diepoxide in wild-
caught female brushtail possums and Norway rats: a comparative 
study 
 Introduction 5.1
In the previous chapter the effects of orally administered 4-vinylcyclohexene diepoxide (VCD) on the 
health and ovarian follicle populations of adult female possums was examined. Two formulations 
aimed at improving the absorbency and efficacy of orally delivered VCD (Study 2) in possums was 
also investigated. There were no decreases in the immature ovarian follicular pools in healthy adult 
female possums when they were orally dosed with VCD. However, the observed treatment-related live 
weight loss during Study 2 suggested that there were some VCD treatment-related effects and that 
formulations may have increased VCD absorbency to some degree. The dosing regimens tested in 
those trials were similar to ones used in previous studies that demonstrated significant primordial 
follicle depletion following oral VCD treatment in the rat (Burd, 2009; Herawati et al., 2010; Mayer et 
al., 2010). The lack of observed effects on possum ovarian primordial or primary follicle populations 
suggests differences in the uptake, metabolism, and fate of VCD in possums compared with rats and 
thus merits examination.       
4-Vinylcyclohexene (VCH), the parent compound of VCD, is metabolized to VCD in a Phase I 
reaction primarily by the hepatic-derived enzyme superfamily cytochrome P450 (CYP450) (Doerr-
Stevens et al., 1999; Doerr et al., 1996; Springer et al., 1996c). Phase I metabolism is usually a 
prerequisite for Phase II conjugative metabolism wherein lipophilic compounds are converted to more 
water-soluble metabolites for excretion (Rushmore, 2002; Xu et al., 2005). Through Phase II reaction, 
VCD is further metabolized in the liver and, to a lesser extent, in the ovary to a non-active tetrol 
metabolite ([1,2-dihydroxy] ethyl-1,2-dihydroxycyclohexane) through the action of microsomal 
epoxide hydrolase (mEH) and glutathione-S-transferase (GST) (Cannady et al., 2002; Devine et al., 
2001; Flaws et al., 1994; Keating et al., 2008a; Keating et al., 2008b; Salyers, 1995). mEH catalyses 
the hydration of alkene epoxides and arene oxides while GST catalyses conjugation of reduced 
glutathione (GSH) with compounds to increase their elimination from the body.  
Species differences in VCD uptake and metabolism have been demonstrated in laboratory-bred mice 
(Mus musculus) and laboratory-bred Norway rats (Kao et al., 1999; Keller et al., 1997; Salyers, 1995; 
Smith et al., 1990b). A disposition study revealed that VCD distributes faster from the blood into the 
tissues of mice compared with rats while excretion of VCD metabolites was primarily through the 
urine in both species (Salyers, 1995). It was also demonstrated that VCD metabolites are eliminated 
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faster in rats and the urinary metabolite profile of each species suggests different pathways for VCD 
metabolism (Salyers, 1995). Comparison of enzymatic metabolism of VCH and VCD revealed that 
mice have higher Phase I metabolic activity but slower Phase II activity rates compared with rats, 
resulting in the capability of mice to metabolise VCH faster than rats. As VCH is detoxified to VCD 
via CYP450, VCD accumulates faster in mice compared with rats due to their slower Phase II activity 
and mice are therefore more susceptible to VCD-induced ovarian toxicity (Doerr-Stevens et al., 1999; 
Doerr et al., 1996; Springer et al., 1996c). It is possible to speculate that a similar species difference in 
VCD metabolism may exist between possums and rats. Therefore, the studies reported here examined 
the rate of VCD clearance from the stomach and uptake into the blood in wild-caught adult female 
brushtail possums and wild-caught Norway rats. In addition, hepatic and ovarian levels of GSH were 
measured to detect any metabolic changes in both species.  It was predicted that possums would 
metabolize VCD to its non-active tetrol metabolite more rapidly than rats.  
 Materials and Methods 5.2
5.2.1 Reagents 
VCD, sunflower oil, cyclohexanone, ethyl acetate, Attane™ isoflurane, and sodium pentobarbital were 
obtained from vendors and used for experimental procedures as previously described in Chapter 3. 
5.2.2 Possum experimental procedures 
Possums (n = 24) were randomly allocated into treatment groups using a randomized block design 
stratified on live weight prior to trial start. Under anaesthesia (5% isoflurane in O2 at 2 L/min) blood 
was collected from the tail vein prior to gavage treatment (control time point 0). Possums were then 
gavaged with a single bolus dose of sunflower oil (vehicle control, n = 8) or VCD (750 mg/kg mixed 
1:3 w/v) in oil (n = 8). Gavage tubes consisted of commercially purchased vinyl tubing (3 mm 
diameter, 30 cm length) attached to a 3-way stop cock and a 10 mL syringe. A different tube was used 
for each treatment group and tubes were discarded daily. Possums were divided into three sub-groups 
which were killed at different time points (either at 0 or 15 minutes or 24 hours post-treatment). For 
group 1 possums (n = 4 per treatment) animals were killed immediately after treatment with an 
intracardiac pentobarbitone overdose (125 mg/kg). For group 2 possums (n = 4 per treatment), while 
under anaesthesia, blood was collected at 1, 3, 5, 10 and 15 minutes post-treatment from the tail vein. 
Group 2 possums were then killed at 15 minutes post-treatment with an intracardiac pentobarbitone 
overdose (125 mg/kg). For group 3 possums (n = 4 per treatment), blood was collected from the tail 
vein at 5, 15, 30, 60, 120 and 360 minutes post-treatment. Animals remained under anaesthesia during 
the 5 and 15 minute time points. For all other time points possums were re-anaesthetised to obtain 
each blood sample. At 24 hours post-treatment, group 3 possums were anaesthetised and a final blood 
sample collected via intracardiac injection and then animals were then euthanized with an intracardiac 
pentobarbitone overdose (125 mg/kg). For each animal, no more than 5% of circulating blood volume 
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(2.0-4.0 mL/time point) was collected to ensure normal circulatory function (Diehl et al., 2001). All 
blood samples were collected into lithium heparin vacutainer tubes (BD Vacutainer®), inverted 
several times and then prepared for GSH or gas chromatography (GC) measurements as outlined 
below. The liver and ovaries were immediately removed and prepared for GSH measurements as 
stated below. The stomach was excised, contents removed and weighed, the pH measured and contents 
prepared for GC analysis as outlined below. The reproductive tract, adrenal glands and kidneys were 
each weighed separately and then placed into 10% neutral-buffered formalin.     
5.2.3 Rat experimental procedures 
Rats (n = 56) were randomly allocated into treatment groups using a randomized block design 
stratified on live weight prior to trial start. Under anaesthesia (5% isoflurane in O2 at 2 L/min) rats 
were gavaged with a single bolus dose of sunflower oil (vehicle control, n = 2-4 per time point) or 
VCD (750 mg/kg mixed 1:3 w/v) in oil (n = 2-4 per time point) using a steel gavage feeding tube (1.2 
mm diameter, 76.2 mm length). Blood (3.0 ± 1.0 mL) was collected at 0, 5, 15, 30, 60, 120, 180 or 360 
minutes post-treatment by intracardiac puncture into lithium heparin vacutainer tubes (BD 
Vacutainer®), inverted several times and then prepared for GSH or GC measurements as outlined 
below. Animals were then euthanized at each of the above time points with an intracardiac 
pentobarbitone overdose (125 mg/kg). The liver and ovaries were immediately removed and prepared 
for GSH measurements as outlined below. The stomach was excised, contents removed and weighed, 
the pH measured and then prepared for GC analysis as outlined below. The reproductive tract, adrenal 
glands and kidneys were each weighed separately and then placed into 10% neutral-buffered formalin.  
5.2.4 Glutathione assay sample preparation  
Blood treatment 
Blood (0.5 mL) was placed into an Eppendorf tube and centrifuged for 5 minutes at 1,500 x g. Plasma 
was removed and placed into an Eppendorf tube wherein 1 times the sample volume of ice-cold 5% 
w/v 5-sulfosalicylic acid (SSA) solution was added to deproteinize the sample. The plasma sample 
was vortex mixed for 10 seconds, incubated at 4°C and then centrifuged for 10 minutes at 10,000 x g. 
The supernatant (~400 µL) was transferred to a cryostat vial, snap frozen with liquid nitrogen and 
stored at -80°C until analysis. In two successive rounds, the red blood cells (RBCs) were suspended 
and washed in 3 times the sample volume with 1x neutral-buffered saline solution (PBS), centrifuged 
for 5 minutes at 1,500 x g and then the supernatant discarded. PBS contained 1368.9 mM NaCl, 26.8 
mM KCl, 101.4 mM Na2HPO4 and 17.6 mM KH2PO4. An equal volume of ice-cold 5% SSA solution 
was added to the volume of RBCs and then vortex mixed for 10 seconds, incubated at 4°C and then 
centrifuged for 10 minutes at 10,000 x g. The supernatant was transferred to a cryostat vial, snap 
frozen with liquid nitrogen and stored at -80°C until analysis.  
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Liver and ovary treatment 
Whole liver and individual ovary weights were recorded. Ovaries were individually snap frozen whole 
with liquid nitrogen and the right ovary was stored at -80°C while the left ovary was placed into 
aluminium foil in preparation for deproteinization treatment with SSA. The liver was perfused with 
ice- cold 1x PBS and then the left lateral lobe (LLL) was removed and placed into aluminium foil, 
sealed and snap frozen with liquid nitrogen. The remaining liver was cut into 5-10 gram pieces, snap 
frozen and stored at -80°C. Individually, the left ovary and the LLL were broken into small pieces 
using a mallet and then 0.1 - 0.2 g measured into an ice-cold glass homogenizer and 7 times the 
sample weight of ice-cold 5% SSA was added and tissue homogenized with 10 passes of the pestle 
while on ice. The solution was incubated at 4°C for 10 minutes and the homogenate transferred to a 
conical tube and centrifuged at 10,000 x g for 10 minutes. Supernatant aliquots (1.0 mL) were placed 
into cryostat vials and snap frozen with liquid nitrogen and stored at -80°C until analysis.  
5.2.5 Gas chromatography analysis 
For each species, VCD was extracted from the stomach contents with the addition of 2 times the 
stomach weight of extraction solution (ES; ethyl acetate containing 1.18 mM cyclohexanone as the 
internal standard). VCD was extracted from the blood of each animal by collecting 2 aliquots of 0.5 
mL whole blood and then adding 2 times the volume of ES. Extraction methods and VCD 
quantification on GC were performed as outlined in Chapter 3. Final VCD concentrations in blood and 
stomach contents are represented as µmoles VCD/L ES, unless otherwise stated.  
To determine the percentage of VCD recovered in the stomach of each animal the total estimated VCD 
concentration in the stomach immediately following gavage was first calculated as follows. The 
amount of VCD stock administered to the animal (mL) was multiplied by the VCD concentration in 
the gavage liquid (365.33 mg/mL oil) and then divided by the amount of ES (mL) added to the sample 
tissue. Because ES was always added at the same rate (2 times the stomach contents weight), VCD 
concentration were standardized to stomach volume for each animal. The amount of recovered VCD 
(mg/mL ES; determined by GC) was then divided by the estimated VCD concentration (mg/mL ES) in 
the stomach and the resultant multiplied by 100. These calculations assume equal rate of acid-induced 
VCD hydrolysis and absorption (uptake) into the gastrointestinal epithelium between species and 
therefore must be accepted with caution.   
5.2.6 Glutathione analysis 
GSH concentration (nmol/µL or mg tissue) in RBCs, plasma and  hepatic (liver) and ovarian tissues 
were analysed using methods described in the GSH assay kit (Sigma, cat# CS0260) with changes as 
outlined in Chapter 3.   
  63 
5.2.7 Statistical analysis 
All general statistical procedures were run as described in Chapter 3. In addition, the concentrations of 
VCD and GSH were analysed using a repeated measure test with animal identification as a random 
variable and treatment group defined by time.  
 Results  5.3
5.3.1 VCD concentration in blood and stomach tissue of possums and rats 
The amount of VCD recovered in the blood and stomach of rats and possums following a bolus dose 
(750 mg/kg) was quantified by GC. At 15 minutes post-gavage the stomach contents of possums 
contained 57.4 ± 20.2 % (90.74 ± 34.3 mM VCD) of the calculated initial dose (158.68 ± 19.77 mM 
VCD) and by 24 hours no VCD was detected (Table 5.1). Following gavage, VCD was detected in 
possum blood up to 15 minutes post-gavage, (Table 5.2).  
VCD was detected in rat stomach contents up to 6 hours post-gavage (Table 5.1). Of the calculated 
initial dose (156.64 ± 15.99 mM VCD) the amount of VCD recovered from the stomach contents of 
rats was substantial from 3 to 120 minutes post-gavage (27.5 – 50.1 % of given dose) but was reduced 
after 180 minutes post-gavage (18.1 – 21.4 % of given dose) (Table 5.1). VCD levels in rat blood were 
elevated initially but declined rapidly and were very low at 31 minutes post gavage (Table 5.2).  
At 15 minutes post-treatment there was no significant difference between species in the proportion of 
VCD dose recovered from the stomach (p > 0.944; possum, 57.4 ± 20.2 % of dose; rat, 43.2 ± 2.42 % 
of dose; Table 5.1). However, there were significantly higher levels of VCD present in the blood of 
rats compared with that of possums from 3 to 30 minutes post-treatment (p < 0.037; Table 5.2). For 
further between-species comparisons the aim was to collect data from rats at 24 hours. However, 
VCD-treated rats did not survive past 7 hours. This was presumably a direct result of the VCD-related 
treatment because the control rats survived perfectly well. It is not understood why the wild-strain of 
Norway rat, when dosed with VCD, is unable to survive to 24 hours as survivability in laboratory 
Norway rats dosed daily for 10-30 days with similar oral VCD regimens is well documented (Burd, 
2009; Schmuki et al., 2011). Thus, this discrepancy may be due to the wild strain being unable to cope 
with VCD treatment. A necropsy revealed normal appearance and parameters for the oesophagus, 
trachea, lungs and vital and reproductive organs and there were no signs of aspiration in each rat. The 
cause of death was undetermined. 
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Table 5.1 Change in VCD concentration in the stomach (mM) of female brushtail possums and 
Norway rats following a single oral dose of oil or VCD (750 mg/kg) suspended in oil 
(1:3 v/v). Statistical significance was set at p < 0.05. Data are means ± SEM; individual 
data are listed for sample sizes < 2. 
Time 
(minutes) 
Species 
Possum Rat 
Control treatment VCD treatment Control treatment VCD treatment 
0 0.0 ± 0.0 (n = 4) 0.0 ± 0.0 (n = 4) 0.0 ± 0.0 (n = 4) 0.0 ± 0.0 (n = 4) 
1 - - - - 
3 - - 0.0 ± 0.0 (n = 4) 82.7 ± 15.3 (n = 4) 
5 - - 0.0/0.0 (n = 2) 40.4/91.7 (n = 2) 
15 0.0 ± 0.0 (n = 4) 90.7 ± 34.3 (n = 4) 0.0 ± 0.0 (n = 4) 58.4 ± 35.4 (n = 4) 
30 - - 0.0/0.0 (n = 2) 49.2/81.1 (n = 2) 
60 - - 0.0/0.0 (n = 2) 58.2/82.6 (n = 2) 
120 - - 0.0/0.0 (n = 2) 27.6/36.4 (n = 2) 
180 - - 0.0 ± 0.0 (n = 4) 29.2 ± 4.7 (n = 4) 
360 - - 0.0 ± 0.0 (n = 4) 23.4 ± 5.9 (n = 4) 
1440     
(24 hours) 
0.0 ± 0.0 (n = 4) 0.0 ± 0.0 (n = 4) - - 
 
Table 5.2 Change in VCD concentration in the blood (µM) of female brushtail possums and Norway 
rats following a single oral dose of oil or VCD (750 mg/kg) suspended in oil (1:3 v/v). * 
indicates difference (p < 0.05) between VCD-treated possums and VCD-treated rats. 
Data are means ± SEM; individual data are listed for sample sizes < 2. 
Time 
(minutes) 
Species 
Possum Rat 
Control treatment VCD treatment 
Control 
treatment 
VCD treatment 
0 0.0 ± 0.0 (n = 4) 0.0 ± 0.0 (n = 4) 0.0 ± 0.0 (n = 4) 0.0 ± 0.0 (n = 4) 
1 0.0 ± 0.0 (n = 8) 221.7 ± 0.07 (n = 8) - - 
3 0.0 ± 0.0 (n = 4) 192.0 ± 0.09 (n = 4) 0.0 ± 0.0 (n = 4) 
*1048.7 ± 137.5 (n = 
4) 
5 0.0 ± 0.0 (n = 8) 178.7 ± 79.5 (n = 8) 0.0/0.0 (n = 2) 
*480.5/*1412.6 (n = 
2) 
10 0.0 ± 0.0 (n = 8) 31.9 ± 1.02 (n = 8) - - 
15 0.0 ± 0.0 (n = 8) 2.45 ± 1.38 (n = 8) 0.0 ± 0.0 (n = 4) *385.1 ± 211.9 (n = 4) 
30 0.0 ± 0.0 (n = 4) 0.0 ± 0.0 (n = 4) 0.0/0.0 (n = 2) *94.5/*115.5 (n = 2) 
60 0.0 ± 0.0 (n = 4) 0.0 ± 0.0 (n = 4) 0.0/0.0 (n = 2) 0.0/0.0 (n = 2) 
120 0.0 ± 0.0 (n = 4) 0.0 ± 0.0 (n = 4) 0.0/0.0 (n = 2) 0.0/0.0 (n = 2) 
180 - - 0.0 ± 0.0 (n = 4) 0.0 ± 0.0 (n = 4) 
360 0.0 ± 0.0 (n = 4) 0.0 ± 0.0 (n = 4) 0.0 ± 0.0 (n = 4) 0.0 ± 0.0 (n = 4) 
1440       
(24 hours) 
0.0 ± 0.0 (n = 4) 0.0 ± 0.0 (n = 4) - - 
 
5.3.2 Gastric pH levels following treatment 
The pH of stomach contents following VCD treatment for each species is reviewed in Table 5.3. 
Compared with controls, the pH of possum stomach contents treated with VCD was elevated by 
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212.5% and 150.0% of controls at 15 minutes and 24 hours, respectively; however this trend was not 
significant (p > 0.100 and p > 0.238, respectively). Rat stomach pH did increase by 30.4% of controls 
by 15 minutes post-treatment although this was not significant (p > 0.065). The mean pH of rat 
stomach contents treated with VCD did increased from 3 to 360 minutes post-treatment compared with 
controls (p < 0.031; control mean, 3.17 ± 0.28 pH; VCD mean, 4.29 ± 0.18 pH). There were no 
between-species differences in stomach pH at 15 minutes following treatment (control, p > 0.221; 
VCD, p > 0.637; Table 5.3).  
 
Table 5.3 Gastric pH levels in the stomach contents of female brushtail possums and Norway rats 
following a single oral dose of oil or VCD (750 mg/kg) suspended in oil (1:3 v/v). 
Statistical significance was set at p < 0.05. Data are means ± SEM; actual values are 
listed for sample sizes < 2. 
Time 
(minutes) 
Species 
Possum Rat 
Control treatment 
VCD treatment 
(n = 8) 
Control treatment VCD treatment 
0 1.00 ± 0.2 (n = 4) 1.13 ± 0.13 (n = 4) 2.88 ± 0.13 (n = 4) 2.88 ± 0.32 (n = 4) 
1 - - - - 
3 - - 3.50 ± 0.50 (n = 4) 3.75 ± 0.25 (n = 4) 
5 - - 0.5/3.5 (n = 2) 4.0/5.0 (n = 2) 
15 1.00 ± 0.0 (n = 4) 3.13 ± 1.05 (n = 4) 3.25 ± 0.25 (n = 4) 3.75 ± 0.25 (n = 4) 
30 - - 2.0/3.5 (n = 2) 4.0/5.0 (n = 2) 
60 - - 3.0/4.0 (n = 2) 4.0/5.0 (n = 2) 
120 - - 0.5/4.5 (n = 2) 4.0/6.0 (n = 2) 
180 - - 3.67 ± 0.33 (n = 4) 3.50 ± 0.50 (n = 4) 
360 - - 3.67 ± 0.60 (n = 4) 4.83 ± 0.17 (n = 4) 
1440       
(24 hours) 
0.50 ± 0.29 (n = 4) 2.50 ± 1.66 (n = 4) - - 
 
5.3.3 GSH concentration in the blood and liver and ovarian tissue of possums and 
rats 
To determine if any differences in VCD metabolism exist between possums and rats, GSH 
concentration was measured in hepatic and ovarian tissues of each species. Because possums served as 
their own controls their pre-treatment (baseline control) GSH concentration in plasma and RBCs were 
compared against post-treatment levels within each group to determine if there were any effects on 
GSH concentration as a result of anaesthesia or handling stress. Within each group, there were no 
significant differences between pre- and post-treatment GSH concentration in RBCs (p > 0.331; Figure 
5.1) and plasma (p > 0.237; Figure 5.2). Therefore, any differences between groups can be attributed 
to effects of the VCD-related treatment.    
Possum plasma and RBC GSH concentrations were not significantly different between treatment 
groups (p > 0.059; Figures 5.1 and 5.2). Both control and VCD treated possum hepatic GSH levels 
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were significantly decreased 15 minutes after treatment (p < 0.011 and p < 0.008, respectively). 
Twenty four hours after treatment, VCD treated possum hepatic GSH levels were increased compared 
to their pre-treatment and 15 minute post-treatment levels, although this was not significant (p > 0.202 
and p > 0.061, respectively; Figures 5.3). Compared to their pre-treatment levels, ovarian GSH levels 
of control treated possums were elevated at 15 minutes (p < 0.022) and 24 hours post-treatment (p < 
0.019) (Figure 5.4). Similarly, elevated ovarian GSH levels of VCD treated possum were observed at 
15 minutes (p < 0.019) and 24 hours post-treatment (p < 0.019) compared with their pre-treatment 
levels (Figure 5.4). 
The effect of VCD treatment on GSH concentration in rat RBCs, plasma, liver and ovaries was 
examined. VCD treatment of rats caused significant decreases in mean GSH concentration in the 
RBCs (p < 0.029; -15.0% of control mean) and in liver (p < 0.0001; -77.5% of control mean) and 
ovarian tissues (p < 0.019; -83.0% of control mean) during the 6 hours following treatment (Figures 
5.1, 5.5 and 5.6 and Table 5.4). Mean plasma GSH concentration in VCD-treated rats was decreased 
by 25.9% of control mean, although this was not significant (p > 0.206; Figure 5.2 and Table 5.4).  
Species comparisons were made between GSH concentration of possums and rats 15 minutes 
following treatment. Rat RBC and plasma GSH levels at pre-treatment and 15 minutes post-treatment 
were lower than that of possums; however this was not significant (p > 0.06; Figure 5.7 and 5.8). Pre-
treatment hepatic GSH levels were similar between rats and possum, regardless of treatment (p > 
0.087; Figure 5.9). However, 15 minutes post-treatment, VCD-treated rat hepatic GSH levels were 
significantly lower than that of control and VCD treated possums (p < 0.002). Pre-treatment ovarian 
GSH concentrations of control and VCD treated rats were significantly higher than that of possum pre-
treatment levels (p < 0.001; Figure 5.10). However, regardless of the elevated ovarian GSH levels of 
rats at pre-treatment, VCD-treated rats were significantly decreased compared to both control and 
VCD-treated possums 15 minutes post-treatment (p < 0.022).  
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Figure 5.1 Red blood cell GSH levels of female brushtail possums and Norway rats following a 
single oral dose of oil or VCD (750 mg/kg) suspended in oil (1:3 v/v). Rats, n = 
2/treatment at 1, 3, 5, 10, 30, 60 and 120 minutes post-treatment; n =4/treatment at -
1 (pre-treatment), 15, 180 and 360 minutes post-treatment. Possums, n = 4/treatment 
at -1 (pre-treatment), 1, 3, 5, 10, and 15; n = 4/treatment at 30, 60, 120, 360 minutes 
and 24 hours post-treatment. Time axis is plotted on a logarithmic scale where -1.0 
represents the pre-treatment sample. Statistical significance was set at p < 0.05. 
Vertical bars represent ± SEM. 
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Figure 5.2 Plasma GSH levels of female brushtail possums and Norway rats following a single oral 
dose of oil or VCD (750 mg/kg) suspended in oil (1:3 v/v). Rats, n = 2/treatment at 1, 3, 
5, 10, 30, 60 and 120 minutes post-treatment; n =4/treatment at -1 (pre-treatment), 
15, 180 and 360 minutes post-treatment. Possums, n = 4/treatment at -1 (pre-
treatment), 1, 3, 5, 10, and 15; n = 4/treatment at 30, 60, 120, 360 minutes and 24 
hours post-treatment. Time axis is plotted on a logarithmic scale where -1.0 
represents the pre-treatment sample. Statistical significance was set at p < 0.05. 
Vertical bars represent ± SEM. 
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Figure 5.3 Average hepatic GSH levels of female brushtail possums following a single oral dose of 
oil or VCD (750 mg/kg) suspended in oil (1:3 v/v). Control treatment, n = 4/time point; 
VCD treatment, n = 4/time point. Values with difference letters are significantly 
different (p < 0.05). Vertical bars represent ± SEM. 
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Figure 5.4 Average ovarian GSH levels of female brushtail possums following a single oral dose of 
oil or VCD (750 mg/kg) suspended in oil (1:3 v/v). Control treatment, n = 4/time point; 
VCD treatment, n = 4/time point. Values with difference letters are significantly 
different (p < 0.05). Vertical bars represent ± SEM. 
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Figure 5.5 Hepatic GSH levels of female Norway rats following a single oral dose of oil or VCD (750 
mg/kg) suspended in oil (1:3 v/v). N = 2/treatment at 1, 3, 5, 10, 30, 60 and 120 
minutes post-treatment; n =4/treatment at -1 (pre-treatment), 15, 180 and 360 
minutes post-treatment. Time axis is plotted on a logarithmic scale where -1.0 
represents the pre-treatment sample. * indicates different (p < 0.05) from control. 
Vertical bars represent ± SEM. 
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Figure 5.6 Ovarian GSH levels of female Norway rats following a single oral dose of oil or VCD (750 
mg/kg) suspended in oil (1:3 v/v). N = 2/treatment at 1, 3, 5, 10, 30, 60 and 120 
minutes post-treatment; n =4/treatment at -1 (pre-treatment), 15, 180 and 360 
minutes post-treatment. Time axis is plotted on a logarithmic scale where -1.0 
represents the pre-treatment sample. * indicates different (p < 0.05) from control. 
Vertical bars represent ± SEM. 
 
Table 5.4 Average GSH concentrations in red blood cells, plasma, liver and ovaries of wild-caught 
female Norway rats during the 6 hours following a single oral dose of oil or VCD (750 
mg/kg) suspended in oil (1:3 v/v). * indicates different from control (p < 0.05). Vertical 
bars represent ± SEM. 
Tissue 
GSH (nmol/µL or mg tissue) 
Control treatment (n = 28) VCD treatment (n = 28) 
Red blood cells 0.79 ± 0.07 *0.67 ± 0.12 
Plasma 0.004 ± 0.001 0.003 ± 0.001 
Liver 4.41 ± 0.59 *0.99 ± 0.35 
Ovaries 4.64 ± 0.31 *0.68 ± 0.20 
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Figure 5.7 RBC GSH levels of wild-caught female brushtail possums and Norway rats during pre-
treatment and 15 minutes following a single oral dose of oil or VCD (750 mg/kg) 
suspended in oil (1:3 v/v). Rats, n = 4/treatment/time point; possums, n = 
4/treatment/time point. Statistical significance was set at p < 0.05. Vertical bars 
represent ± SEM. 
 
 
Figure 5.8 Plasma GSH levels of wild-caught female brushtail possums and Norway rats during pre-
treatment and 15 minutes following a single oral dose of oil or VCD (750 mg/kg) 
suspended in oil (1:3 v/v). Rats, n = 4/treatment/time point; possums, n = 
4/treatment/time point. Statistical significance was set at p < 0.05. Vertical bars 
represent ± SEM. 
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Figure 5.9 Hepatic GSH levels of wild-caught female brushtail possums and Norway rats during pre-
treatment and 15 minutes following a single oral dose of oil or VCD (750 mg/kg) 
suspended in oil (1:3 v/v). Rats, n = 4/treatment/time point; possums, n = 
4/treatment/time point. Values with different letters are significantly different (p < 
0.05). Vertical bars represent ± SEM. 
 
 
Figure 5.10 Ovarian GSH levels of wild-caught female brushtail possums and Norway rats during 
pre-treatment and 15 minutes following a single oral dose of oil or VCD (750 mg/kg) 
suspended in oil (1:3 v/v). Rats, n = 4/treatment/time point; possums, n = 
4/treatment/time point. Values with different letters are significantly different (p < 
0.05). Vertical bars represent ± SEM. 
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 Discussion 5.4
In an attempt to ascertain species differences in VCD-induced ovarian toxicity of wild Norway rats 
and brushtail possums, the fate and metabolism of orally administered VCD was examined. VCD was 
detected in the blood of possums and rats as early as 1 to 2.5 minutes following treatment, 
demonstrating that VCD, once present in the stomach, is rapidly absorbed. The concentration of VCD 
in the blood was significantly greater in rats compared with possums. One reason for this could be that 
the amount of VCD available for absorption from the stomach into the blood was higher in the rats. 
However, 15 minutes after treatment there were no differences in the amount of VCD recovered in the 
stomach contents of each species. It is reasonable to assume that any VCD not present in the stomach 
had either been absorbed into the blood stream or was rapidly hydrolysed by stomach acid. Therefore, 
these differences in blood VCD concentration during the first 15 minutes following treatment may 
suggest differences in the stomach environment or the VCD uptake rate for each species.   
VCD, when exposed to acidic environments, is hydrolyzed to an inactive tetrol metabolite (Figure 
2.5). The pH of possum stomach contents ranges between 1.0 and 2.0 and does not appear to be 
affected by time since feeding (Drs J. Duckworth & F. Molinia, pers. comm.). Conversely, pH of 
rodent stomach contents ranges between 3.2 (fed) and 3.9 (fasted) (McConnell et al., 2008). 
Considering these species differences in stomach pH it is plausible to assume that VCD administered 
orally to possums would be hydrolysed at a faster rate than in rats. Fifteen minutes after VCD 
treatment, the stomach pH of both possums and rats was elevated but this effect was more pronounced 
in the possum stomach (possum: pH increase of 212% of control; rat: pH increase of 30% of control). 
These species differences in stomach pH following oral administration of VCD may explain why VCD 
was still detected in the blood of rats for at least 30 minutes post-treatment and why VCD had 
disappeared by 10 to 15 minutes post-treatment in the possums. However, as there were only three 
measurements of stomach pH recorded from the possums, these conclusions should be treated with 
some caution.  
VCD treatment caused GSH depletion in the liver and ovary of the rat up to 6 hours following 
treatment. Previous studies in rats and mice treated with VCD show similar patterns wherein GSH is 
reduced from 1 to 6 hours following treatment (Giannarini et al., 1981; Salyers, 1995). Rodent studies 
have also revealed that the two expoxides of VCD are substrates for GSH conjugation which form 
VCD-monoGSH and VCD-diGSH adducts (Rajapaksa, 2007). In mice, VCD-monoGSH and VCD-
diGSH adducts do form in both the liver and ovaries and by 24 hours post-treatment it is presumed 
that the adducts are excreted via the urine or bile (Salyers, 1995) as levels are undetectable (Rajapaksa, 
2007).  
Conversely, VCD treatment of possums did not cause hepatic or ovarian GSH levels to differ from 
controls. However, it must be noted that there are only two post-treatment time points at which 
samples were collected. One possibility is that VCD did induce reductions in possum GSH levels that 
were missed by this sampling regimen. Interestingly, hepatic and ovarian GSH levels of the VCD 
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treated possums were higher at 24 hours than at pre-treatment and 15 minutes. Previous research has 
demonstrated that following initial VCD-induced GSH reduction in rodents hepatic and ovarian GSH 
levels rebound and surpass both their initial levels and those of controls by 25 hours (Salyers, 1995). 
This rebound effect of liver GSH following initial depletion in rodents is common and elevated GSH 
can be sustained for several days (Viña, 1990). It is possible that the elevated GSH levels of VCD-
treated possums measured at 24 hours were responding in a similar fashion. If so, this would give 
support to the possibility that VCD-induced effects were occurring to some degree in the liver and 
ovaries of possums. VCD-treated rats did not survive to 24 hours so it is not possible to speculate 
whether a similar pattern in overcompensation of GSH would have occurred during this study.  
An alternative and more likely explanation for the lack of effects to possum GSH levels is that there 
were insufficient amounts of VCD reaching the liver and ovaries in the possums to impact on GSH 
metabolism in those tissues. This is supported by the low levels of VCD detected in possum blood and 
similar patterns observed in GSH levels of control possums at 24 hours. It is more likely that the 
observed increase in GSH levels measured at 24 hours represents a recovery (rebound) period 
following anaesthetic-induced GSH reduction. Possums were continuously kept under anesthesia for 
approximately 15 to 17 minutes during pre- and post-treatment blood sampling. Hepatic GSH levels in 
both control and VCD-treated possums at 15 minutes post-treatment are slightly reduced compared to 
pre-treatment levels which may be indicating effects from anesthesia. Although published studies have 
demonstrated that isoflurane/O2 anaesthesia does not affect plasma GST levels (Allan et al., 1987; 
Hussey et al., 1988) or induce hepatotoxicity in rodents and humans (Raper et al., 1987), the present 
observation could be interpreted as evidence for isoflurane having hepatotoxic effects in the possum.   
There were no differences in hepatic GSH pre-treatment levels of untreated (control) rats and 
possums. Following treatment with VCD GSH levels in the liver and ovary of rats were much lower at 
15 minutes than in the possums. At first glance, this may seem to suggest that the rat is more sensitive 
to VCD-induced GSH detoxification but again the very low amount of VCD measured in the blood of 
the possums indicates that there may have been insufficient levels of VCD reaching the liver and 
ovaries of possums to induce any reductions in GSH. The limited number of data points available from 
this study makes it difficult to compare VCD detoxification rates between possums and rats. It is well 
established that there are species differences in metabolism between laboratory-bred mice and rats 
(Kao et al., 1999; Keller et al., 1997; Salyers, 1995; Smith et al., 1990b) and so it is possible that there 
are differences in VCD metabolism between possums and rats. In rodents, metabolism of VCD is also 
achieved through the action of EH (Hoyer and Sipes, 2007; Van Kempen et al., 2011). Measurement 
of EH content following VCD treatment in possums may bring to light potential species differences in 
VCD metabolism. It was my aim to examine VCD-induced effects on hepatic and ovarian EH levels in 
each species. However, the methods were beyond the scope of this project.   
Potential similarities or differences between possum and rat metabolism may further be explained by 
examining other metabolic pathways. 4-Vinylcyclohexene (VCH), the parent compound of VCD, is 
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metabolized to VCD in a Phase I reaction primarily by CYP450 (Doerr-Stevens et al., 1999; Doerr et 
al., 1996; Springer et al., 1996c). Rats and marsupials, including possums, the tammar wallaby 
(Macropus eugenii) and the koala (Phascolarctos cinereus), have demonstrated similarities in the 
content, activity and inhibition of CYP450 (Stupans et al., 2001). Although the effect of VCH 
treatment has not been compared between rats and possums, it can be hypothesised that because of 
these CYP450 similarities, possums may metabolize VCH via a Phase 1 reaction in a similar fashion 
to that of rats. It may be further hypothesized that similarities in Phase II reactions (i.e. GSH and EH) 
exist between these two species. In this report, untreated rats and possums showed similarities in 
hepatic GSH content, supporting the potential for species similarities in Phase II metabolism. 
However, without a broader understanding of the effects of VCD on the content and activity of 
possum Phase II metabolism little can be concluded on the differences or similarities between rats and 
possum metabolism.   
The dietary evolution of possums may suggest a potential enhanced ability for metabolic clearance of 
xenobiotics such as VCD. Brushtail possums evolving in Australia relied greatly on specific 
Eucalyptus species, which are high in plant secondary metabolites (PSMs), as their major food source 
(Stupans et al., 2001). As a result of this dietary specialization, it has been postulated that they evolved 
highly efficient Phase I and II enzyme systems for metabolism of PSMs. Therefore, although there 
may be species similarities in the GSH content, it is possible that possums are simply more efficient at 
metabolizing xenobiotics such as VCD. A study examining the toxicity of a commonly used poison, 
brodifacoum, demonstrated that the length of sickness and time to death were shorter in Norway rats 
compared with possums at the same dose per kg live weight (Littin et al., 2000). There were no 
species differences in absorption and distribution of the poison (Littin et al., 2000), therefore 
suggesting that rats have reduced detoxification capacity compared to possums. In addition, it has been 
demonstrated that carnivorous marsupials are able to metabolize the commonly used poison, sodium 
monofluoroacetate (1080), more readily than carnivorous eutherians of comparable size and diet (feral 
cat, Felis catus; dingo, Canis familiaris dingo) (McIlroy, 1981). Collectively, these studies suggest 
that marsupials possess an enhanced metabolic ability for detoxifying xenobiotics such as VCD than 
that of rodents.  
In order to utilize VCD as a chemosterilant for wild pest populations such as possums and rats, it 
should be deliverable through an oral route. The data presented here support the conclusion that the 
high acidic environment of the possum stomach poses an initial barrier for orally delivered VCD. If 
sufficient quantities of VCD were able to overcome the high stomach acidity of possums, the 
questions would be whether ovarian toxicity could occur or would the presumed high efficiency of the 
possums phase II hepatic reaction negate any possible effects on the ovarian follicle populations? It 
was our aim to provide proof-of-principle for VCD-induced primordial follicle depletion in possums 
through in vitro ovarian follicle culture. However, due to the difficulties discussed in Chapter 6, these 
trials were not conducted. Therefore, examination of VCD and VCH in vitro hepatic metabolism in 
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possums and rats is described in the following chapter. In addition, there is an exploration of the in 
vitro effects of stomach acidity on VCD hydrolysis for each species.      
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Chapter 6 
The fate of 4-vinylcyclohexene diepoxide in blood and stomach 
tissues and its effects on liver metabolism of female brushtail 
possums and Norway rats  
 Introduction 6.1
In the previous chapter the effects of orally delivered VCD on stomach acidity and on VCD’s 
chemical clearance rates, its uptake into the blood, and its effects on liver and ovarian glutathione 
(GSH) levels in possums and rats were examined. VCD treatment resulted in rat stomach pH 
increasing within 5 minutes of treatment and it remained elevated for up to 6 hours whereas the pH of 
possums’ stomachs did not change. The highly acidic nature of possums’ stomach contents (pH 
between 1.0 and 2.0; Drs J. Duckworth & F. Molinia, pers. comm.) and their ability to maintain low 
pH levels following VCD treatment would infer that VCD hydrolysis should occur rapidly; yet some 
of the VCD dose was still detected at similar levels in both rats and possums at 15 minutes post 
treatment. This, in combination with the lower VCD levels detected in possum blood compared with 
that of rats, may indicate that the stomach contents of possums are able to absorb and protect the 
chemical from acid hydrolysis to some degree.  
Protection of VCD may prolong absorption of the chemical from the stomach and intestines into the 
blood. It is believed that VCD’s ovarian toxicity is largely due to repeated exposure, thereby 
overwhelming and ultimately reducing the capacity of the detoxifying enzymes (i.e. liver and ovarian 
derived GSH and epoxide hydrolase)  (Hu et al., 2002; Keating et al., 2008a; Keating et al., 2010). 
Therefore, the presumed slower rate of VCD absorption in the possum gastrointestinal tract may in 
fact prove serendipitous as it could offer a prolonged period of time for the detoxifying enzymes to 
become overwhelmed by repeated, slow exposure to VCD.  
It was further speculated in Chapter 5 that the dietary evolution of possums may explain, in part, why 
VCD is not effective at reducing their immature ovarian follicle populations. Brushtail possums 
evolving in Australia consumed specific Eucalyptus leaves, which are high in plant secondary 
metabolites (PSMs) (Stupans et al., 2001). As a result of this dietary specialization, it has been 
postulated that possums have evolved highly efficient Phase I and II enzyme systems for metabolism 
of PSMs. Therefore, it was proposed that possums would likely metabolise VCD more rapidly and 
efficiently compared with rats; presuming sufficient quantities of VCD were able to reach the liver and 
ovaries.  
The studies presented here first examine the in vitro effects of acid on VCD hydrolysis and whether 
the presence of stomach contents of each species alters the rate of hydrolysis. VCD’s effects on GSH 
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are further examined through in vitro incubation of liver tissue from possums and rats with VCD. It 
was predicted that the stomach contents of possums would absorb, retain, and protect VCD more 
effectively than those of rats, thereby providing a potential protection mechanism of possums against 
xenobiotic toxicity. In addition, it was predicted that possum liver tissue would metabolize VCD more 
readily than the liver tissue of rats. 
A pilot study examining potential differences in phase I metabolism of each species was also 
investigated. 4-Vinylcyclohexene (VCH), the parent compound of VCD, is metabolized to VCD in a 
Phase I reaction primarily by the hepatic-derived enzyme superfamily cytochrome P450 (CYP450) 
(Doerr-Stevens et al., 1999; Doerr et al., 1996; Springer et al., 1996c). Therefore, liver microsomes of 
possums and rats were incubated in vitro with VCH and changes to CYP450 concentrations compared 
over time. It was predicted that possums would be more efficient than rats at metabolizing VCH.    
 Materials and Methods   6.2
6.2.1 Reagents 
VCD, VCH 1,2-isomer, cyclohexanone, ethyl acetate, sunflower oil, Attane™ isofluorane, and sodium 
pentobarbital were obtained from vendors and used for experimental procedures as previously 
mentioned in Chapter 3. M199 medium (M4530) was purchased from Sigma-Aldrich (Auckland, NZ). 
4-vinyl-1-cyclohexene (VCH; lot #A0332276; cas. 100-40-3) was purchased from Acros Organics 
(New Jersey, USA). Sodium hydrosulphite, glycerol and sucrose were purchased from Sigma-Aldrich 
(Auckland, New Zealand). EDTA and TrisCl , used to create buffers, were purchased from BDH 
(Radnor, USA). Carbon monoxide was purchased from BOC gases (Wellington, New Zealand).  
6.2.2 Animal procedures  
Animals (rats, n = 6; possums, n = 11) were anaesthetized (5% isoflurane in O2 at 2 L/min) and once 
sedated blood samples were collected via intracardiac puncture into lithium heparinised tubes (BD 
Vacutainer®) and then treated as outlined below. Animals were euthanized with an intracardiac 
injection of pentobarbitone (125 mg/kg). The stomach was excised and the contents removed, weighed 
and pH measured using pH indicator strips (Merck) and then treated as outlined below. The liver was 
immediately removed, weighed and then prepared for GSH or CYP450 analysis as outlined below. 
6.2.3 VCD hydrolysis in a range of acidic environments 
In order to better understand the effects of acid on VCD hydrolysis, VCD was exposed to a range of 
acid environments for a set period of time. The physiological buffer solution, M199, was used as the 
standard diluent for all experimental procedures. In a pilot study, the effect of diluting with ultrapure 
water and M199 were compared to ensure that the additives in the M199 medium were not influencing 
VCD hydrolysis or protecting VCD from acid degradation. The pH of the ultrapure water was adjusted 
to 1.0 or 2.5 pH (± 0.2) while M199 was adjusted to 1.0, 2.5, or 5.0 (± 0.2). Both diluents were 
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warmed to 21 ± 1 °C and then aliquoted into glass scintillation vials (2.0 mL/vial). VCD (0.0, 1.84, 
3.69, 5.53, or 7.40 mM; mixed 1:3 v/v in oil) was added to each of the solution combinations, mixtures 
were vortex mixed for 15 seconds and then placed in a shaking incubator (300 rpm, 21°C) for 15 
minutes. Reactions were then terminated by the addition of 2 times the sample volume of ethyl acetate 
(EA) containing the internal standard 4-vinyl-1-cyclohexene-1,2-isomer (VCH-isomer; 1.05 mM). 
VCD and its tetrol metabolites were extracted from each solution in three successive rounds wherein 
vials were vortex mixed for 30 seconds and shaken for 10 minutes at 500 rpm. Phases were separated 
by centrifugation (3000 x g for 10 min, 21°C) and three aliquots (500 µL) of the organic layer (top 
layer) were placed into 2.0 mL amber Crimp-Top vials. The samples were run on gas chromatography 
(GC) in triplicate and VCD quantified as outlined in Chapter 3. Following this pilot study there was 
some evidence that a portion the VCH-isomer (internal standard) was degraded during the EA 
extraction step. This was indicated by the presence of VCD in the control vials (no VCD added) 
following acid treatment. An additional trial utilizing the internal standard cyclohexanone (1.18 mM) 
was run as verification for the presence of VCD in the control vials. Following positive confirmation, 
the effect of VCH-isomer conversion to VCD was thereafter corrected by subtracting the 
concentration of VCD in control samples from the VCD concentrations in each corresponding 
treatment vial. From these studies it was determined that there were no differences in the hydrolysis 
rate of VCD diluted in either water or M199. Therefore, all subsequent experiments used M199 as the 
diluent.      
6.2.4 VCD hydrolysis in stomach contents and blood 
Stomach treatment 
The effect of stomach acid and stomach contents on VCD hydrolysis was examined in possum and 
rats. To mimic temperatures found in vivo, in vitro conditions were matched by incubating the 
stomach contents of each species at 37°C throughout the experiment. The pH of possum stomach 
contents ranges between 0.5 and 2.0 (Chapter 5; Drs J. Duckworth & F. Molinia, pers. comm.) while 
that of a rodent stomach ranges between 0.5 and 3.7 (Chapter 5). For between-species comparisons 
and to standardise pH levels across replicates, the pH of possum stomach contents was adjusted to 1.0 
± 0.1 or 2.5 ± 0.1 (i.e. typical possum in vivo pH range) and rodent stomach contents were adjusted to 
a pH of 2.5 ± 0.1 (i.e. typical rat in vivo pH range). Stomach contents were collected fresh from 
animals just prior to the trial starting. For each species, equal aliquots of stomach contents (0.1 – 0.2 g) 
were placed into glass scintillation vials and 4 times the sample volume of M199 (heated to 37°C) was 
added and the pH of each sample was then altered to within ±0.1 of desired range. For each unique 
treatment a corresponding blank (M199 only, equal pH and volume as stomach contents) and a 
corresponding neutral blank (pH 7.0) were examined at each time point. To avoid stomach contents 
adhering to the sides of the container, samples were centrifuged for 2 minutes (3000 x g at 37°C) to 
ensure all stomach contents were retained within the solution. Reactions began by the addition of VCD 
(0.0, 1.22 or 2.43 mM mixed 1:3 v/v in oil) and gently vortex mixed (500 rpm) for 15 seconds to 
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ensure even distribution throughout the stomach contents matrix. Samples were placed into a shaking 
incubator at 37°C and reactions terminated at 3, 5, 10, 15, 30, 60, 120 and 360 minutes with the 
addition of EA containing the internal standard, VCH-isomer. VCD was extracted and samples 
prepared for GC analysis as stated in section 6.2.3.  
Whole blood treatment 
The aim of this experiment was to examine if VCD is affected by the blood matrix as it is transported 
to the target organ, the ovary. Whole blood (3.0 - 4.0 mL) was collected into lithium heparin 
vacutainer tubes (BD Vacutainer®) which were inverted several times, and then kept at 37°C during 
the experimental period. For each species’ blood sample, two treatments were prepared in glass 
scintillation vials: A) whole blood (0.167 – 0.375 mL) diluted with 4 times the sample volume of 
M199 (heated to 37°C) or B) whole blood only (0.67 – 1.5 mL; volumes were matched to treatment 
A). A corresponding blank (M199 only; final volume matched to treatments A and B) was also 
examined at each time point. Reactions began by the addition of VCD (0.0, 0.185 or 0.364 mM mixed 
1:3 v/v in acetone) and gently vortex mixed (500 rpm) for 15 seconds to ensure even distribution 
throughout the blood matrix. Samples were placed into a shaking incubator at 37°C and reactions 
terminated at 3, 10, 15, 20, and 30 minutes with the addition of EA containing the internal standard, 
VCH-isomer. VCD was extracted and samples prepared for GC analysis as stated in section 6.2.3. 
6.2.5 Glutathione assay sample preparation and analysis 
The effect of VCD on possum and rat Phase II metabolism was examined by measuring in vitro 
changes in hepatic GSH concentrations. Originally the aim was also to examine in vitro the effect of 
follicle stage (primordial, primary, and secondary follicles) on the GSH response to VCD; hence, the 
selection of M199 as the sample diluent. However, follicle isolation techniques (Flaws et al., 1994) 
proved difficult and we could not procure sufficient amounts of ovarian tissue from appropriately aged 
animals (pouch young aged 80-100 days:  age at which primordial follicles are first formed) (Eckery et 
al., 1996) during the course of the studies. Attempts at in vitro culturing of 1 x 1 mm explants (Wandji 
et al., 1996) from the cortex of adult possum ovaries were also made (D. Eckery, personal comm.). 
Although harvesting of the explants was successful, the resulting tissue destruction resulted in low 
follicle survival rates. In addition, primordial follicles were not evenly distributed throughout the 
cortex of each ovary and therefore very large replicates would be required to obtain statistically 
significant results. It was evident that variation would likely affect the power of any statistical analyses 
and solving such difficulties was beyond the scope of this project.  
For each species, livers were perfused with ice-cold PBS and then placed into aluminium foil, sealed 
and snap frozen with liquid nitrogen. Individually, frozen livers, wrapped in aluminium foil, were 
broken into small particles using a mallet and then combined into one liver stock preparation. Initially, 
microsomes, prepared as outlined for the CYP450 experiments (section 6.2.6), were utilized for these 
GSH experiments. However, interference with the microsomal buffers occurred when running the 
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GSH assay. In addition, purified microsomal GSH concentrations were below the detection limit. 
Therefore, supernatant 9000 (S9) liver fractions were prepared by adding 2.5 g of liver stock into an 
ice-cold glass homogenizer and then 4 times the volume of ice-cold PBS was added and tissue 
homogenized with 10 passes of the pestle while on ice. The homogenate was transferred to conical 
tubes and centrifuged at 10,000 x g for 30 minutes at 4°C. The concentrated supernatant was then 
transferred to cryostat vials and immediately snap frozen. The protein content of the S9 fraction was 
measured using the Bradford protein assay (Bio-Rad Laboratories) using bovine serum albumin (BSA) 
as a standard.  
For each species, the S9 fraction was slowly defrosted on ice to prevent activation or denaturing of 
enzymes. The solution was diluted to a protein content of 15 mg/mL using ice-cold PBS and then 
divided into two glass scintillation vials. One vial was kept on ice while the other vial was placed in a 
boiling water bath (100 ± 5°C) for 10 minutes to ensure all protein was denatured and then the sample 
was divided evenly into two glass scintillation vials, creating two treatments: 1) negative control: heat-
shocked S9 fraction (no additives); 2) negative treatment: heat-shocked VCD-treated S9 fraction (7.13 
mM). Samples were allowed to cool to room temperature before trial start. The live S9 fraction sample 
kept on ice was divided evenly into two glass scintillation vials, creating two treatments: A) positive 
control: live S9 fraction (no additives); and B) positive treatment: live VCD-treated S9 fraction (7.13 
mM). Live sample vials were then placed into a shaking incubator (37⁰C) for 10 minutes at 200 rpm to 
allow enzymes to activate. The trial began with the addition of VCD into the live and heat-shocked 
treated vials. At 0, 5, 10, 15, 20 30, 45 and 60 minutes 100 µL of each solution was removed, placed 
into a cryostat tube and snap frozen with liquid nitrogen. All vials were kept in a heated shaker (37°C) 
during the incubation period and all experimental procedures were run in duplicate. 
In preparation for GSH concentration quantification, all samples were slowly defrosted on ice. 
Samples were then deproteinized by removing 20 µL of sample and adding it to 560 µL (28 times the 
sample volume) of ice-cold 5% SSA. Samples were incubated at 4°C for 10 minutes and then 
centrifuged at 10,000 x g for 10 minutes at 4°C. GSH concentration (nmol/mg protein solution) was 
measured in triplicate for each sample using methods described in the GSH assay kit (Sigma, cat# 
CS0260) with changes as outlined in Chapter 3.    
6.2.6 CYP450 pilot study 
Hepatic CYP450 sample preparation  
For each species, livers were perfused with ice-cold PBS and then snap frozen with liquid nitrogen. 
For each species, (possums, n = 8; rats, n = 8) the livers of individual animals were combined to make 
one stock, wrapped in aluminium foil and then broken into small particles using a mallet. 
Approximately 5 g of liver stock was measured into an ice-cold glass homogenizer and 4 times the 
sample volume of GET buffer (20% glycerol, 0.5M EDTA, 1.0M TrisCl, pH 7.4) was added and liver 
homogenized with 15 passes of the pestle. The homogenate was then aliquoted into ultracentrifuge 
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tubes and centrifuged at 9000 x g for 30 minutes at 4⁰C using a Beckman JL-90 ultracentrifuge fitted 
with a JA-20 rotor. The supernatant was pooled and then transferred into ultracentrifuge tubes and 
centrifuged at 105,000 x g for 60 minutes at 4⁰C. The supernatant was discarded and the pellet 
suspended with SET buffer (1.0 mL/g organ weight; 25% sucrose, 0.5M EDTA, 1M TrisCl, pH 7.4). 
To ensure the pellet was well redistributed, the mixture was transferred to an ice-cold homogenizer 
and homogenized with 5 passes of the pestle while on ice. The homogenate was transferred back into 
ultracentrifuge tubes and centrifuged at 105,000 x g for 60 minutes at 4⁰C. The supernatant was 
discarded and the pellet suspended in GET buffer (1.0 mL/g organ weight). The suspension was snap 
frozen (1.0 mL aliquots) in liquid nitrogen and stored at -80⁰C until analysis. Protein content was 
analysed using the Bradford protein assay (Bio-Rad Laboratories) using BSA as a standard.  
CYP450 assay method development and validation 
Optimization of carbon monoxide exposure method and incubation time 
To determine the optimal method for measuring CYP450 content in possum and rat hepatic 
microsomes, two carbon monoxide (CO) exposure methods were tested and compared (Choi et al., 
2003; Omura and Sato, 1964). For each species, hepatic microsomes were transferred from a -80⁰C 
freezer into a -20⁰C freezer for 30 minutes and then placed on ice to allow samples to defrost slowly. 
Microsomes were diluted to 1.0 mg protein/mL with GET buffer and then bubbled with CO for 30 
seconds (0.5 mL aliquots in glass scintillation vials) (Omura and Sato, 1964) or placed into a 96-well 
flat bottom plate (200 µL aliquots). The plate was then placed into a CO chamber (Figure 6.1), the 
chamber was sealed and then CO was allowed to flow freely into the chamber for 2 minutes (0.5 
L/min) while on a shaker (300 rpm) (Choi et al., 2003). The exit hose was placed into a water-filled 
beaker to ensure gas flow was continuous. The CO chamber was located within a fume hood to avoid 
any potential harm from gas vapours. For each method, following CO treatment samples were 
transferred into disposable cuvettes (10mm light path; LPI, Italy) and the baseline absorbency 
recorded. The haemoproteins in the sample were then reduced (solubilized) by the addition of 5.0 mg 
of sodium hydrosulphite (SHS) powder, left to stabilise for 2 minutes, and then the resulting spectra 
between 400 and 500 nm were measured (Omura and Sato, 1964). It was determined that the CO 
chamber (Choi et al., 2003) would be the most appropriate method to use as both methods offered 
similar repeatability but absorbency readings were higher for each species (Figure 6.2) and sample 
analysis would be more efficient and precise when using the CO chamber.  
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Figure 6.1 The carbon monoxide (CO) chamber (15 x 10 x 4 cm). A 96-well flat bottom plate 
containing samples is placed inside the chamber, the chamber is sealed and then CO is 
allowed to flow freely into the chamber. The exit hose was placed into a water-filled 
beaker to ensure gas flow was continuous. All procedures were carried out within a 
fume hood. Adapted from Choi et al. (2003). 
 
 
Figure 6.2 Comparison of absorbency potential of female possum and rat hepatic microsomes using 
the CO chamber or the CO bubbling method. Absorbance (ABS) was measured 
between 400 and 500 nm.   
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Optimization of CO chamber incubation time 
To determine the optimal CO chamber incubation time, hepatic microsomes were diluted to 1.0 mg 
protein/mL GET buffer and 6 samples (200µL) were prepared as follows. Three replicates were 
designated as reduced P450 (PR) samples (negative control). To prevent the P450-CO complex 
forming in these PR samples, the wells were sealed with tape to ensure no CO access. The other 3 
samples were designated as reduced P450-CO complex (PC) samples (positive control) and the wells 
were allowed full exposure to the CO chamber environment. In addition, the PR and PC samples were 
kept at a maximum distance from each other within each plate to further ensure separate treatment 
parameters were met.  The plate was then placed into the CO chamber, the chamber was sealed and 
CO administered for 0 to 12 minutes as previously described. The plate was removed from the CO 
chamber, the PR sample tape was removed and PR and PC samples reduced with 10.0 µL of a 0.5 M 
SHS solution (in ultrapure water) (Choi et al., 2003) using a multichannel pipette. SHS, when in a 
liquid state, oxidizes on contact with air. Therefore, SHS powder was pre-measured before each 
experiment and ultrapure water was added just prior to its use (< 2 minutes). Absorbance was 
measured at 450 nm (Soret peak) and 490 nm (Isobestic point) on a microplate reader (VarioSkan 
Flash, Thermo Scientific, USA) at 37⁰C. The change in absorbency was calculated using the following 
formulas: ΔAPC = APC450 – APC490 and  ΔAPR = APR450 - APR490, where ΔAPC is the absorbance of 
the P450-CO complex (PC) sample and ΔAPR is the absorbance of the P450-reduced (PR) sample 
(Choi et al., 2003). The absorbency difference was calculated by subtracting ΔAPC from ΔAPR. The 
concentration of CYP450 was calculated using the following formula: [CYP450](mM/mg microsomal 
protein) = ΔAPC - ΔAPR)/91 where 91 is the millimolar difference extinction coefficient (Omura and 
Sato, 1964). An optimal incubation time of 2 minutes within the CO chamber was selected (Figure 
6.3). 
 
 
Figure 6.3 Optimization of CO chamber incubation time for female possum and rat hepatic 
microsomes. 
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Optimization of SHS reduction volume 
To determine the optimal SHS reduction volume hepatic microsomes (possum or rat) were diluted to 
1.0 mg/mL and then 3 replicates (200 µL) for each PR or PC treatment were placed into the wells of a 
96-well flat bottom plate. The PR samples were sealed with tape, the plate placed into the CO chamber 
and samples exposed to CO as previously described. The plate was then removed from the CO 
chamber, the PR sample tape was removed and samples were reduced with 0.0, 5.0, 10.0 or 15.0 µL of 
a 0.5 M SHS solution and then the difference in absorbency measured as previously described. It was 
determined that a volume of 10.0 µL of SHS was most stable and efficient at reducing the 
haemoproteins in each species (Figure 6.4). 
 
 
 
Figure 6.4 Optimization of SHS volume addition for reduction of female possum (A) or rat (B) 
microsomes. 
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Optimization of protein content  
To determine the optimal protein concentration for each species, hepatic microsomes were diluted to 
0.0, 0.05, 0.09, 0.19, 0.38, 0.75, 1.5, 3.0 or 6.0 mg protein/mL in GET buffer. Three aliquots of 200 
µL per concentration were added to a 96-well flat bottom plate and placed into the CO chamber for 2 
minutes, reduced with 10.0 µL of SHS and the difference in absorbency measured as previously 
described. Changes in absorbency showed a strong linear relationship over time and a 1.0 mg/mL 
protein concentration was selected for subsequent assays (Figure 6.5).   
 
 
Figure 6.5 Optimization of microsomal protein content for female possum and rat hepatic 
microsomes. 
 
CYP450 analysis 
For each species, hepatic microsomes were transferred from a -80⁰C freezer into a -20⁰C freezer for 
30 minutes and then placed on ice to allow samples to defrost slowly. Samples were diluted to 1.0 mg 
protein/mL using GET buffer and then divided evenly into two glass scintillation vials. One vial was 
kept on ice while the other vial was placed in a boiling water bath (100 ± 5°C) for 10 minutes to 
ensure all protein was denatured. To avoid any disruption from the protein residues created following 
boiling, the sample was filtered through a tissue sieve (Cellectortm, 75µm, Belco Glass Inc., New 
Jersey, USA) and then the sample was divided into glass scintillation vials for the following 
treatments: 1) negative control: dead microsomes (no additives); 2) negative treatment: dead VCH-
treated microsomes (0.0, 4.0 or 8.1 mM). Samples were allowed to cool to room temperature before 
treatment started. The live microsome sample was kept on ice and aliquoted into two glass scintillation 
vials for the following treatments: A) positive control: live microsomes (no additives); B) positive 
R² = 0.9564 
R² = 0.9663 
R² = 0.9915 
R² = 0.9887 
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0 1 2 3 4 5 6 7
Δ
 A
B
S 
Protein content (mg/mL) 
Possum PR Possum PC Rat PR Rat PC
  89 
treatment: live VCH-treated microsomes (0.0, 4.0 or 8.1 mM). Live sample vials were then placed into 
a shaking incubator (37⁰C) for 10 minutes at 200rpm to allow microsomes to activate. The trial began 
with the addition of VCH to the live and dead treatment vials. Vials were placed into a shaking 
incubator (37°C, 200 rpm) and at each time point (possums: 3, 10, 15, 30, 60 and 120 minutes; rats: 3, 
15, 30, 60 and 120 minutes) 6 aliquots of 200 µL were removed from each treatment and transferred to 
a 96-well flat bottom plate. Three aliquots of each treatment were designated as PR samples and tape 
was placed on these wells to ensure no CO access. In addition, the PR and PC samples were kept at a 
maximum distance from each other within each plate to ensure treatment parameters were met. The 
plate was then placed into the CO chamber, exposed to CO, samples reduced with 10.0 µL SHS and 
the difference in absorbency was recorded as previously described. Three readings (0, 1, and 2 
minutes) were collected and the average absorbency was used to calculate cytochrome P450 
(CYP450) content as outlined above.       
6.2.7 Statistical Analysis    
All general statistical procedures were run as previously outlined in Chapter 3. The concentrations of 
VCD and GSH were analysed using a repeated measure test with treatment group defined by time.  
 Results   6.3
6.3.1 VCD hydrolysis in a range of acidic environments 
To determine the effects of acid on VCD hydrolysis, VCD was incubated at room temperature (21 ± 1 
°C) in a range of acid levels (1.0, 2.5 or 5.0) in either ultrapure water or M199 medium and then the 
percentage of the total VCD dose remaining after 15 minutes was compared with a VCD dose 
incubated in a neutral environment (pH 7.0). There were no differences in VCD hydrolysis when 
incubated in water or M199, regardless of pH (p > 0.117). Therefore, only the effect of the medium 
M199 on VCD will be reported in detail. Incubating two concentration levels of VCD (1.84 or 3.69 
mM) in an M199 pH-neutral solution for 15 minutes resulted in 44.4 ± 0.13 and 70.5 ± 0.22 %, 
respectively, of the total chemical concentration being hydrolysed (Figure 6.6). At an acidity level of 
pH 1.0 and 2.5, 99.9 ± 0.01 and 99.0 ± 0.02 %, respectively, of VCD was hydrolysed, regardless of the 
initial concentration (Figure 6.6 and Table 6.1). A pH of 5.0 caused 88.0 ± 2.0 % of VCD to 
hydrolyse, regardless of the initial concentration (Figure 6.6). Acid significantly reduced VCD 
concentrations (1.84, 3.69, 5.53, or 7.38 mM) at all pH exposure levels (1.0, 2.5, or 5.0 pH) compared 
with a pH of 7.0 (p < 0.015; Figure 6.6). 
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Figure 6.6 The effect of acid on VCD hydrolysis when incubated in pH-altered M199 at 21 ± 1 °C for 
15 minutes. Following incubation, remaining VCD was extracted using ethyl acetate 
and quantified on GC. Percentages above each data set represent the amount of VCD 
that was hydrolysed during incubation. Levels not connected by the same letter are 
significantly different (p < 0.05). Vertical bars represent + SEM.    
 
Table 6.1 Percentage of VCD hydrolysed when incubated for 15 minutes at a pH of 2.5 in M199 at 
room temperature (21 ± 1 °C), M199 medium heated to biological temperature (37 ± 1 
°C) or the stomach contents of rats or possums mixed 1:4 (v/v) in M199 medium 
heated to 37 ± 1 °C. Data are means ± SEM.      
Matrix 
Amount of VCD 
added (mM) 
Amount of VCD 
remaining (mM) 
% VCD 
hydrolyzed 
M199 @ 21°C 
0.00 0.00 ± 0.00 N/A 
1.84 0.02 ± 0.001 99.0 ± 0.06 
3.69 0.04 ± 0.001 99.0 ± 0.11 
5.53 0.05 ± 0.003 99.1 ± 0.06 
7.38 0.08 ± 0.002 98.9 ± 0.2 
M199 @ 37°C 
0.00 0.00 ± 0.00 N/A 
1.22 0.24 ± 0.12 79.3 ± 6.59 
2.43 0.54 ± 0.27 77.9 ± 11.1 
Rat stomach contents + M199 
@ 37°C 
0.00 0.00 ± 0.00 N/A 
1.22 0.0 ± 0.0 100.0 ± 0.00 
2.43 0.16 ± 0.02 93.5 ± 0.70 
Possum stomach contents + 
M199 @ 37°C 
0.00 0.00 ± 0.00 N/A 
1.22 0.41 ± 0.002 66.3 ± 0.19 
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6.3.2 VCD hydrolysis in stomach contents  
VCD was incubated in pH-controlled M199-diluted stomach contents (1:4, v/v; 37 ± 1 ºC) of rats or 
possums or in pH-controlled M199 only (37 ± 1 ºC) and the rate of chemical hydrolysis was compared 
between species and treatments. When 1.22 mM VCD was incubated in the stomach contents of rats 
(pH 2.5), VCD was only detected at minute 3 of incubation (Figure 6.7). A higher dose of VCD (2.43 
mM) incubated in rat stomach contents (pH 2.5) resulted in the chemical being detected up to 15 
minutes but by 30 minutes it was undetectable (Figure 6.8). When rat stomach contents were 
neutralized (pH 7.0), incubation with 1.22 or 2.43 mM VCD resulted in chemical concentrations 
peaking at 5 or 10 minutes then dropping off and stabilizing from 15 to 120 minutes (p > 0.169) and 
by 360 minutes VCD concentrations had fallen significantly (p < 0.005; Figures 6.7 and 6.8). 
Incubation of 2.43 mM VCD at pH 2.5 resulted in a lower mean VCD concentration in rat stomach 
contents compared with M199 only (p < 0.049; Figures 6.8 and 6.9).  
Possum stomach contents at a pH of 1.0 caused 100 % hydrolysis of VCD by 3 minutes, regardless of 
the initial chemical concentration (p < 0.001; Figures 6.7 and 6.8). Similarly, VCD incubated at 1.0 pH 
in M199 only was 100 % hydrolysed within 3 minutes (p < 0.001; Figure 6.9). When the pH in 
possum stomach was raised to 2.5, VCD concentrations (1.22 or 2.43 mM) were highest at 3 to 5 
minutes and then consistently dropped after 10 minutes until no VCD was detected at 120 minutes 
(Figures 6.7 and 6.8). There were no differences in VCD concentration incubated in possum stomach 
contents (pH 2.5) or M199 only (pH 2.5) from 3 to 60 minutes (p > 0.077; Figures 6.8 and 6.9). 
However, at 120 and 360 minutes VCD concentrations levels were significantly lower in possum 
stomach contents than in M199 (p < 0.023 and p < 0.009, respectively). VCD (1.22 or 2.43 mM) 
incubated in neutralized possum stomach contents had a peak concentration at 5 minutes and then 
remained somewhat stable for up to 360 minutes of incubation (Figures 6.7 and 6.8). There were no 
differences in VCD concentrations in neutralized possum stomach contents compared with neutralized 
M199 (p > 0.081) with the exception of lower VCD levels in possum stomach contents at 30 and 60 
minutes (p < 0.0004 and p < 0.022, respectively; Figures 6.8 and 6.9).   
Incubation in stomach contents at pH 2.5 resulted in higher concentrations of VCD, regardless of 
initial dose, in possums compared with rats (p < 0.001; Figure 6.7 and 6.8 and Table 6.1). 
Additionally, VCD was detected for a longer period of time in possum stomach contents (1.22 mM: up 
to 60 min; 2.43 mM: up to 120 min) compared with rat stomach contents (1.22 mM: up to 3 min; 2.43 
mM: up to 15 min). When a low dose of VCD (1.22 mM) was incubated in a neutralized stomach 
environment, more VCD was recovered in possum stomach contents then that of rats (p < 0.023; 
Figure 6.7 and 6.8). However, there were no between-species differences in VCD concentration 
following incubation with a high dose in a neutral environment (2.43 mM; p > 0.605).  
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Figure 6.7 The effects on 1.22 mM VCD when incubated in pH-controlled rat or possum stomach 
contents (37 ± 1 °C). At each time point, VCD was extracted from a subsample using 
ethyl acetate and quantified on GC (n = 3 – 6 replicates/time point). Values not 
connected by the same letter are different (p < 0.05). Vertical bars represent ± SEM. 
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Figure 6.8 The effects on 2.43 mM VCD when incubated in pH-controlled rat or possum stomach 
contents (37 ± 1 °C). At each time point, VCD was extracted from a subsample using 
ethyl acetate and quantified on GC (n = 3 – 6 replicates/time point). Values not 
connected by the same letter are different (p < 0.05). Vertical bars represent ± SEM. 
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Figure 6.9 The effect of acid and heat (37 ± 1 °C) on VCD hydrolysis when incubated in pH-altered 
M199. At each time point, VCD was extracted from a subsample using ethyl acetate 
and quantified on GC (n = 3 – 6 replicates/time point). Values not connected by the 
same letter are different (p < 0.05). Vertical bars represent ± SEM. 
 
6.3.3 VCD hydrolysis in blood  
VCD was incubated in undiluted blood or M199-diluted blood (37 ± 1 ºC) of rats and possums or 
M199 only (37 ± 1 ºC) and the rate of chemical hydrolysis was compared between species and 
treatments. VCD, when incubated in M199-diluted or undiluted rat blood, was only marginally 
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0.117) but from 15 to 30 minutes, VCD’s concentration consistently dropped (p < 0.049; Figure 6.10 
and Table 6.2). Conversely, there were no effects on VCD concentrations when it was incubated in 
M199-diluted or undiluted possum blood at all time points examined (p > 0.096; Figure 6.11 and 
Table 6.2).  
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The addition of M199 to the blood of each species did result in lower VCD concentrations throughout 
the incubation period (p< 0.026; Figure 6.11 and Table 6.2). However, there were no differences in the 
rate of VCD hydrolysis in M199-diluted blood of each species compared with M199 only (p > 0.201; 
Table 6.2). There were no between-species differences in VCD concentrations over time when 
incubated in M199-diluted blood (0.185 mM VCD, p > 0.061; 0.364 mM VCD, p > 0.429) or in 
undiluted blood (0.185 mM VCD; p > 0.071) of each species (Figures 6.10 and 6.11). However, when 
0.364 mM VCD was incubated in undiluted blood of each species, more VCD was recovered from rat 
blood than that of possums (p < 0.001; Figures 6.10 and 6.11).       
 
 
Figure 6.10 VCD concentration over time when incubated in undiluted blood or diluted blood 
(M199, 1:4, v/v) of female rats (n = 6) or M199 only. Values not connected by the same 
letter are different (p < 0.05). Vertical bars represent ± SEM. 
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Figure 6.11 VCD concentration over time when incubated in undiluted blood or diluted blood 
(M199, 1:4, v/v) of female possums (n = 11) or M199 only. Values not connected by 
the same letter are different (p < 0.05). Vertical bars represent ± SEM. 
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Table 6.2 VCD in whole diluted or undiluted blood of possums or rats or in M199 only. VCD was 
incubated for 0, 3, 5, 10, 15, 20 or 30 minutes whole blood or whole blood diluted (1:4, 
v/v) in M199 (37°C). Data are means ± SEM.    
Matrix 
Amount of VCD 
added (mM) 
Amount of VCD (mM) 
remaining at 20 minutes 
Rate of VCD change 
over time 
Rat whole blood 
0.00 0.00 ± 0.00 - 
0.185 0.07 ± 0.007 -1.1 µM/min 
0.364 0.14 ± 0.005 -1.5 µM/min 
Rat whole blood 
diluted in M199 
0.00 0.00 ± 0.00 - 
0.185 0.03 ± 0.010 -0.4 µM/min 
0.364 0.09 ± 0.004 -1.0 µM/min 
Possum whole blood 
0.00 0.00 ± 0.00 - 
0.185 0.06 ± 0.005 +0.2 µM/min 
0.364 0.13 ± 0.002 +0.9 µM/min 
Possum whole blood 
diluted in M199 
0.00 0.00 ± 0.00 - 
0.185 0.05 ± 0.008 +0.2 µM/min 
0.364 0.10 ± 0.008 +0.1 µM/min 
M199 only @ 37°C 
0.00 0.00 ± 0.00 - 
0.185 0.04 ± 0.004 -0.4 µM/min 
0.364 0.09 ± 0.008 -0.1 µM/min 
 
6.3.4 Hepatic GSH concentrations following in vitro incubation with VCD 
The effect of VCD on liver metabolism was examined in rat and possum hepatic GSH concentrations 
following in vitro incubation with VCD. Incubation with VCD (7.13 mM) caused GSH concentrations 
in live S9 hepatic cells of rats to decrease significantly from 1 to 60 minutes compared with live 
controls (p < 0.001; Figure 6.12). There were no differences in GSH concentration in heat-shocked 
control and heat-shocked VCD-treated rat S9 hepatic cells (p > 0.211; Figure 6.12). GSH levels 
overall were lower in heat-shocked VCD-treated rat S9 hepatic cells compared with live VCD-treated 
cells, although this was not significant (p > 0.054; Figure 6.12). GSH concentrations in rat S9 hepatic 
cells were lower in heat-shocked controls than that of live controls (p < 0.04). 
Live possum S9 hepatic cells incubated in VCD had no differences in GSH concentration from that of 
live controls from 0 to 10 minutes (p > 0.081; Figure 6.13). However, from 15 to 60 minutes VCD 
treatment caused GSH levels to decrease significantly compared with controls (p < 0.049; Figure 
6.13). There were no differences in GSH concentration in heat-shocked controls compared with live 
controls (p > 0.081) and heat-shocked VCD-treated possum S9 hepatic cells (p > 0.392; Figure 6.13). 
GSH levels overall were lower in heat-shocked VCD-treated possum S9 hepatic cells compared with 
live VCD-treated cells, although this was not significant (p > 0.192; Figure 6.13).  
Between-species comparisons revealed that mean GSH concentrations in live, untreated possum S9 
hepatic cells (0.95 ± 0.03 nmol/mg protein content) were 10.3% lower than those of untreated rats 
(1.06 ± 0.01 nmol/mg protein content; p <0.0001). However, treatment with VCD resulted in the GSH 
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concentrations in rat S9 cells being reduced by 76.8% (0.09 ± 0.05 nmol/mg protein content) 
compared with VCD-treated possums (0.38 ± 0.11 nmol/mg protein content; p <0.001). Within 1 
minute of VCD addition, rat GSH levels were reduced by 72.6% of controls and by 30 minutes 100% 
of the GSH stock was depleted. On the other hand, possum GSH levels at 1 minute post-VCD addition 
were reduced by only 34.3% of controls but by 30 minutes 98.1% of their GSH stock was depleted. 
There were no between-species differences in mean GSH concentrations in heat-shocked controls or 
heat-shocked VCD-treated S9 hepatic cells (p > 0.166).  
 
 
Figure 6.12 Change in rat hepatic GSH levels following in vitro incubation with 7.13 mM VCD. N = 3 
replicates/time point; levels not connected by the same letter are different (p < 0.05). 
Vertical bars represent ± SEM. 
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Figure 6.13 Change in possum hepatic GSH levels following in vitro incubation with 7.13 mM VCD. 
N = 3 replicates/time point; levels not connected by the same letter are different (p < 
0.05). Vertical bars represent ± SEM. 
 
6.3.5 CYP450 concentration following in vitro incubation with VCH 
VCH-induced Phase I metabolism was examined in rats and possums by measuring the liver 
concentration of CYP450 following in vitro incubation with VCH. Compared with controls, mean 
CYP450 concentration in rat microsomes was significantly reduced following incubation with VCH 
(4.0 mM, p < 0.0001; 8.1 mM, p < 0.0004; Figure 6.14). There were no differences in mean CYP450 
concentrations between heat-shocked rat microsomes treated with a high dose of VCH (8.1 mM) and 
the heat-shocked controls (p > 0.081). However, heat-shocked rat microsomes treated with a low dose 
of VCH (4.0 mM) had reduced mean concentrations of CYP450 compared with heat-shocked controls 
(p < 0.002; Figure 6.14). 
Mean CYP450 concentrations in possum microsomes were significantly reduced following incubation 
with VCH (4.0 or 8.1 mM) compared with controls (p < 0.0001; Figure 6.15). There were no 
differences in mean CYP450 concentrations in heat-shocked possum microsomes treated with VCH 
compared with heat-shocked controls (4.0 mM, p > 0.417; 8.1 mM, p > 0.120; Figure 6.15). 
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There were significant differences in the CYP450 concentrations of control-treated (p < 0.0001) and 
heat-shocked (p < 0.008) rat and possum hepatic microsomes. Mean rat CYP450 levels in live and 
heat-shocked microsomes were 71.8 ± 2.42 % and 80.3 ± 74.5 % lower, respectively, than levels 
measured in possums. In addition, mean CYP450 levels measured in rat VCH-treated microsomes (4.0 
or 8.1mM) were 77.1 ± 11.4 and 83.3 ± 8.4 % lower, respectively, compared with possums. Three 
minutes after addition of VCH, rat CYP450 levels in live microsomes were reduced by 97.7% (4.0 
mM) and 100% (8.1 mM) to that of live controls. On the other hand, possum CYP450 levels in live 
VCH-treated microsomes were not reduced below those of controls until 10 (8.1 mM; 6.0%) and 30 
minutes (4.0 mM; 79.6%). 
 
 
Figure 6.14 Changes in female rat hepatic CYP450 concentration levels following in vitro incubation 
with VCH (4.0 or 8.1 mM). Time scale is represented by Log10 (minute) where -1 
represents pre-treatment CYP450 levels. Levels not connected by the same letter are 
different (p < 0.05). N = 6 replicates/time point. Vertical bars represent ± SEM. 
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Figure 6.15 Changes in female possum hepatic CYP450 concentration levels following in vitro 
incubation with VCH (4.0 or 8.1 mM). Time scale is represented by Log10 (minute) 
where -1 represents pre-treatment CYP450 levels. Levels not connected by the same 
letter are different (p < 0.05). N = 6 replicates/time point. Vertical bars represent ± 
SEM. 
 
 Discussion 6.4
These results confirm the implications from the previous findings (Chapters 4 and 5) that orally 
administered VCD is handled differently in possums than in rats. The utilization of VCD as a potential 
oral chemosterilant for the control of vertebrate pest populations has been proposed with evidence 
supporting its efficacy in rodents (Burd, 2009; Herawati et al., 2010). However, the results presented 
in Chapter 4 demonstrated that the VCD dosing regimens and formulations examined had no effect on 
the pool of immature ovarian follicles of healthy adult female possums. The present study has 
attempted to investigate the species difference in VCD ovarian toxicity between possums and rats by 
determining the fate of VCD in the blood and stomach and its effects on metabolism through the in 
vitro measurement of hepatic-derived GSH.   
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At a pH of 1.0, 100% of VCD was hydrolysed within minutes of incubation in possum stomach 
contents. These data support the hypothesis that a large portion of an oral VCD dose is quickly 
reduced once it arrives in the stomach of possums. Furthermore, as with the in vivo studies, the 
proposed protective effects of possum stomach contents were demonstrated when the pH was 
increased to 2.5. Higher concentrations of VCD were recovered in the stomach contents of possums 
(up to 60 or 120 minutes) compared with rats (up to 3 or 15 minutes). Both rats and possums were fed 
the same pelleted diet. Thus, the contents of their stomachs would have been very similar suggesting a 
species effect in their ability to retain VCD in the stomach. VCD is a lipophilic chemical and, although 
lipid content was not measured, reasons for these between-species differences at pH 2.5 may be that 
the stomach contents of possums contain a higher proportion of lipids than those of rats. Alternatively, 
the species difference may be due to differences in particle size of the digesta or rates of stomach 
emptying which would influence the rate of VCD degradation. It is difficult to determine how relevant 
this between-species difference is in vivo as the average stomach contents pH range for possums is 
usually pH 1.0 to 2.0, significantly lower than in the rat. 
VCD, when incubated in whole blood of possums and rats, was not affected and its chemical 
concentration remained stable. This finding seems to suggest that the blood is not involved in a 
detoxifying capacity; rather it primarily serves as a transportation medium for VCD. However, in these 
in vitro studies the only observation recorded was the presence (or disappearance) of VCD over time 
with no measurements of the detoxifying agents (i.e. GSH or epoxide hydrolase). Following an oral 
dose of VCD, mean intracellular GSH content in red blood cells of rats was decreased (Chapter 5). 
This suggests that, given sufficient levels of VCD present in the blood, GSH may serve a 
detoxification role to some degree. It should be noted that, in the plasma, much of the GSH originates 
from the liver and thus serves as an indicator of liver GSH content (Viña, 1990). In addition, 
extracellular GSH has a short half-life (1.9 min in the mouse) (Viña, 1990) suggesting that any GSH 
detoxification occurring in the blood is likely to be a result of red blood cell-derived GSH action rather 
than plasma-derived GSH. In the in vitro studies presented here, an NADPH regeneration system was 
not employed. Glutathione reductase, the enzyme responsible for converting glutathione disulphide 
(GSSG) to GSH, is NADPH-dependant and without a suitable in vitro culture set-up, the reformation 
of GSH from GSSG was not possible (Akerboom and Sies, 1980). Thus, while VCD concentrations 
appeared to be stable over time, the contribution of GSH cycling to the detoxification of VCD may 
have been underestimated in the present study.    
VCD incubation with possum and rat hepatic S9 cell fractions caused GSH levels to become depressed 
and species differences in the timing and degree of GSH depletion were evident. VCD-induced 
reduction of rat liver GSH content occurred within the first minute (69.8% reduction of controls) and 
this was comparable to the reduction in GSH levels measured in the rat at 1 minute following an oral 
VCD dose (Chapter 5; 70.5% reduction of controls). Although GSH content in possum liver cells was 
also reduced following incubation with VCD, this occurred at a slower rate compared with rats. These 
results support the hypothesis that possums have a higher capacity for detoxifying xenobiotics, such as 
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VCD, compared with rats. From this it can be presumed that, even if sufficient quantities of VCD were 
able to avoid degradation by the high stomach acidity of possums, the increased hepatic metabolism of 
VCD would likely negate any potential effects on fertility.  
CYP450 levels were reduced in both possum and rat liver microsomes following 2 hours of incubation 
with VCD’s parent compound, VCH. Treatment with VCH has been shown to induce hepatic CYP450 
levels in mice (Doerr-Stevens et al., 1999; Fontaine et al., 2001a; Fontaine et al., 2001b). However, 
these studies measured CYP450 induction following 10 days of daily intraperitoneal (i.p.) injections 
with VCH (7.5 mmol/kg/day) and therefore the increase in CYP450 levels over a long period of time 
is not surprising. Smith et al. (1990b) reported reduced hepatic CYP450 content levels 1 hour 
following an i.p. dose of VCH. However, the CYP450 inhibitor, chloramphenicol, was utilized as a 
pre-treatment and therefore CYP450 reductions were likely a direct result of chloramphenicol. The 
effect of VCH on CYP450 content without the use of a chloramphenicol pre-treatment was not 
examined (Smith et al., 1990b).    
To my knowledge, examination of the short-term effect (<1 day) of VCH on hepatic CYP450 levels 
has not been examined in vivo nor in vitro. It is difficult to determine if the results presented here 
would be a true reflection of the short-term effects of VCH on CYP450 levels experiences in vivo. 
However, studies examining the short-term effects of various other xenobiotics have reported reduced 
or inhibited activity levels of CYP450 from 1 to 24 hours following treatment (Gueguen et al., 2006; 
Vuppugalla and Mehvar, 2004). It should be noted that the pilot in vitro study presented here did not 
utilize an NADPH regenerating system. Therefore, similar to the GSH studies, it is possible that the 
reduction in CYP450 reflected loss of NADPH over time and thus a suspension of CYP450 activity 
(Vernieulcn, 1996). However, the methods utilized to measure CYP450 did not require an NADPH 
regeneration system on a short-term time scale (Choi et al., 2003). Therefore, the change in CYP450 
level from 0 to approximately 15 minutes is likely to be a true reflection of VCH’s effects, whereas 
any interpretation of data past 15 minutes should be made with caution.    
Indications for species differences in CYP450 content and response to VCH treatment were noted. The 
reduced levels of CYP450 content in untreated (control) microsomes of rats compared with possums 
suggest that possums may have a higher capacity for Phase I metabolism. This is further supported by 
species differences in the pattern of CYP450 reduction following VCH treatment. CYP450 levels in 
rat hepatic microsomes were rapidly decreased within 3 minutes following the addition of VCH and 
remained depressed until 120 minutes. On the other hand, possum CYP450 levels did not begin to 
drop until approximately 15 to 30 minutes after the addition of VCH. The delay in possum CYP450 
reduction may have been partly due to the higher CYP450 content of their microsome levels prior to 
trial start compared with rats. Nevertheless, the delay in VCH-induced CYP450 reduction observed in 
possums suggests that rat’s capacity for metabolizing VCH may not be as robust as possums. These 
data reflect and are supported by the between-species differences observed in the GSH data previously 
discussed here.    
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The potential differences between possums and rats in VCH and VCD metabolism may reflect similar 
differences to those previously reported between mice and rats (Keller et al., 1997; Smith et al., 1990a; 
Smith et al., 1990b). Mice have an increased capacity for VCH metabolism yet they are more 
susceptible to VCD treatment due to reduced hepatic and ovarian GSH and epoxide hydrolase activity 
compared with rats (Salyers, 1995; Smith et al., 1990a). These species similarities between possums 
and mice suggest that possums may respond to in vivo VCH treatment in a similar fashion to that of 
mice. Further speculation on these species similarities would indicate that possums should be 
susceptible to VCD-induced effects. Yet, results presented in Chapters 4 and 5 showed that a VCD 
gavage dose which induces follicle loss in rodents (500 – 750 mg/kg/day) (Burd, 2009; Herawati et al., 
2010), when administered to possums, had no effect on the immature follicle populations of possums 
nor did it induce hepatic or ovarian GSH changes. The GSH data presented here clarify these results 
and support the hypothesis that possums have a higher capacity for Phase I and II metabolism than 
rats.  
In preparation for the CYP450 and GSH experiments, the aim was to create negative control and 
negative VCD-treated samples by submerging the S9 liver fractions in boiling water for 10 minutes. 
Although this was successful for the CYP450 enzyme experiment, the GSH data suggest otherwise. 
GSH levels in heat-shocked samples were similar to live, nonheat-shocked samples indicating that this 
method was not successful and may have been inappropriate for the inactivation of GSH. GSH, a 
tripeptide, plays a vital role in cellular protection from environmental insults including toxic 
chemicals, ionizing radiation, and heat (Arrick and Nathan, 1984). Cellular thermotolerance can be 
achieved short-term (<1 hour) through the action of heat-shock proteins and their facilitation of the 
GSH-redox cycle (Baek et al., 2000; Kregel, 2002). Intracellular GSH levels will increase in response 
to temperatures of 43 to 45.5°C for up to 1 hour with reversal effects occurring past 1 hour (Mitchell et 
al., 1983; Russo et al., 1984). In the study reported here, the boiling temperature reached 100 ± 5 °C 
and coagulation of denatured proteins was visualized. It is difficult to imagine that intracellular GSH 
would survive for 10 minutes at such an extreme temperature yet GSH levels in the heat-shocked 
samples indicate activity was still present. Regardless, VCD treatment seems to have amplified the 
reduction of GSH levels in heat-shocked possum and rat samples to some degree. Future work should 
utilize a GSH inhibitor for a true reflection of negative control and treated samples.  
The findings presented here support the previous results and hypotheses presented in Chapter 5. The 
rapid hydrolysis of VCD in the presences of varying acidity levels was described. The greater ability 
of possum stomach contents to retain and thus inadvertently protect VCD from acid degradation 
compared with rats provides some explanation for why possums may be less susceptible to VCD 
ovarian toxicity. Evidence for the proposed increased capacity of possum liver tissue to detoxify VCD 
compared with rats’ livers presented here is corroborated by the similar effect of VCH on CYP450 
concentrations in each species. Initial considerations of these data suggest that VCD may not be a 
suitable agent for fertility control in possums. However, a full summation of these findings and those 
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presented in Chapters 4 and 5 plus their implications for VCD’s use in possums and rats will be 
provided in the General Discussion (Chapter 8).  
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Chapter 7 
Examination of a novel rodent fertility control bait, ContraPest®: 
palatability, acceptance and health and reproduction effects in wild-
caught female Norway rats 
 Introduction  7.1
The studies reported here examined the intake and palatability of ContraPest
®
 in wild-caught female 
Norway rats (Rattus norvegicus) and its effects on the health and ovarian follicle populations of 
treated animals. ContraPest
®
 bait has been developed by researchers at SenesTech, Inc
®
 (Flagstaff, 
Arizona, USA) for control of rodent pest populations. The current formulation contains the orally 
active ingredients, 4-vinylcyclohexene diepoxide (VCD), an industrial chemical, and triptolide (TR), a 
plant extract from the thunder god vine (Tripterygium wilfordii). Extensive toxicological studies have 
demonstrated the efficacy of VCD at reducing the pool of primordial and small primary ovarian 
follicles in mice and rats while not directly affecting numbers of preantral and antral follicles 
(Danilovich and Sairam, 2006; Hoyer et al., 2001; Mayer et al., 2004; Mayer et al., 2002). In addition, 
it has been demonstrated that orally-delivered VCD is effective at reducing the immature ovarian 
follicle pool of laboratory bred Norway rats (Burd, 2009; Mayer et al., 2010; Schmuki et al., 2011) and 
their in utero exposed offspring (Burd, 2009) as well as immature follicle numbers in wild-caught 
ricefield rats (R. argentiventer) (Herawati et al., 2010). TR, on the other hand, targets the pool of 
larger developing follicles, specifically the secondary follicle population, by reducing the number of 
developing follicles and increasing the number of atretic follicles (Liu et al., 2011; Xu and Zhao, 
2010). In addition, treatment with TR has been shown to reduce circulating oestrogen and 
progesterone (P4) levels, increase circulating levels of follicle stimulating hormone (FSH) and 
luteinizing hormone (LH), and to cause prolonged oestrous cycles in laboratory-bred rodents (Liu et 
al., 2011; Xu and Zhao, 2010).  
Preliminary results have demonstrated that ContraPest
®
 is effective in reducing the primordial, 
primary and secondary ovarian follicle populations of adult female Sprague Dawley (SD) rats 
following 15 days of bait consumption (Dyer et al., 2013). Investigation of the long-term fertility 
effects in female SD rats following ContraPest
®
 consumption is underway (Drs. L.P. Mayer and C. A. 
Dyer, personal comm.). In an effort to determine if similar effects can be achieved in wild rodents, 
researchers at the Commonwealth Scientific and Industrial Research Organisation (CSIRO) in 
Australia have examined the effects of ContraPest
®
 consumption in wild house mice (M. domesticus). 
Initial findings revealed high palatability and acceptance rates and up to 50% depletion of primordial 
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follicles in mice presented with control emulsion or ContraPest
® 
emulsion (Dr. L.A. Hinds, 
unpublished).  
To date, no work has been undertaken examining the effectiveness of ContraPest
®
 as a chemosterilant 
in wild Norway rats. The studies described in this chapter were designed to examine if consumption of 
ContraPest
®
 by wild-caught female Norway rats would achieve similar findings to those reported for 
the laboratory strain of Norway rats and for wild mice. In the first study a liquid ContraPest
®
 emulsion 
was tested in wild type Norway rats to determine: 1) effects on general health and food and water 
consumption, 2) palatability, and 3) the effectiveness of pre-baiting with control (non-active) emulsion 
on acceptance of the active formulation. The second study tested the addition of a sweetener, sodium 
saccharine, to the liquid formulation of ContraPest
®
 and examined the effects on: 1) emulsion 
acceptance rates, 2) effects on general health and food and water consumption, and 3) effects on 
ovarian follicular populations.   
 Materials and Methods 7.2
7.2.1 Reagents 
VCD, cyclohexanone, Attane™ isoflurane, and sodium pentobarbital were obtained from vendors and 
used for experimental procedures as previously described in Chapter 3. Control emulsion and 
ContraPest
®
 emulsion was developed and provided by SenesTech Inc
® 
(Flagstaff, AZ, USA). The 
proprietary formulation was a mixture of food grade, generally regarded as safe (GRAS) emulsifier, 
soy bean oil (80%), laboratory grade water (20%) with different concentrations of microencapsulated 
VCD and TR. Saccharin was used as an emulsion sweetener for Study 2 (Necta Sweet, NSI 
Sweeteners Inc, Lincolnshire, IL, USA).      
7.2.2 Gas chromatography analysis of VCD concentration contained within 
ContraPest® emulsion  
Two batches of emulsion were prepared by SenesTech Inc
®
 in Flagstaff, Arizona for use during the 
studies and air transported to New Zealand by courier. Study 1 used emulsion from batch 1 while 
Study 2 used emulsion from batch 2. The effect of international transportation time and temperature on 
VCD stability within the ContraPest
®
 emulsion was examined within 4 ± 2 days of emulsion arrival 
using gas chromatography (GC). It must be noted that TR concentration analysis was not performed 
after arrival in NZ as the addition of this active compound was decided shortly before the emulsion 
was prepared and no suitable method for quantifying TR was available.  
For each batch, two 1.0 mL aliquots were collected into glass scintillation vials upon arrival and 
following each trial completion (± 3 days). VCD was extracted from the emulsion by the addition of 
three times the sample volume of extraction solution (ES; ethyl acetate containing 1.18 mM 
cyclohexanone as the internal standard). Extraction methods and VCD quantification on GC were 
performed as outlined in Chapter 3. To determine VCD extraction efficiency from the emulsion 
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matrix, three equal aliquots of control emulsion were spiked with 1.0 mg VCD/mL (7.134 mM). The 
samples were vortex mixed and then VCD was extracted as previously described. VCD extraction 
efficiency from VCD-spiked control emulsion was 36.9 %. Therefore, VCD concentrations in 
ContraPest
®
 emulsions were estimated by dividing the measured concentration of VCD by the 
emulsion extraction efficiency, 0.369 ± 0.03.   
7.2.3 Temperature stability analysis of VCD contained within the ContraPest® 
emulsion  
The stability of VCD contained within the ContraPest
®
 emulsion at different temperatures was 
examined to determine if temperature and time affect VCD concentration. VCD concentrations in 
batches were measured by colourimetric analysis in Arizona prior to being transported.  Upon arrival, 
control and ContraPest
®
 emulsion was stored at 4°C until use. Emulsion was prepared for the 
temperature stability experiment by collecting three 5.0 mL aliquots of control emulsion or 
ContraPest
®
 emulsion and treated as follows: 1) control emulsion (no VCD added); 2) control 
emulsion spiked with 0.913 mM VCD; or 3) ContraPest
®
 emulsion. Samples were stored at 4, 21 or 
37°C and, on days 0, 1, 3, 6, and 20, two 0.5 mL samples were collected from each treatment vial and 
VCD extracted and quantified on GC as previously described in Chapter 3. VCD extraction efficiency 
from VCD-spiked control emulsion was 39.8 %. Therefore, VCD concentrations in ContraPest
®
 
emulsions were estimated by dividing the measured concentration of VCD by the emulsion extraction 
efficiency, 0.398.   
7.2.4 Study 1 
At the beginning of the study water and pellet consumption and live weight (LW) were monitored 
daily for 6 days to determine normal reference ranges for each animal. Rats often display neophobic 
behaviour (avoidance of novel stimuli) (Barnett, 1958; Mitchell, 1976). Therefore, to reduce any 
potential influence of neophobia, a 50 mL glass beaker, intended to hold the emulsion during the trial, 
was placed into a wire rack in the corner of each cage (Figure 7.1A). On a daily basis, fresh water was 
added to the glass beaker to allow animals to acclimate to consuming from the beaker. Animals were 
then randomly allocated into two groups (G) using a randomized block design stratified by LW during 
the monitoring phase. In the first treatment phase (P1; choice trial) animals were offered either control 
(group 1, phase 1; G1P1; n = 4) or ContraPest
®
 emulsion (group 2, phase 1; G2P1; n = 6) at a rate of 
5-10% LW for 6 nights (Figure 7.2). The concentration of the active ingredients within the 
ContraPest
®
 emulsion was 2.96 mM (8.3 mg/kg LW) for VCD and 5.55 µM for TR (100 µg/kg). LW 
and consumption of pellets, water and control and ContraPest
®
 emulsion were measured and recorded 
each day. Palatability of control and ContraPest
®
 emulsion was determined with the following 
formula: (emulsion consumption weight) / [(pellet consumption weight) + (emulsion consumption 
weight)]. Beakers were cleaned and refilled with fresh emulsion each day. To determine evaporation 
rates, 3 water containers and 3 beakers containing control or ContraPest
®
 emulsion were placed evenly 
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throughout the room and replaced as necessary. Evaporation rates for water and control and 
ContraPest
®
 emulsion were recorded and subtracted from their corresponding daily consumption rates 
each day. The presence of faeces within the emulsion or signs of emulsion being spilt were recorded. 
These aberrations were often accompanied by consumption measurements registering above 0.5 g 
when it was believed that the animal did not consume any emulsion. Based on these observations, it 
was decided that if an animal’s consumption rate was below <0.6% mg emulsion/g LW/day, then 
consumption would be registered as zero. Percentage LW rates of water and pellet consumption were 
determined by dividing the consumed weight (g) by the animal’s LW (g) and multiplying by 100. 
In the second phase (P2) to determine if pre-feeding with control emulsion would increase subsequent 
acceptance of the active ContraPest
® 
emulsion formulation, the animals which were previously fed 
with control emulsion (G1P1) were switched to pellets plus ContraPest
®
 emulsion for 6 nights (G1P2) 
(Figure 7.2). Emulsion storage conditions, the amount of emulsion provided, evaporation rate 
measurements and the consumption of pellets, water, and emulsion were collected and consumption 
rates calculated as stated for P1. 
To examine the acceptance rate of ContraPest
®
 emulsion when offered as the only source of food 
animals which were provided with ContraPest
®
 emulsion in the first phase (G2P1) were placed into a 
no choice trial (phase 2, G2P2; Figure 7.2). During the no choice trial, pellets were removed and only 
ContraPest
®
 emulsion and water were provided. Before treatment started an end point for the no 
choice trial was put in place wherein the trial would be stopped, emulsion removed and pellets 
replaced if animals experienced significant LW loss (>10 %) since trial start. Following the no choice 
trial (P2) animals were rested for 24 hours prior to the commencement of phase 3. 
In the third phase (P3) to examine whether exposure to ContraPest
®
 would influence palatability of the 
non-active control emulsion (i.e. cause aversion), G2 animals were offered control emulsion and 
pellets for 3 nights (G2P3) (Figure 7.2). Emulsion storage conditions, the amount of emulsion 
provided, evaporation rate measurements and the consumption of pellets, water, and emulsion were 
collected and consumption rates calculated for P2 and P3 as stated for P1. 
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Figure 7.1 Representative images of cage set up during the monitoring phase (A) and treatment 
phases (B). During the monitoring phase, water was provided in the glass beaker 
which was intended to contain the emulsions during treatment. When treatment 
began, the water glass was replaced so that control and active emulsions could be 
provided in the glass beaker.   
 
A 
B 
  111 
 
Figure 7.2 Study 1 trial design for Group 1 and 2. 
 
7.2.5 Study 2 
A new formulation of ContraPest
®
 emulsion containing an artificial sweetener (ContraPest
®
-S), 
saccharin (1.94 mg/mL), was examined for its effects on palatability, animal health and immature 
ovarian follicle populations. One week prior to trial start a 50 mL glass beaker was placed into each 
animal’s cage and fresh water added daily as outlined in Study 1 (Figure 7.1A). At trial start water and 
pellet consumption and LW were monitored daily for 4 days to determine normal reference ranges for 
each animal (Figure 7.3). In addition, all animals were pre-fed with control emulsion at a rate of 5-
10% LW for 4 days. Animals were then randomly allocated into treatment groups using a randomized 
block design stratified by LW during the pre-feeding phase. Animals were provided with pellets plus 
control or ContraPest
®
-S emulsion at a rate of 5-10% LW for 15 days in 2 blocks with 7 rest days 
between treatment phases (7-8 days per phase; Figure 7.3). The concentration of the active ingredients 
within the ContraPest®-S emulsion was 4.68 mM (13.1 mg/kg LW) for VCD and 11.0 µM for TR 
(200 µg/kg). Emulsion storage conditions, the amount of emulsion provided, evaporation rate 
measurements and the consumption of pellets, water, and emulsion were collected and consumption 
rates calculated as stated for Study 1. Animals were euthanized 3 days post-treatment with an 
intracardiac injection of pentobarbitone (125 mg/kg). The liver, kidneys, adrenal glands, uterus, and 
ovaries were excised, trimmed of fat, weighed, examined for gross pathology and then fixed in 10% 
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neutral-buffered formalin for histological purposes. The eyes were removed and treated as outlined 
below for age analysis.  
 
 
Figure 7.3 Study 2 trial design. 
 
7.2.6 Rodent aging  
Animal age was determined using methods described by Hardy, Quy and Huson (1983) with some 
modifications. Eye balls were fixed in 10% neutral-buffered formalin for 4 weeks. Eye balls were then 
slit open and the lenses removed by applying light pressure. Lenses were individually stored in open-
topped Eppendorf tubes and air dried for 67 hours at 80 ± 1 °C. Lenses were weighed and then 
reweighed at 115 hours to verify stability of lens weights. To minimize atmospheric moisture 
absorbance, lenses were removed from the oven individually immediately prior to being weighed. 
Animal age was determined using the following female-specific, species-specific correction formula: 
Y = (10
xm + b
) – 22 where Y: age in days, x: paired lens weight (mg), m: 0.021 (slope); b: 1.297 
(intercept); and 22 represents the average gestation length in days for R. norvegicus (Hardy et al., 
1983).  
7.2.7 Histology and follicle analysis 
Ovaries were trimmed of fat, weighed, prepared for histological examination, analysed and quantified 
as previously outlined in Chapter 3.  
7.2.8 Statistical analysis   
All general statistical procedures were run as previously outlined in Chapter 3. In addition, LW and 
water, pellet and emulsion consumption rates during treatment were analysed using a repeated 
measure test with animal identification as a random variable and treatment group defined by time as a 
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covariant. Ovarian follicle estimates were tested for covariance with ovarian weight and animal age 
and normalized where appropriate. LW covariance was determined for all organ weights and data were 
normalized to LW where appropriate.   
 Results   7.3
7.3.1 Concentration analysis of ContraPest® emulsion 
Initial concentrations of VCD in each ContraPest
®
 emulsion were 57.6 mM (batch 1) and 50.3 mM 
(batch 2) (Table 7.1). On average, international transportation resulted in hydrolysis of 1.96 ± 0.3 mM 
VCD per day. At the end of each study, the concentration of VCD in batch 1 and 2 was estimated to be 
2.96 ± 0.06 and 4.68 ± 0.35 mM, respectively (Table 7.1). It should be noted that the methods used to 
quantify VCD pre-transportation (colorimetric analysis) differ from that of post-transportation (gas 
chromatography). Therefore, the differences in VCD concentrations between pre- and post-
transportation should be accepted with caution. To determine if VCD loss was a result of potential 
high temperatures during shipment or natural hydrolysis within the emulsion matrix, the VCD 
concentration in unopened bottles (batch 2; stored at 4°C) was measured at 11 and 47 days post-
emulsion creation. VCD hydrolysis in VCD-spiked control emulsion and ContraPest
® 
emulsion during 
storage at the research facility (4ºC) occurred at a rate of 0.13 ± 0.07 and 0.05 ± 0.03mM/day, 
respectively.   
 
Table 7.1 The concentration of VCD contained within ContraPest® emulsion batches 1 and 2 prior to 
international transport and following trial end. Initial VCD concentrations were 
measured by colorimetric analysis. Final VCD concentrations were measured by gas 
chromatography. Data are means ± SEM. 
Batch 
number 
Initial 
concentration 
of VCD (mM) 
Final 
concentration 
of VCD (mM) 
Percentage of 
VCD loss due to 
international 
transport, 
storage and time 
Time from 
emulsion 
production 
(AZ) to arrival 
(NZ) (days) 
Time from trial 
start to final 
VCD 
measurement 
(days) 
Batch 1 57.6 2.96 ± 0.06 94.9 % 15 14 
Batch 2 50.25 4.68 ± 0.35 90.7 % 7 28 
 
7.3.2 Temperature stability analysis of ContraPest® emulsion 
To further understand the rate of natural hydrolysis and the effect of temperature on VCD contained 
within ContraPest
®
 emulsion, a temperature stability study was performed. When stored at 4°C, the 
VCD concentration in VCD-spike control emulsion and ContraPest
®
 emulsion was not affected by 
time or temperature. In fact, the VCD concentration in both emulsions increased slightly from day 1 to 
day 20 which was likely due to evaporation (p < 0.001; Figures 7.4 and 7.5). Storage of emulsions at 
21°C caused VCD concentrations to decline steadily from 3 – 20 days and this effect was emphasised 
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when emulsions were stored at 37°C (p < 0.0001; Figures 7.4 and 7.5). VCD loss per day in VCD-
spike control emulsion and ContraPest
®
 emulsion was 0.04 and 0.17 mM/day, respectively, when 
stored at 21°C and 0.05 and 0.22 mM/day, respectively, when stored at 37°C. 
 
 
Figure 7.4 The effect of time and temperature on VCD hydrolysis within control emulsion spiked 
with 0.913 mM VCD. Replicates at each time point were analysed in triplicate on gas 
chromatography. Values with different letters are significantly different (p <0.05). 
Vertical bars represent ± SEM. 
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Figure 7.5 The effect of time and temperature on VCD hydrolysis within ContraPest® emulsion 
(batch 2). Replicates at each time point were analysed in triplicate on gas 
chromatography. Values with different letters are significantly different (p <0.05). 
Vertical bars represent ± SEM. 
 
7.3.3 Study 1   
Choice study (Group 1 and 2, phase 1) 
During the monitoring phase, there were no significant differences between groups in percentage 
weight gain or water and pellet consumption (p > 0.364; Figures 7.6 - 7.8). When these parameters 
were compared between the monitoring phase and phase 1 (P1), there was no change in the mean LW 
of each group (p > 0.295; Figure 7.8). Animals offered control emulsion (G1) consumed less water (p 
< 0.012; Figure 7.6A) and pellets (p < 0.037; Figure 7.7A) on average compared with their 
consumption levels measured during the monitoring phase. Animals offered ContraPest
®
 emulsion 
(G2) consumed the same amount of pellets (p > 0.667; Figure 7.6B) but significantly more water (p < 
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more pellets (p < 0.017; Figure 7.7) and gained more weight (p < 0.014; Figure 7.8) than G1 control 
animals.  
The ContraPest
®
 emulsion consumption rate of G2 animals was significantly reduced compared with 
G1 consumption of control emulsion throughout P1 (p < 0.0001, Figure 7.9 and Table 7.2). All G1 
animals consumed control emulsion on a regular basis (Table 7.3). However, of the G2 animals, 3 rats 
did not consume ContraPest
®
 emulsion while the other 3 consistently consumed throughout P1 (Table 
7.3).  
 
 
 
Figure 7.6 Water consumption in wild-caught female rats during Study 1 for group 1 (A; n = 4) and 
group 2 (B; n = 6). Values with different letters are significantly different (p < 0.05). 
Vertical bars represent ± SEM. 
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Figure 7.7 Pellet consumption in wild-caught female rats during Study 1 for group 1 (A; n = 4) and 
group 2 (B; n = 6). Values with different letters are significantly different (p < 0.05). 
Vertical bars represent ± SEM. 
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Figure 7.8 Percentage live weight change in wild-caught female rats during Study 1 for group 1 (A; n 
= 4) and group 2 (B; n = 6). Values with different letters are significantly different (p < 
0.05). Vertical bars represent ± SEM. 
 
-4
-2
0
2
4
6
8
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Monitoring period Phase 1: Control emulsion + pellets Phase 2: ContraPest® emulsion + pellets
P
e
rc
e
n
ta
ge
 li
ve
 w
e
ig
h
t 
ch
an
ge
 
Treatment day 
A 
ABC 
BC 
BC 
ABCD ABCD 
ABD 
C 
ABCD 
ABD 
AD AD 
D 
E 
E 
C BC 
BC 
ABCD 
-14
-12
-10
-8
-6
-4
-2
0
2
4
6
8
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Monitoring period Phase 1: ContraPest® emulsion + pellets Phase 2:
ContraPest®
emulsion
without
pellets
24
hour
rest
period
Phase 3: Control
emulsion + pellets
P
e
rc
e
n
ta
ge
 li
ve
 w
e
ig
h
t 
ch
an
ge
 
Treatment day 
B 
  119 
 
 
Figure 7.9 Emulsion consumption in wild-caught female rats during Study 1 for group 1 (A; n = 4) 
and group 2 (B; n = 6). Values with different letters are significantly different (p < 
0.05). Vertical bars represent ± SEM. 
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Table 7.2 Consumption parameters for control and ContraPest® emulsion for group 1 (G1, n = 4) and group 2 (G2; n = 6) rats during Study 1 and control-treated 
(C; n = 8) and ContraPest®-treated (CP; n = 9) rats during Study 2. Statistical significance was set at p < 0.05. LW: live weight. For each measured 
parameter, values with different letters are different (p <0.05). Data are means ± SEM. 
Measurement 
Parameter 
Study 1 Study 2 
Phase 1 Phase 2 Phase 3 Monitoring Phase Treatment Phase 
G1 G2 G1 G2 G2 C CP C CP 
Emulsion provided 
Control + 
pellets 
ContraPest® 
(batch 1) + 
pellets 
ContraPest® 
(batch 1) + 
pellets 
ContraPest® only    
(batch 1) 
Control + 
pellets 
Control + 
pellets 
Control + 
pellets 
Control + 
pellets 
ContraPest® 
(batch 2) + 
pellets 
VCD concentration 
(mM) in ContraPest® 
N/A 2.96 ± 0.1 2.96 ± 0.1 2.96 ± 0.1 N/A N/A N/A N/A 4.68 ± 0.7 
VCD consumption 
(mg/kg LW/day) 
N/A A3.68 ± 0.95 B20.0 ± 5.0 B15.7 ± 4.1 N/A N/A N/A N/A B14.7 ± 1.2 
TR consumption 
(µg/kg LW/day) 
N/A A17.8 ± 4.6 B96.3 ± 24.1 B75.6 ± 19.8 N/A N/A N/A N/A B88.6 ± 7.0 
Emulsion intake 
(mg/g LW/day) 
AB68.6 ± 
6.7 
E8.9 ± 2.3 C33.3 ± 3.4 C37.8 ± 9.9 
C45.4 ± 
9.2 
A73.3 ± 
6.4 
A72.4 ± 
5.3 
B58.5 ± 
1.9 
D22.4 ± 1.8 
Emulsion palatability 
AEF0.58 ± 
0.03 
B0.08 ± 0.02 CD0.36 ± 0.03 N/A 
D0.32 ± 
0.06 
EF0.59 ± 
0.03 
E0.64 ± 
0.03 
F0.58 ± 
0.01 
G0.25 ± 0.02 
1
20 
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Effect of pre-feeding with control emulsion (Group 1, phase 2) 
During P2, G1 animals previously offered control emulsion were offered ContraPest
®
 emulsion to 
determine the effects of pre-feeding on palatability. Animals consumed significantly less ContraPest
®
 
emulsion during P2 compared with control emulsion consumed during P1 (p < 0.0001; Figure 7.9A 
and Table 7.2). Of the four rats, 2 rats consumed ContraPest
®
 emulsion at a similar rate as measured 
during P1 (Table 7.3). However, the other 2 rats’ consumption of ContraPest® emulsion was decreased 
compared with P1. G1 rats consumed significantly more ContraPest
®
 emulsion (p < 0.0001) during P2 
compared with G2 rats consumption during P1 (Figure 7.9 and Table 7.2).   
The amount of VCD consumed by G1 animals during P2 was compared with previous reports 
demonstrating VCD-induced ovarian primordial follicle reduction with oral gavage. G1’s mean 
consumption of VCD during P2 (20.0 ± 5.0 mg VCD/kg LW/day) was 96.0 % lower than the amount 
of VCD that would be delivered through via oral gavage (500 mg VCD/kg LW/day) (Table 7.2). 
Similarly, TR consumption by G1 rats during P2 was compared with previous reports demonstrating 
TR-induced ovarian follicle effects through oral gavage. G1 rats’ mean consumption of TR during P2 
(96.3 ± 24.1 µg TR/kg LW/day) was only 3.8 % lower than the amount of TR that would be delivered 
through an oral gavage route (100 µg TR/kg LW/day) (Table 7.2).  
There were no changes in G1 LW (p > 0.955) or pellet (p > 0.273) and water consumption (p > 0.113) 
between P1 and P2 (Figures 7.3A – 7.5A). When P2 parameters were compared against the monitoring 
phase, there were no changes in G1 LW (p > 0.435, Figure 7.5A). However, G1 water (p < 0.006; 
Figure 7.6A) and pellet (p < 0.043; Figure 7.7A) consumption were significantly lower during P2.    
No choice study (Group 2, phase 2) 
G2 animals previously offered ContraPest
®
 emulsion for 6 days (P1) were placed into a no choice trial 
for 48 hours (P2) to measure the acceptance rate of the ContraPest
®
 emulsion. When given no other 
food option, G2 animals consumed more water (p < 0.008; Figure 7.6B) and ContraPest
®
 emulsion (p 
< 0.006; Figure 7.9B and Table 7.2) during P2 compared with P1. However, G2 animals lost a 
significant amount of LW (-9.1 ± 0.58 %; p < 0.008; Figure 7.8B) and therefore the no choice 
treatment was stopped after 48 hours due to animal welfare concerns.  
Choice trial (Group 2, phase 3) 
Following a 24 hour rest period, G2 animals were moved into the third trial phase (P3) wherein they 
were offered control emulsion (3 days) for an intake comparison with ContraPest
® 
emulsion. G2 
animals consumed significantly more control emulsion during P3 than ContraPest
®
 emulsion during 
P1 (p < 0.05; Figure 7.9B and Table 7.2). In contrast, there were no differences between control 
emulsion consumed during P3 and ContraPest
® 
emulsion consumed during P2 (p > 0.073).  
To determine if control emulsion consumption rates during P3 were affected by the previous exposure 
to ContraPest
® 
emulsion during P1 and P2, a comparison was made between G2P3 and G1P1 control 
emulsion consumption rates. G2 animals consumed less control emulsion during P3 compared with 
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that of G1 animals during P1, although this was not significant (p > 0.073; Figure 7.9 and Table 7.2). 
Of the G2 rats, the 2 which did not consume ContraPest
® 
emulsion during P1 again did not consume 
control emulsion during P3 (Table 7.4). 
 There were no changes in G2 water (p > 0.088; Figure 7.6B) or pellet (p > 0.975; Figure 7.7B) 
consumption between P1 and P3. However, G2 water consumption dropped significantly during P3 
compared with P2 (p < 0.023). G2 mean LW dropped significantly during P2 (p < 0.002) and, 
although it recovered slowly during P3, it was still significantly lower (p < 0.042) compared with P1 
(Figure 7.8B).  
 
Table 7.3 Consumption parameters of control or ContraPest® for individual animals in group 1 
during phase 1 and 2 (Study 1). Data are means ± SEM. 
Treatment phase Rat A Rat B Rat C Rat D 
Phase 1           
(6 days) 
Emulsion consumption           
(mg emulsion/g LW/day) 
39.1 ± 6.8 72.8 ± 10.9 108.4 ± 9.5 54.0 ± 5.6 
Percentage emulsion intake 
relative to LW 
3.9 ± 0.7 % 7.3 ± 1.1 % 10.8 ± 1.0 % 5.4 ± 0.6 % 
Phase 2          
(6 days) 
Emulsion consumption           
(mg emulsion/g LW/day) 
38.0 ± 4.7 45.0 ± 5.3 30.7 ± 8.6 19.4 ± 4.4 
Percentage emulsion intake 
relative to LW 
3.8 ± 0.5 % 4.5 ± 0.5 % 3.1 ± 0.9 % 1.9 ± 0.4 % 
 
Table 7.4 Consumption parameters of control or ContraPest® for individual animals in group 2 
during phase 1, 2 and 3 (Study 1). Data are means ± SEM. 
Treatment phase Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 
Phase 1   
(6 days) 
Emulsion consumption           
(mg emulsion/g LW/day) 
22.1 ± 
8.3 
0.5 ± 
1.2 
0.1 ± 
0.6 
0.0 ±  
0.7 
9.4 ±  
2.6 
22.1 ±  
4.8 
Percentage emulsion intake 
relative to LW 
2.2 ± 
0.8% 
0.0 ±  
0.1 % 
0.0 ±  
0.1 % 
-0.1 ±  
0.1 % 
0.9 ±  
0.3 % 
2.22 ±  
0.5 % 
Phase 2   
(2 days) 
Emulsion consumption           
(mg emulsion/g LW/day) 
23.9 ± 
1.4 
42.0 ± 
41.0 
40.0 ± 
38.6 
43.6 ±  
43.6 
43.4 ±  
32.7 
33.9 ±  
7.0 
Percentage emulsion intake 
relative to LW 
2.4 ±  
0.1 % 
4.2 ±  
4.1 % 
4.0 ±  
3.9 % 
4.4 ±  
4.4 % 
4.3 ±  
3.3 % 
3.4 ±  
0.7 % 
Phase 3   
(3 days) 
Emulsion consumption           
(mg emulsion/g LW/day) 
84.0 ± 
15.9 
2.2 ± 
0.6 
30.6 ±  
9.9 
0.2 ±  
0.4 
78.0 ±  
10.2 
77.5 ±  
4.2 
Percentage emulsion intake 
relative to LW 
8.4 ±  
1.6 % 
0.2 ±  
0.1 % 
3.1 ±  
1.0 % 
0.0 ±  
0.0 % 
7.8 ±  
1.0 % 
7.8 ±  
0.4 % 
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7.3.4 Study 2 
Treatment parameters  
ContraPest
®
 emulsion containing the artificial sweetener (ContraPest
®
-S), saccharin, was examined for 
its effects on palatability, animal health and immature ovarian follicle populations. To determine if 
there were any changes between the monitoring/pre-feed phase and treatment phase, LW and 
consumption of pellets and water were compared within each group. LW change and consumption of 
water, pellets and control emulsion of the controls were unaltered between the phases (p > 0.104; 
Figures 7.10 - 7.13). Similarly, the percentage LW gain of the ContraPest
®
-S group during treatment 
did not differ between phases (p > 0.436; Figure 7.13). However, the ContraPest
®
-S
 
group consumed 
more water and pellets during treatment compared with the pre-feeding phase (p < 0.001) and when 
compared with controls during treatment (p < 0.001; Figures 7.11 and 7.12). Throughout the trial all 
animals gained weight, regardless of treatment (p < 0.001; Figure 7.13).  
Animals were pre-fed with control emulsion for 4 days to optimize the acceptance of ContraPest
®
-S 
emulsion. During the 4 day pre-feed phase, both groups consumed an average of 72.9 ± 4.1 % of the 
total amount of control emulsion offered (Figure 7.10 and Table 7.2). When switched to ContraPest
®
-S 
emulsion, consumption rates fell by 69.1% during the 15 day treatment period (p < 0.0001; Figure 
7.10 and Table 7.2). Interestingly, consumption of control emulsion during treatment also fell by 
20.2% (p < 0.033; Table 7.2). The minimum and maximum consumption of control emulsion during 
treatment was 50.3 ± 3.96 and 73.5 ± 6.81 mg/g LW/day, respectively. The minimum and maximum 
consumption of ContraPest
®
-S emulsion was 1.75 ± 0.61 and 57.3 ± 4.36 mg/g LW/day, respectively. 
Of the 9 rats offered ContraPest
®
-S emulsion, 2 consumed <0.6% g emulsion/g LW, 3 consumed 0.6 – 
2.0% g emulsion/g LW, and the remaining 4 consumed 3.2 – 3.5% g emulsion/g LW.  
The amount of VCD consumed during Study 2 was compared with previous reports demonstrating 
VCD-induced ovarian primordial follicle reduction through oral gavage. The amount of VCD 
consumed during the trial (14.7 ± 1.2 mg VCD/kg LW/day) was 97.1% lower than the amount of VCD 
that would be delivered through an oral gavage route (500 mg VCD/kg LW/day). This figure was 
minimally affected when the animals which did not consume ContraPest
®
-S emulsion on a regular 
basis (<0.6% g emulsion/g LW) were removed from the data set (23.3 ± 4.1 mg VCD/kg LW/day; 
95.3% decrease).   
Similarly, the amount of TR consumed during Study 2 was compared with previous reports 
demonstrating TR-induced ovarian follicle effects through oral gavage. The mean consumption of TR 
during the trial (88.6 ± 7.0 µg TR/kg LW/day) was 11% lower than the amount of TR that would be 
delivered through an oral gavage route (100 µg TR/kg LW/day). When the animals which did not 
consume ContraPest
®
-S emulsion on a regular basis were removed from the data set, TR consumption 
(140.8.0 ± 24.5 µg TR/kg LW/day) was 40.9% higher than that of an oral TR dose.  
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Dietary choices in rats are often influenced by social interactions and with age and experience, animals 
learn avoidance of and preferences for certain food items (Galef and Clark, 1971). Therefore, animal 
age and consumption rates of control or ContraPest
®
-S emulsion were examined for correlations. 
There were no age correlations indicated in animals consuming control emulsion (p > 0.790; Figure 
7.14). Conversely, there was a positive correlation for age and ContraPest
®
-S emulsion consumption 
(p < 0.032; Figure 7.14).  
 
 
Figure 7.10 Emulsion consumption rates in wild-caught female rats during Study 2 (control, n = 8; 
ContraPest®-S, n = 9). * indicates different (p <0.05) from control. Vertical bars 
represent ± SEM. 
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Figure 7.11 Water consumption rates in wild-caught female rats during Study 2 (control, n = 8; 
ContraPest®-S, n = 9). * indicates different (p <0.05) from control. Vertical bars 
represent ± SEM. 
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Figure 7.12 Pellet consumption rates in wild-caught female rats during Study 2 (control, n = 8; 
ContraPest®-S, n = 9). * indicates different (p < 0.05) from control. Vertical bars 
represent ± SEM. 
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Figure 7.13 Percentage live weight change in wild-caught female rats during Study 2 (control, n = 8; 
ContraPest®-S, n = 9). Vertical bars represent ± SEM. 
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Figure 7.14 Emulsion consumption levels of wild-caught female rats during Study 2 graphed against 
animal age (months). Vertical and horizontal bars represent ± SEM. 
 
Comparisons of emulsion consumption between Study 1 and 2 
To determine if the addition of the sweetener saccharin would increase palatability, the consumption 
rates of sweetened control and ContraPest
®
-S emulsion during Study 2 was compared with 
consumption rates during Study 1. There were no differences in consumption of sweetened or 
unsweetened control emulsion (p > 0.601; Table 7.2). Pre-feeding with control emulsions resulted in 
greater intake of unsweetened ContraPest
®
 (Study 1, G1P2: 33.3 ± 4.1 mg/g LW/day) than that of 
ContraPest
®
-S emulsion (Study 2: 22.3 ± 1.72 mg/g LW/day) (p < 0.015; Table 7.2).       
Necropsy parameters 
There were no significant differences in post mortem LW or the weights of liver, paired kidneys, 
paired adrenal glands, uterine or paired ovaries between treatment groups (p > 0.2275; Table 7.5). In 
addition, there were no differences in age between treatment groups (p > 0.891; Table 7.5).  
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Table 7.5 Animal age, live weight (LW) and somatic and reproductive tissue weights in wild-caught 
female rats when offered control or ContraPest®-S emulsions daily for 15 days during 
Study 2. Somatic and reproductive tissues were normalized to final LW. Statistical 
significance was set at p < 0.05. Data are means ± SEM. 
 
Ovarian follicle estimates  
There was no correlation between age or ovarian weight with primordial, secondary and antral 
follicles (p > 0.132). However, age and CL counts were positively correlated (p < 0.001). Therefore, 
CL counts were normalized to age prior to examining for treatment effects by dividing the CL counts 
by animal age. Animals receiving ContraPest
®
-S emulsion had fewer primordial follicles (827.7 ± 
198.87) than controls (1312.0 ± 160.30); however this was not significant (p < 0.076; Figure 7.15). 
Because not all animals consumed ContraPest
®
-S emulsion (n = 2), primordial follicle counts were re-
examined in the rats which consumed emulsion on a regular basis (>0.6% g emulsion/g LW; n = 7). In 
this group, primordial follicle counts were significantly reduced in rats which consumed ContraPest
®
-
S emulsion (592.59 ± 131.76) when compared with controls (1307.53 ± 181.69; 54.7% reduction; p < 
0.009; Figure 7.15). Rats which did not consume ContraPest
®
-S emulsion were within the range of 
control animals (1650.48 ± 434.44). There were no significant differences in numbers of secondary (p 
> 0.683) and antral (p > 0.909) follicles or CL (p > 0.757) between treatment groups (Figures 7.16 and 
7.17). There was a trend for reduced secondary follicles in rats which consumed ContraPest
®
-S 
emulsion (10.29 ± 1.43) compared with controls (13.25 ± 1.30); however this was not significant (p > 
0.132, 22.4% reduction). Rats which did not consume ContraPest
®
-S emulsion were within the range 
of control animals (13.50 ± 0.5).  
 
Measured parameter 
Treatment group 
Control ContraPest® 
N 9 9 
Age at death (month) 7.11 ± 0.77 7.25 ± 0.71 
Final LW (g) 234.8 ± 17.6 257.6 ± 17.5 
Liver (mg/mg LW) 42.2 ± 1.4 43.4 ± 1.4 
Paired kidney (mg/mg LW) 6.94 ± 0.29 7.44 ± 0.29 
Paired adrenal gland (mg/mg LW) 0.40 ± 0.03 0.39 ± 0.02 
Uterus (mg/mg LW) 1.97 ± 0.17 1.99 ± 0.24 
Paired ovary (mg/mg LW) 0.29 ± 0.02 0.30 ± 0.02 
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Figure 7.15 Mean total primordial ovarian follicle estimates in wild-caught female rats when 
offered control or ContraPest®-S emulsions daily for 15 days during Study 2. Counts 
were recorded from the left ovary of each animal and total counts estimated using a 
correction factor formula (Gougeon and Chainy, 1987). Control, n = 8; animals which 
did not consume ContraPest®-S, n = 2; animals which did consume ContraPest®-S, n = 7. 
* indicates different (p < 0.05) from control. Vertical bars represent + SEM. 
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Figure 7.16 Mean total secondary ovarian follicle estimates in wild-caught female rats when 
offered control or ContraPest®-S emulsions daily for 15 days during Study 2. Counts 
were recorded from the left ovary of each animal and total counts estimated using a 
correction factor formula (Gougeon and Chainy, 1987). Control, n = 8; animals which 
did not consume ContraPest®-S, n = 2; animals which did consume ContraPest®-S, n = 7. 
Vertical bars represent ± SEM. 
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Figure 7.17 Mean total antral ovarian follicle counts and corpus luteum counts in wild-caught 
female rats when offered control or ContraPest®-S emulsions daily for 15 days during 
Study 2. Counts were recorded from the left ovary of each animal. Control, n = 8; 
animals which did not consume ContraPest®-S, n = 2; animals which did consume 
ContraPest®-S, n = 7. Vertical bars represent ± SEM. 
 
 Discussion 7.4
To find a more humane and sustainable alternative solution for pest control in NZ, the chemosterilant 
emulsion, ContraPest
®
, was examined for its palatability and effects on animal health and the ovarian 
follicle populations of wild-caught Norway rats. The ultimate success of ContraPest
® 
as a pest control 
method will lie in its ability to be delivered as bait that is palatable, effective and able to induce 
permanent fertility cessation in females.  
Consumption rate of ContraPest
® 
emulsion during each study was less than that of the control 
emulsion, indicating that rats were able to detect the active components (whether the aversion is to 
VCD or TR, or both is yet to be determined). Within rodent genomes, rats have ~1400 functional 
olfactory receptors (or ~6% of its genes) whereas humans have only ~400, thus highlighting the 
importance of olfaction in this species (Ache and Young, 2005).  To help overcome the highly 
developed sense of smell in rodents, the active ingredients were microencapsulated within the 
emulsion. It is believed that microencapsulation of VCD and TR helps to reduce their olfactory and 
palatability deterring effects (Dyer et al., 2013). In addition, microencapsulation of these active 
components may help improve their uptake into the gastrointestinal tract as well as provide the 
chemicals with a protective barrier from stomach acid (Carr et al., 1996; Florence, 2005; Jani et al., 
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1990). VCD, when in direct contact with the oral or nasal cavity, can cause irritation and lesions 
(personal observation) as well as epithelial hyperplasia of the fore stomach (NTP, 1986). It must be 
noted that these pathological findings were a result of oral gavage doses (200 – 5000 mg/kg/day, 14 
days to 2 years) far above what would be achieved through consumption of VCD contained within 
ContraPest
® 
emulsion. Nevertheless, microencapsulation of VCD and TR should help to reduce 
potential irritation during consumption of the emulsion bait.   
The reduced intake of ContraPest
® 
emulsion compared with controls would suggest that rats were able 
to detect some chemical traces within the emulsion. This may have been due to incomplete removal of 
any unincorporated active ingredients during washing or due to the microcapsules breaking down 
during international shipping and storage. The temperature stability study demonstrated that VCD, 
when stored at 4°C, is relatively stable. ContraPest
® 
emulsion was stored at 4°C following arrival at 
the research facility and throughout the course of each study. Therefore it can be assumed that 
microcapsule degradation was minimal throughout each study period. However, during international 
transport (batch 1: 15 days; batch 2: 7 days), it is reasonable to assume that the ContraPest
® 
emulsions 
would have been exposed to warmer temperatures (>21°C; ambient) which have been shown to affect 
VCD, regardless of whether the chemical is microencapsulated or not. In fact, VCD concentrations in 
the ContraPest
® 
emulsions were substantially reduced following international transport (95%) and this 
was likely a result of microcapsule degradation due to warm transportation temperatures. Thus, 
reduced ContraPest
® 
emulsion consumption may have, in part, been due to release and hydrolysis of 
the active ingredients from the microcapsules resulting in olfactory and palatability chemical 
detection. Despite the deterring effects from the active ingredients, rats did consume ContraPest
® 
to 
some degree, demonstrating that the emulsion formulation used during these studies was somewhat 
successful.  
Pre-feeding with control emulsion increased the acceptance of ContraPest
® 
emulsion but did not 
completely overcome the aversion. It is well understood that rodents are neophobic (avoidance of 
novel stimuli) (Barnett, 1958; Mitchell, 1976) and often require time to adjust to changes in their 
environment and food sources. The practice of pre-baiting with a non-toxic bait has been utilized in an 
attempt to increase poison control operation success and to help overcome ‘conditioned bait aversion’ 
(Buckle and Smith, 1994) . In an open field environment, pre-baiting draws in animals from 
surrounding areas and allows the animals to habituate to the bait, the bait boxes and any potential 
environmental changes that may have occurred as a result of human interference. In these studies, 
animals were exposed to a water-filled glass beaker for 6-7 days prior to the start of the trial in order to 
reduce any potential rejection of emulsion as a result of neophobic behaviour. No avoidance behaviour 
was noted. In the first study, consumption rates of ContraPest
® 
emulsion with and without pre-feeding 
with control emulsion confirmed the effectiveness of the pre-feeding period. Thus, in the second 
study, a pre-feeding strategy was adopted to optimize intake of the ContraPest
® 
emulsion.   
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Interestingly, during each study ~50% of rats consumed ContraPest
® 
emulsion at comparable levels to 
those observed during the control emulsion pre-feed period while the other rats consumed ContraPest
® 
emulsion either at very low levels or not at all. It is not clear why this 50/50 split was observed across 
the studies. However, in any population, animals that do not respond to treatment (i.e. non-consumers, 
non-responders) will inevitably exist. A study examining neophobic tendencies of wild Norway rats in 
geographically separated areas revealed that, on average, 8-10% of individuals show no neophobic 
behaviours while 4-10% show extreme neophobia (Macdonald et al., 1999). It is possible that we were 
observing similar results on a smaller scale.     
There was a positive correlation between age and ContraPest
®
-S emulsion consumption during Study 
2. It was observed that older animals consumed more ContraPest
®
-S
 
emulsion per gram live weight 
compared with that of younger animals. Although this finding was unexpected, it may be that the older 
animals were more willing to sample the emulsion in small quantities while the younger animals 
avoided the emulsion all together. Dietary choices in rats are often influenced by social interactions 
and with age and experience, animals learn avoidance of and preferences for certain food items (Galef 
and Clark, 1971; Galef et al., 1992). Rats typically consume their meals in small bouts and, when 
offered new food items, they will often take a small sample and only return to that food item pending 
no ill effects (Jensen et al., 1983; Lee and Clifton, 2002; Macdonald et al., 1999). Such behaviours are 
believed to result in bait shyness following a sub-chronic dose of poisoned bait (Barnett and Spencer, 
1949; Bhardwaj and Khan, 1979). Full avoidance of the emulsion would indicate that the olfactory 
cues alone were able to deter some of the rats. Consumption of ContraPest
®
-S emulsion by the older 
animals could indicate that they were either not detecting the active ingredients or that they found no 
ill effects from consuming the emulsion and therefore no avoidance behaviour developed. In addition, 
the rats which did consume ContraPest
®
-S emulsion regularly may have been showing preference for 
the non-active ingredients (e.g. saccharine, high lipid content), whether for their masking effects of the 
active ingredients or for their palatability preferences, or both.         
Saccharin was employed during Study 2 to help disguise any potential deterring factors from the 
active components in the ContraPest
® 
emulsion. Research has demonstrated that female rats prefer 
sweetened water to unsweetened water and, when given a choice between glucose or saccharine, they 
prefer the latter (Mook, 1974; Valenstein et al., 1967). Surprisingly, there was no effect from the 
addition of a sweetener on consumption rates of ContraPest
®
-S emulsion. ContraPest
® 
emulsion is a 
mixture of oil and water (20:80%, v/v). Because consumption rates of ContraPest
® 
emulsion following 
a control pre-feed period were higher during Study 1 compared with Study 2, this may indicate that the 
rats were in fact showing preference for the lipids in the emulsion rather than the saccharine. It has 
been suggested that a rats preference for sweetened solutions is in fact an indicator for a fluid food 
source (thus informational) rather than for pleasure (Mook, 1974). When offered a choice between 
saccharin-sweetened or bland liquid diets, rats rarely showed preference between the two. Thus, if 
there are food-associated cues present, sweetness becomes redundant (Mook, 1974). In addition, rats 
offered minced liver, flour, wheat grains and sugar did sample from all food types but sugar was 
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consumed the least (Barnett, 1956). Therefore, it is possible that the rats were consuming ContraPest
®
-
S
 
emulsion for its fat source rather than for its sweetened properties.   
Alternatively, the lack of success with the use of saccharine may be that the active ingredients in the 
ContraPest
®
-S emulsion overpowered the smell and taste of the sweetener, negating any potential 
benefits. The VCD content was higher in the batch used during Study 2 and this may have caused an 
increased deterrent effect. Saccharine has been used in the past to mask rat olfactory cues of toxins 
(e.g. lithium chloride) presented in a liquid state (Rusiniak et al., 1976). When given a choice between 
saccharine-sweetened liquid with or without toxins, it was more difficult for rats to distinguish 
between the liquids but still possible (Rusiniak et al., 1976). Nevertheless, the proposed benefits of the 
sweetener did not increase the palatability of the ContraPest
®
-S emulsion in the present case.  
For successful application of ContraPest
® 
as a rodent control method, it will be imperative to reduce, 
remove or disguise any potential olfactory or palatability deterrents. Currently, researchers at 
SenesTech
® 
(Flagstaff, AZ, USA) are working on reducing the olfactory and palatability cues in 
ContraPest
® 
emulsion. Their preliminary work in adult female laboratory-bred Sprague Dawley rats 
has demonstrated high consumption rates of 6-10% of their live weight in new formulations of 
ContraPest
® 
emulsion (Drs. C.A. Dyer and L.P. Mayer, unpublished data).  
When rats were offered ContraPest
®
-S, primordial follicle populations were significantly reduced in 
those animals that consumed the emulsion. This result is promising considering that the VCD dose in 
ContraPest
®
-S was 95% below that of a VCD dose (500 mg/kg/day) which has shown efficacy in 
depleting the immature ovarian follicle pool in rats by oral gavage  (Burd, 2009; Herawati et al., 2010; 
Mayer et al., 2010). In addition, the level of primordial follicle reduction in this study (54 - 64.1%; 15 
days; 14.7 – 20.0 mg/kg/day) is comparable to oral gavage studies in rats (58 - 88%, 15 days, 500 – 
750 mg/kg/day; Dr. L. A. Hinds, CSIRO, Australia, unpublished data). One reason for the primordial 
follicle reducing success of ContraPest
®
-S
 
may be due to the incorporation of VCD into the 
microcapsules as previously discussed. Encapsulation of VCD likely protected the chemical from 
acidic breakdown or digestion in the gastrointestinal tract or alternatively by promoting uptake across 
the mucosal surfaces into the blood (Carr et al., 1996; Florence, 2005; Jani et al., 1990).  
The success of ContraPest
®
-S in reducing the primordial follicle pool of consuming rats may also, in 
part, be due the feeding behaviour of rats. Rat feeding behaviours have been extensively studied in 
both laboratory- and field-based settings (Berdoy and MacDonald, 1991; Bernstein, 1975; Galef and 
Clark, 1971; Galef et al., 1992; Galef Jr and Giraldeau, 2001). Rats typically consume their meals at 
night in small bouts (1-3 g food/meal; 10-15 meals/day) (Jensen et al., 1983; Lee and Clifton, 2002) 
with females foraging in multiple small trips while male forage trips are fewer and longer (Macdonald 
et al., 1999). It has been hypothesized that VCD ovarian toxicity is largely due to repeat exposure, 
thereby overwhelming and ultimately reducing the capacity of the detoxifying enzymes glutathione 
(GSH) and epoxide hydrolase (EH) (Keating et al., 2008a). Thus, because of the nature of female rat 
feeding habits, it is likely that the rats in Study 2 were continually ingesting VCD on a nightly basis. If 
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indeed this was the case, the detoxifying enzymes could become overwhelmed, allowing for the 
follicle-reducing effects of VCD to occur over the span of the nocturnal feeding window. It seems that 
the rodent feeding patterns may prove serendipitous for the use of ContraPest
®
 as a rodent fertility 
control agent.  
Interestingly, there was no observed effect of TR on the secondary follicle populations in ContraPest
®
-
consuming rats. A recent study by Dyer et al. (2013) examined the effects of a bait containing 1% 
VCD plus three different concentrations of TR on the ovarian follicle populations of laboratory bred 
Sprague Dawley female rats. Ovarian follicle counts (primordial, secondary, antral) were reduced and 
no corpora lutea (CL) were present in animals consuming a bait containing VCD (1%) + a medium 
dose of TR (50 µg/kg) for 15 days compared with controls.  However, 15 days of bait consumption 
with VCD (1%) plus a low (25 µg/kg) or high (100 µg/kg) dose of TR did not affect the ovarian 
follicular pools compared with controls. In fact, the number of CL’s was increased in the low and high 
TR dose groups compared with controls (Dyer et al., 2013).  
The reason for TR’s ability to cause effects to the follicle pool based on dosage level is not clear. It is 
thought that TRs method of action is through alteration of the intracellular calcium influx pattern 
(Leuenroth et al., 2007; Lue et al., 1998). Signal transduction pathways that control the decision for a 
cell to divide, differentiate or die are activated by increases in intracellular calcium concentrations 
(Ermak and Davies, 2002; McKinsey et al., 2002; Orrenius et al., 2003). Thus, TRs ability to increase 
intracellular calcium levels can lead to cessation of follicular development and the onset of follicular 
apoptosis. Assuming sufficient quantities of TR were reaching the ovaries of rats which consumed 
ContraPest
®
-S, it is likely that apoptosis of the secondary follicle pool would have occurred. The 
numbers of healthy secondary follicles were reduced in rats which consumed ContraPest
®
-S
 
when 
compared with rats which did not consume ContraPest
®
-S. Although this was not significant, the 
lower secondary follicle numbers may indicate TR-induced apoptosis of the secondary follicle pool 
was occurring. Without quantitative measurement of atretic secondary follicles in rats which 
consumed ContraPest
®
-S, we can only speculate on the potential effects from TR contained within the 
ContraPest
®
-S emulsion. 
Results presented here and by Dyer et al. (2013) suggest a possible interaction between VCD and TR 
which may be enhancing their effects on the primordial follicle pool. As previously discussed, the 
concentration of VCD that was being consumed during this study was well below that of an effective 
oral dose yet primordial follicles were significantly reduced. Dyer et al. (2013) observed this same 
effect in the medium TR dose group. A report on the effects of TR alone (60 or 120 µg/kg/day, 35 
days) showed that the number of healthy and atretic secondary follicle numbers were increased while 
the primordial follicle pool was unaffected (Xu and Zhao, 2010). As expected, TR-induced 
suppression of follicle development resulted in an accumulation of secondary follicles with no impact 
on the primordial follicle pool. It is possible that the reduction in primordial follicles observed here is 
strictly a result of VCD’s effects, although evidence for potentiation of VCD plus TR is evident.     
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The studies presented here have demonstrated the effectiveness of a pre-baiting system and its ability 
to increase the palatability of ContraPest
®
 emulsion. Microencapsulation of the active components 
seems to have protected the chemicals from warm temperatures encountered during international 
transportation and from stomach acidity and digestion sufficiently to induce effects on the immature 
follicle pool of ovaries in consuming rats. Although the VCD concentration in the ContraPest
®
-S 
emulsion was well below an average gavage dose, consumption rates were sufficient to reduce the 
primordial follicles pools of ContraPest
®
-consuming rats to levels comparable with those observed in 
oral gavage studies. Collectively, these studies have provided evidence that ContraPest
®
 shows 
potential as a chemosterilant bait for control of rodent populations. Successful application of 
ContraPest
®
 will required an understanding of foraging behaviours of the target species. Reduction or 
elimination of potential deterring effects from the environment (i.e. bait, bait boxes) and within the 
emulsion itself (i.e. active components) will be essential for success. Increased protection of the active 
components within ContraPest
® 
from warmer temperatures during international transport and 
laboratory and field use will also prove efficacious.  
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Chapter 8 
Synthesis and Conclusions  
 Chapter summary 8.1
The aim of the studies presented in this thesis was to examine the potential of the chemosterilant, 4-
vinylcyclohexene diepoxide (VCD), for fertility control of New Zealand (NZ) pest mammals, 
specifically the brushtail possum. To achieve this aim four main objectives were identified: 1) 
determine if an oral VCD dose delivered to female possums would result in the depletion of their 
ovarian primordial follicle pools (Chapter 4); 2) examine the uptake and metabolism of orally 
administered VCD in rats and possums (Chapter 5); 3) investigate the in vitro metabolic differences 
and effects of acid and stomach contents on VCD in rats and possums (Chapter 6); and 4) Investigate 
the potential use of ContraPest
®
 as a chemosterilant for the control of rodent pests in NZ (Chapter 7). 
This chapter synthesises the results obtained from this research and presents recommendations for 
improvement and future study. In addition, the implications of these findings for science and 
vertebrate pest management are discussed.       
 Summary of thesis findings 8.2
The main findings of this research were: 
1. VCD, when orally delivered does not induce primordial follicle depletion in adult female 
possums. 
a. The health of animals was not affected by VCD dosing. However, there was evidence 
that anaesthetic-induced stress and handling stress may negatively impact on the 
animal’s well-being. 
b. There was no evidence that Intralipid and QuickEZE®, two formulations believed to 
improve VCD uptake and efficacy, were effective in the possum.  
2. VCD-induced toxicity was less evident in possums compared with rats. It was hypothesized 
that this was due to a combination of the possum’s stomach contents being naturally more 
acidic resulting in greater protection (i.e. containment) of VCD in their stomach compared 
with rats. The ability of possum stomachs to contain and inadvertently protect VCD was 
evidenced by: 
a. In vitro VCD hydrolysis in the stomach contents (pH 2.5) of possums was less 
compared with rats  
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b. Reduced in vivo levels of VCD measured in the blood of possums compared with the 
blood of rats    
c. Ovarian and liver glutathione (GSH) levels of possums were unaffected whereas rat 
GSH levels in each tissue were depleted following in vivo treatment  
3. The capacity to metabolize VCD and its parent compound, 4-vinylcyclohexene (VCH), appear 
to be greater in possums compared with rats as evidenced by: 
a. Higher in vitro concentrations of hepatic CYP450 in untreated possum microsomes 
compared with rat 
b. Reduced in vitro effects of VCH on hepatic CYP450 levels in the possum compared 
with that of the rat 
c. Reduced in vitro effects of VCD on hepatic GSH levels in the possum compared with 
that of the rat  
4. Rats consuming an emulsion of ContraPest® had reduced ovarian primordial follicle 
populations. In addition, it was determined that:  
a. Pre-feeding with control emulsion proved efficacious for increasing the acceptance of 
ContraPest
®
 emulsion 
b. Consumption rates of ContraPest® emulsion were unaffected by the addition of a 
sweetener (saccharine) 
 Synthesis of findings  8.3
8.3.1 Possums 
The findings presented here have demonstrated that an oral dose of VCD does not induce primordial 
follicular depletion in the ovaries of possums. The lack of VCD-induced ovarian toxicity is likely due 
to a combination of factors. First, the typical in vivo pH of possum stomach contents ranged between 
0.5 and 1.0 while that of the rat ranged between 0.5 and 3.6 (Chapter 5). Because VCD hydrolysis is 
pH dependant (Chapter 6), these natural pH differences between species would suggest that VCD 
hydrolysis in the stomach of possums would occur more rapidly compared with the rat. In the possum, 
this initial effect would likely hydrolyse a large portion of the VCD dose to its inactive tetrol form, 
ultimately reducing the amount of VCD available for absorption into the blood. The use of an antacid, 
QuickEZE
®
, was employed to help reduce the hydrolysis of VCD following oral gavage (Chapter 4). 
Although dosing possums with bicarbonate or QuickEZE
®
 formulations increases and maintains a 
higher pH in stomach contents (pH 5.0 – 6.5 for 3 – 7 hours), this formulation did not affect VCD 
ovarian toxicity in vivo.  
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Secondly, differences in digestion of possums and rats may also be contributing to differences in VCD 
efficacy. Species differences in food retention times, food passage, and partitioning of fluid 
components from solid food would all contribute to VCD containment time within the stomach and 
ultimately VCD efficacy. VCD was more readily contained in the stomach contents of possums 
compared with rats (Chapter 6). Foods in the stomach of possums are not well mixed; so much so that 
discrete, homogenous food layers can often be identified in the order they were eaten (Nugent et al., 
2000). Such an effect may inadvertently provide protection of VCD from acid hydrolysis, resulting in 
reduced rates of VCD uptake from the stomach and intestines into the blood stream of possums. If 
sufficient amounts of VCD were retained in the stomach, uptake of VCD may in fact be occurring 
over a longer period of time in the possum. This, in combination with the feeding behaviour of possum 
(1-3 bouts per night with 2-3 hours between each bout) (Nugent et al., 2000) could seem serendipitous 
considering that VCD ovarian toxicity is believed to occur due to repeat exposure to by overwhelming, 
and ultimately reducing, the capacity of the detoxifying enzymes (Hu et al., 2002; Keating et al., 
2008a; Keating et al., 2010). However, daily oral dosing with VCD for 10 or 13 days (Chapter 4) did 
not affect the immature ovarian follicle pools of possums. Thus, it can be predicted that either the 
concentration of VCD was insufficient to induce ovarian toxicity or hepatic and ovarian detoxifying 
enzymes remained functional and at high enough levels to metabolise VCD efficiently. It is likely a 
combination of these two factors that explains why, in part, VCD is ineffective when administered to 
possums.  
Third, there was no effect of VCD on stomach acidity of possums following oral gavage (Chapter 5). 
On the other hand, the stomach contents pH of rats was increased and remained elevated for up to 6 
hours. This would imply that, in the possum, any VCD not contained by the stomach contents or taken 
up into the blood stream would be exposed to a highly acidic degrading environment, ultimately 
reducing VCD concentrations in the stomach even further. In the rat, however, acid hydrolysis of VCD 
in the stomach would not occur as quickly and the amount of VCD available for uptake into the blood 
would be greater than that of possums. In fact, this was demonstrated by higher levels of VCD 
measured in the blood of rats over a longer period of time compared with possums (Chapter 5).  
Fourth, hepatic GSH concentration levels of possums were not as severely depleted in vivo (Chapter 5) 
and in vitro (Chapter 6). These findings together suggest that possums have a higher capacity to 
detoxify VCD compared with rats. The GSH results were further corroborated by the in vitro CYP450 
results. Possum hepatic CYP450 levels were both higher and more robust than that of rats when 
exposed to VCD’s parent compound, VCH, in vitro. Considering these issues, greater effort to protect 
VCD from acid degradation in the stomach and improve its uptake into the blood will be needed if a 
VCD-induced follicle-depleting effect is ever to be achieved in the possum. Further discussion on the 
requirements needed for consideration of VCD’s use in possums is discussed below.       
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8.3.2 Rats 
The findings presented here have confirmed previous reports examining the effects of VCD on hepatic 
and ovarian metabolism as measured by GSH. The fate and uptake of VCD, once present in the rat 
stomach, was also revealed (Chapter 5 and 6). In addition, the first study on the use of the potential 
chemosterilant, ContraPest
®
, for its effects on the ovarian follicle populations of wild Norway rats was 
conducted here (Chapter 7). As previously discussed for the possum, several factors affect the degree 
to which VCD-induced ovarian toxicity will occur; and, in the case of the rat, these factors appear to 
be advantageous.   
First, in contrast with the possum, the in vivo stomach contents pH range of rats was higher and 
overall less acidic (control mean, 3.17 ± 0.28 pH; Chapter 5) implying that the rate of acid hydrolysis 
of VCD was likely to be slower in the rat stomach. Usually following consumption of food, the 
stomach pH of a rat decreases in order to aid digestion (McConnell et al., 2008) and therefore might 
increase the rate of acid hydrolysis in the stomach. Interestingly, however, the effect of a bolus dose of 
VCD/oil caused the stomach pH of rats to increase (Chapter 5) which would increase both the 
availability of VCD for absorption into the blood as well as prolong the period over which VCD 
would be available for absorption. This effect was corroborated by higher levels of VCD in the blood 
of rats over a longer period of time compared with possums following an oral bolus dose of VCD 
(Chapter 5). The pH of rat stomach contents following consumption of the ContraPest® emulsion was 
not measured but it is possible that a similar effect on pH may have occurred. Regardless, the 
encapsulation of VCD and triptolide contained within the ContraPest
®
 emulsion is likely to have 
protected them to some degree, from acid degradation in the stomach and concomitantly aided their 
absorption into the blood stream.       
Second, the feeding behaviour of rats (i.e. multiple small feeding bouts) may actually increase the 
efficacy of VCD due to repeated and continual exposure to the chemical (Chapter 7). Repeated 
exposure to VCD is thought to cause reduced capacity of the detoxifying enzymes glutathione (GSH) 
and epoxide hydrolase (EH) (Keating et al., 2008a). Third, the capacity of rats to metabolize VCD in 
vivo, as measured by their liver and ovarian GSH concentrations, was lower than that of possums 
(Chapter 6). This finding was corroborated by the reduced capacity of rat liver S9 cell fractions to 
metabolize VCD and VCH in vitro compared with that of possum liver S9 cell fractions (Chapter 6). 
The combination of rat feeding behaviour and their reduced capacity to metabolize VCD demonstrate, 
in part, why VCD reduces their primordial and primary ovarian follicle numbers.      
 Recommendations for future study  8.4
If future consideration for VCD’s use in the possum is undertaken, it will be imperative to demonstrate 
that VCD is ovotoxic in the possum. It was my aim to develop an ovarian culture system for the 
possum (Figure 1.1) in order to provide proof-of-concept for VCD ovarian toxicity although 
unforeseen issues (as discussed in Chapter 6) prevented this objective being achieved. Species 
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similarities in ovarian folliculogenesis (reviewed in Chapter 2) allow for speculation that VCD’s 
effects on the ovaries of possums may be similar to the effects observed in rats. However, the findings 
presented in Chapters 4, 5 and 6 suggest that, even if VCD ovarian toxicity was demonstrated with an 
in vitro culture system, the issues associated with stomach acidity and metabolism would likely negate 
any potential effects of orally delivered VCD on the ovaries of possums.  
Although these issues may be difficult to overcome, there are methods which may protect VCD from 
breakdown in the gastrointestinal tract and increase its efficacy once absorbed into the blood stream 
and which should be considered for future research. Formulations such as those found in the 
ContraPest
®
 emulsion (i.e. encapsulation of active ingredients, lipid emulsion matrix for increased 
absorption) may prove efficacious for future use in the possum. Evidence was presented in Chapter 4 
which suggested that an antacid pre-treatment may have protected VCD from acid degradation in the 
stomach of possums to some degree. Thus, antacid inclusion as an additional emulsion ingredient or 
outer coating around bait may be considered for future formulations.  
Second, additional in vivo or in vitro examination of the capacity of possums to metabolize VCD may 
aid in developing different formulations for VCD and their potential application for possum control. A 
reassessment of the ovarian, gastric and metabolic effects following an oral VCD dose in combination 
with protective formulations (i.e. encapsulation) should be considered.  
Third, if additional in vitro studies are to be carried out for the possum, several areas for improvement 
should be noted. First, the effects on both ovarian GSH and EH should be measured in vitro to 
determine the full effects of VCD and the capacity of the possum ovary to metabolise it. Assuming an 
in vitro ovarian culture system is not developed for the possum, ovarian S9 cell fractions (as outlined 
in Chapter 6) could be utilized as an alternative for such experiments. Secondly, a re-evaluation of 
liver metabolism, as measured by GSH and EH and their associated inhibitors, should be performed in 
conjunction with an in vitro culture protocol (i.e. inclusion of an NADPH regeneration system) to 
mimic in vivo conditions as closely as possible. Third, it may be useful to measure the rate of 
disappearance of VCD (Chapter 5) from hepatic and ovarian tissues under in vitro conditions. Such 
results would help to confirm the rate of conversion of VCD to its inactive tetrol metabolites by these 
tissues. This, in turn, could also be useful if future examination of the effects of VCD’s parent 
compound, VCH, on possum metabolism were to be undertaken. Collectively, in vitro examination of 
VCD (or similar compounds) may help in the formulation of methods to improve VCD efficacy for 
fertility control in the possum.     
 Implications for vertebrate pest management   8.5
To my knowledge, the findings presented on the effects of orally applied VCD in possums were the 
first of their kind. The summation of these findings indicates that the use of VCD for the control of 
fertility in the possum is not plausible at this time. Furthermore, the implication of these findings in 
the possum is that VCD may not be an effective management tool for other marsupials or eutherians 
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species with similar physiology or dietary habitats. It has been hypothesized that possums are effective 
metabolizers of VCD due to their dietary evolution (i.e. consumption of eucalypt foliage which is high 
in plant secondary metabolites (PSMs); Chapter 4). Thus, it may be hypothesized that species which 
regularly consume foliage high in PSMs would likely respond to VCD treatment in a similar manner 
to that of possums.  
To date, the only other examination of VCD’s effects on a marsupial were carried out on the tammar 
wallaby (Macropus eugenii) (Koehn, 2008). Fifteen days of subcutaneous or intramuscular injections 
of VCD did not reduce immature ovarian follicle pools of treated females. Although no direct 
correlations can be made, it is possible that, in part, the lack of VCD effects were due to the tammar 
wallaby having evolved an efficient metabolic capacity for detoxifying xenobiotics such as discussed 
and demonstrated here for the possum. In fact, tammar wallabies and koalas have shown similarities in 
their metabolism of xenobiotics to that of possums (Stupans et al., 2001) further supporting the 
hypothesis that VCD’s effects on the ovarian follicular pools of species which regularly consume 
foliage high in PSMs may be similar.  
The success of ContraPest
®
 emulsion at reducing the primordial follicle pools of wild Norway rats 
(Chapter 7) is encouraging for its potential use as a fertility control management strategy for rodents. 
For successful application of a chemosterilant, such as ContraPest
®
, future work will require several 
aspects for development and investigation. First, reduction or elimination of deterring odour and taste 
cues from the active ingredients within the bait may be necessary, especially for species, such as 
rodents, which rely on their highly sensitive olfactory and gustatory cues to identify acceptable food 
sources (Jensen et al., 1983; Lee and Clifton, 2002; Macdonald et al., 1999). If an ideal chemosterilant 
emulsion or bait can be produced which demonstrates high acceptability by a species then 
consideration for its use in the field could begin. It will be important to understand the effects of the 
fertility control bait on all components of the population of interest such as males, pregnant females, 
lactating females and juveniles. In addition, the effects of the bait on non-target species and the 
environment will need to be to be undertaken.   
Other factors that may improve bait acceptance for the species of interest would be identification of an 
optimal pre-baiting protocol and how the bait should be applied within the environment. Pre-baiting 
with non-active emulsion increases the acceptance and intake of the active emulsion formulation 
(Chapter 7). In addition, pre-baiting may reduce or prevent neophobic-induced behaviours (Barnett, 
1958; Buckle and Smith, 1994; Mitchell, 1976), thus further increasing acceptance of the active 
formulation. It would be advantageous to utilize local knowledge and vertebrate pest control experts, 
where possible, to improve the success of each baiting scheme (Buckle and Smith, 1994). For 
international applications, it will be important to further understand the effects of transportation time 
and temperature on all active ingredients within the fertility control bait. The effect of time and 
temperature on the active ingredients would also apply for developing bait strategies in the field.        
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Development and integration of a new pest control product, such as a chemosterilant, will require an in 
depth understanding of its impacts on the species of interest. The impact of a chemosterilant will vary 
depending on the species’ ability to absorb, metabolize, and detoxify the active components as well as 
the efficacy of the active components on the target organ and its downstream effects on fertility. For 
the successful application of a chemosterilant bait, its acceptance and palatability needs to be 
understood in the target species. Understanding the reproductive biology (i.e. age at first litter, size of 
litters) of the target species may also aid in development of treatment protocols and strategies for 
dealing with acute (i.e. mouse plagues) and chronic pest populations.   
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